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My three-year PhD course in Drug Discovery and Development at the 
Department of Pharmacy of Salerno University was started in November 2015 
under the supervision of Prof. Giuseppe Bifulco.  
My research project mainly focused on the application of computational 
chemistry techniques for the design and/or the identification of new anti-tumor 
and anti-inflammatory molecules, and their synthesis for the subsequent 
biological evaluation.  
In detail, basing on a project founded by AIRC (Associazione Italiana per la 
Ricerca sul Cancro, Italian Association for Cancer Research) I was interested 
in the identification of new inhibitors of a membrane enzyme, microsomal 
Prostaglandin E2 Synthase-1 (mPGES-1). A second part of the research 
activity concerned the discovery of new inhibitors of a molecular chaperone, 
Heat Shock Protein 90 (Hsp90). Both the targets have been shown to be 
involved in inflammation and cancer processes. 
Biological tests on small molecules that I designed and/or synthesized were 
performed in collaboration with Prof. Oliver Werz of Friedrich Schiller 
University (Germany). 
Furthermore, in order to improve my knowledge on synthetic chemistry, I 
moved to the Department of Chemistry and Applied Biosciences of ETH 
(Zurich) in 2018 (March until the end of October 2018) under the supervision 
of Prof. Jeffrey W. Bode. 
During the period of my internship in their laboratory of Organic 
Chemistry, I applied new synthetic strategies developed in the last few years. I 
mainly worked on SnAP chemistry, using it as chemical route for the synthesis 
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In the last few years, computational chemistry has played an important role 
in disclosing novel compounds with relevant biological activity. Inflammation 
and cancer processes have been recently linked, and the identification of new 
molecular entities able to interfere with biological targets involved in these 
pathologies is strongly needed. The analysis of ligand-macromolecule 
interactions and the evaluation of possible “binding modes” are the starting 
points in the design and the identification of new and more powerful drugs. 
Also, in silico Virtual Screening campaigns of large libraries of compounds on 
a specific target allow the selection of the most promising, leading the 
identification of new hits. Moreover, the coupling between versatile synthetic 
approaches and computational protocols is a powerful tool to obtain optimal 
results with time optimization. Thus, in this thesis both topics are applied at 
the same time, as they are connected to each other.  
The research work was mainly focused on mPGES-1 (microsomal 
Prostaglandin E2 Synthase) as a promising target for the treatment of the 
pathologies above. This enzyme is a homotrimeric membrane protein involved 
in the arachidonic acid cascade and it acts as downstream synthase in the 
cyclooxygenase pathway, catalyzing the conversion of the unstable peroxidic 
intermediate prostaglandin H2 (PGH2) in prostaglandin E2 (PGE2). Among the 
three different isoforms of the enzyme, selective inhibition of the inducible 
mPGES-1 may be considered a valid therapeutic approach to interfere with 
inflammation-induced PGE2 formation, avoiding to block the biosynthesis of 
constitutive prostanoids. Also, it is over-expressed in tumor pathologies. In 
light of this, in order to identify novel molecular platforms able to inhibit the 




protocol was applied starting from selected privileged scaffolds coupled to a 
synthetic chemical route. Specifically, new libraries of 2-aminobenzothiazole, 
2-aminothiadiazole and 2-carboxamidepyrrole-based molecules were 
generated, and they were docked onto the 3D structure of mPGES-1 (PDB 
code: 4BPM) crystallized in 2014. Using the interactions with the receptor 
counterpart as a qualitative filter, a collection of compounds for each library 
was selected, synthesized and submitted to biological investigation. Finally, 
cell-free and cell line assays confirmed some of them (benzothiazole 
derivatives 1, 3, 6, 9 and 13, thiadiazole derivatives 18-20 and 22, pyrrole 
derivatives 45 and 47) as novel promising mPGES-1 inhibitors.  
Furthermore, the same computational approach focused on mPGES-1 was 
applied on substituted saturated N-heterocycles, whose synthesis was 
performed at the Department of Chemistry and Applied Biosciences at ETH 
(Zurich). In detail, the libraries were docked onto the crystal structure co-
crystallized with the inhibitor 6PW (PDB code: 5K0I), leading to the selection 
of 21 compounds (62-82). The synthesis was performed using the SnAP 
(Stannyl Amine Protocol) chemistry, which consists of a reaction between an 
aminotributylstannane and an aldehyde to form an imine as the first step, 
followed by an intramolecular cyclization. Biological investigations are in 
progress on the synthesized compounds.  
In order to deeply combine computational tools and this versatile and 
suitable synthetic approach, a large database of about 1,300,000 synthetically 
accessible compounds was created in silico starting from iSnAP (Iterative 
SnAP) reagents, a new generation of SnAP reagents bearing a further 
functional group. The prepared database was then submitted to virtual 




now), in order to select the best candidates for the synthesis and the biological 
evaluation. 
Finally, the application of multi-step computational protocols including 
both ligand and structure based approaches took place in the identification of 
two novel 3-hydroxy-3-pyrrolin-2-one-based hits (compounds 87 and 88) as 
promising mPGES-1 inhibitors, starting from a large library of commercially 
available compounds.  
A second research work regarded Hsp90, a molecular chaperone involved 
in the development, survival and proliferation of cancer cells, regulating the 
homeostasis of oncoproteins. Most of the developed Hsp90 inhibitors interact 
with the N-terminal domain, but this type of modulation induces toxicity 
issues connected to the induction of the deleterious heat shock response 
(HSR). Contrariwise, since C-terminus inhibitors do not produce this effect 
and only a few of them have been developed so far, an aim of this research 
work consisted of the individuation of novel C-terminus binders. Thus, a 
biological screening on a small library of 48 commercially available 
compounds was performed and two novel inhibitors were identified 
(compounds 100 and 103) able to interact selectively with the C-terminal 
domain. Starting from these results, a computational rationalization was 
performed, applying Induced Fit Docking studies and Molecular Dynamic 
Simulations.  
In conclusion, in order to perform an optimization campaign, three large 
libraries of derivatives of compound 103 were generated using the multi-step 
computational protocol above, and a total number of 21 molecules have been 









































-CHAPTER 1-  












 1.1 Inflammation and cancer  
The connection between inflammation and cancer is a concept disclosed as 
early as 1863, when Virchow confirmed the sites of chronic inflammation as a 
potential source for cancer development.
1
 A sequence of factors is involved in 
neoplastic risk, since the proliferation of cells alone does not induce cancer, 
and an environment rich in inflammatory cells and related agents potentiates 
and supports its growth. The purpose of the inflammatory response is to repair 
and regenerate tissues exposed to injury associated with wounding. When the 
damage is repaired, proliferation is blocked and inflammation goes out. In 
tumors, the proliferation of damaged cells persists in microenvironments of 
inflammation.
2
 In the next sections, the fundamental pathways of connection 
between the two pathologies will be described. Moreover, although the 
relationship between cancer and inflammation is broadly known, many of the 
molecular and cellular mechanisms useful for well understanding the 
development of the cancer-related inflammation are not disclosed.
3
 
1.2 Inflammation: an overview 
The word “inflammation” derives from the Latin “inflammation”, whose 
meaning is “fire”. This single word is a resume of the five signs of the 
pathology: calor (heat and fever), tumor (swelling), rumor (redness), dolor 
(pain), functio laesa (inability of the area affected by inflammation to maintain 
its functionalities). 
The inflammatory response is triggered by pathogens or tissue traumas 
caused by several factors, such as physical or chemical insults.
4
 Several 







. After the invasion of pathogens, for example, the release of 
peptides, carbohydrates and nucleic acids stimulates the tissues to produce 
substances such as uric acid, extracellular ATP and other dendrites. The 
immune response is induced by the binding of these molecules to PRR 
(Pattern Recognition Receptors) proteins (an example are the Toll-Like 
Receptors, TLRs) expressed by dendritic cells, macrophages, monocytes, 
neutrophils in the innate immune response.
6
 Thus, the granulocytes product 
substances involved in the ongoing inflammatory response (histamine, tumor 
necrosis factor α, nitric oxide), and the subsequent dilatation of blood vessels 
and the increasing of the levels of cellular junctions induce the release of 
plasma proteins in the tissue. In some cases, platelets and plasma proteins 
penetrate the tissue and recruit components of the matrix, taking part in the 
formation of clots.
6
 Vascularization damage releases platelets and blood cells 
into the tissue. Although in the absence of physical trauma, cytokines and 
granulocytes may increase permeability through endothelial junctions, 
allowing plasma fluid and proteins to filter through the wall and to wet the 
surrounding tissue. This way, fibronectin and fibrinogen components induce 
the three-dimensional extracellular matrix to repair the tissue with immediate 
cell infiltration. Then, growth factors carried from blood regulate the 
recruitment of immune cells. 
7, 8
 
Furthermore, the flow of plasma through the interstitium and the structural 
remodeling of matrices act as a signal for the recruitment of plasma proteins 
and growth factors into damaged tissue, and the mechano-biological activation 
is useful for the migration of leukocytes and fibroblasts.
9
 Also, the filtration of 




concentration near the vessel wall. The combination of this with vessel 
dilatation increases erythrocyte aggregation.
9
  
Endothelial adhesion molecules (ICAM-1, VCAM-1, PECAM-1, E-selectin 
and P-selectin) are regulated by growth factors such as histamine, interleukins, 
ROS and TNF,
10
 deriving from granulocytes. The leukocytes flow along the 
wall of the blood vessel and stop in the tissue. Some of the cytokines produced 
during the inflammatory process act as chemokines, generating chemical 
gradients.
10
 At this point, cells of the inflammatory response are recruited. 
Neutrophils are involved in phagocytosis of assaulting agents, and in the 
generation of neutrophilic traps, known as NET (neutrophil extracellular 
traps), that may trap and kill extracellular bacteria without phagocytosis 
processes.
11
 Hypoxia conditions may occur considering the high grade of 
activities in the repair of the damage. In response to these events new blood 
vessels can be generated in order to increase the oxygen availability, a phase 
which presents as main components angiogenic growth factors, such as VEGF 
(vascular endothelial growth factor).
12
 
In a successful inflammatory response, these processes are able to restore 
homeostasis. Several control mechanisms, such as a short half-life of 
mediators of inflammation and the ability to reorganize the tissue 
microanatomy after removing the insult, are fundamental for the resolution. 
Unfortunately, this safety mechanism is limited in pathological and chronic 
inflammation.
7, 8  
1.2.1 Inflammation mediators  
One of the main mediators of inflammatory processes is prostaglandin E2 




fever, hypersensitivity of peripheral neurons, and it acts as a chemotactic and 
mitogenic factor. 
13
 Once released, it is able to interact with four different G-
protein coupled receptor subtypes (EP1, EP2, EP3, EP4), taking part in the 
inflammatory effects.
14
 Moreover, PGE2 plays a series of different roles in the 





 protective gastric mucosa
17
 and renal function.
18
 Also, it 
participates in tumor development, since it promotes tumor growth, immune 
suppression, angiogenesis and apoptosis inhibition.
13
 Recently, some studies 
reported that the concentration of PGE2 increases in a wide variety of human 
tumors,
19
 such as colorectal
20
 and breast cancers.
21
  
Fundamental mediators of the inflammatory response are other eicosanoids 
(prostacyclins, thromboxanes and leukotrienes).
22, 23
 In particular, prostacyclin 
interferes with the formation of blood clots and induces vasodilatation; 
thromboxane has also vasodilating effects, but favours platelet aggregation 
and bronchospasm; leukotrienes are responsible for the delayed phase of the 
asthmatic reaction, acting as powerful bronchoconstrictors.
24
  
Other examples of molecules able to act as mediators in the inflammatory 
performances are histamine, NO (nitric oxide), TNF-α (tumor necrosis factor 
α) and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), 
whose activities will be described in the next sections. 
25-27
 
1.2.2 Eicosanoids biosynthesis 
A brief description of the biosynthesis of eicosanoids in the inflammatory 
cascade is reported, since a purpose of this research work is to interfere with 




Eicosanoids derive from the oxidation of arachidonic acid (AA), 
characterized by a 20 carbons chain and released from cell membranes due to 
the activity of Phospholipase A2 (PLA2).
22, 23
 The activation of the mentioned 





 or the interaction of inflammation mediators with 
G-protein coupled receptors. Then, AA may be undergone to two different 
enzymatic pathways: cyclooxygenase (COX)
29
 or lipoxygenase (LOX) 
activities.
30
 In particular, cyclooxygenase leads to the formation of 
prostaglandins, thromboxane and prostacyclin,
29
 whereas lipoxygenase is 
involved in the synthesis of leukotrienes and lipoxins (Figure 1). 
30
  
In details, in the COX pathway it is possible to distinguish two 
cyclooxygenases: COX-1, constitutively expressed, and COX-2, inducible 
isoform. Both of them firstly lead to the formation of the AA-derived 
endoperoxide PGG2 in the cyclooxygenase site of the COXs,
31
 then reduced at 
the peroxidase site of COXs into the unstable peroxide intermediate 
prostaglandin H2 (PGH2).
32
 The latter is converted to the stable isomer 
prostaglandin E2 (PGE2) by prostaglandin E2 synthase, or other prostaglandins 
(PGD2, PGF2α), prostacyclin (PGI2) and thromboxane (TXA2) by the proper 
synthase (Figure 1). 
23, 33 
 PGE2 and the other prostaglandins interact with G-








Figure 1 Biosynthesis of prostaglandins (A) and leukotrienes (B).
23
 
1.2.3 From acute to chronic inflammation 
In inflammation, all recruited cells play a crucial role in defense of the 
damaged tissue against infection. Control of the duration of the response is 




too long and the generation of the conditions for cancer development.
35
 In the 
shift from tissue damage to tissue repair both pro-inflammatory and anti-
inflammatory mechanisms are implicated, since a balance between promoting 
and suppressing is crucial for the retaining of the homeostasis. Different 
molecules take part in this equilibrium, performing the two activities by the 
case. A dual job is carried out from prostaglandin E2,
36
 transforming growing 
factor-β,
37
 reactive oxygen and nitrogen intermediates.
38
 A programmed 
removal of inflammatory cells from the tissue with a following resolution of 
the response is provided by dendritic cells, macrophages, and phagocytes, 
inducing apoptosis and phagocytosis.
11, 39
 
Moreover, if the breaking down of the inflammatory response is 
dysregulated, a shift to a chronic response is induced. In this situation, the 
persistence of macrophages and other inflammation cells in the 
microenvironment develops growth factors, cytokines and reactive oxygen and 
nitrogen species, and may cause DNA damages. The described conditions may 
lead to the progression of a tumoral state. 
1, 8
 
1.3 Cancer: an overview 
A neoplasm is an abnormal and extensive growth (neoplasia) of a tissue, 
which usually forms a mass called tumor.
40
 In a benign neoplasm, cells are not 
differentiated from those of the original tissue and lack the ability of 
invasion.
41
 Moreover, the main problem is the need for space as it may 
become dangerous if it exerts pressure on nearby vital structures. The 
malignant evolution of a neoplasm is called cancer. Cancer cells, likely to 
generate in almost every organ and tissue, are endowed with metastatic growth 






 Cancer development is a multi-step process, in which 
uncontrolled cell growth follows the activation of oncogenes and/or the 
deactivation of tumor suppression genes. Six several characteristics 
(hallmarks)
42
 lead to the progression of cancer: evading apoptosis and 
extension of the number of cells; self-sufficiency in growth signals and 
insensitivity to anti-growth signals, where in contrast a normal cell cannot 
proliferate in absence of external stimulatory signals; tissue invasion and 
metastasis that requires a down-regulation of cell adhesion receptors as well as 
an up-regulation of receptors involved in cell motility; limitless replicative 
potential, deriving from growth signals autonomy; substained angiogenesis, 
which ensures the supply of nutrients and oxygen for the survival of cells. 
42
 
Epigenetic alterations are also implicated in cancer and may be considered 
another hallmark. In fact, modifications affecting histones and DNA residues 
are crucial in the generation of cancer progenitor cells. 
43
 
The evolution of cancer is complicated and a combination of different 
signaling processes. Moreover, it is essential to stress the correlation between 
chronic inflammation and carcinogenic conditions. 
1.4 Connecting inflammation and cancer  
As reported above ( section 1.1), the connection between inflammation and 
cancer was first presented in the nineteenth century. It is estimated that 20% of 
cancers derive from persistent inflammation.
1
 Two different pathways can be 
distinguished: an extrinsic, in which inflammatory conditions increase the risk 
of cancer development, and an intrinsic, in which genetic alterations are reason 
of inflammation and tumor. In the intrinsic path the expression of oncogenes 




Moreover, both the pathways converge to the activation of transcription 
factors. 
Macrophages populate the environment as the main cellular component in 
chronic inflammation. Those and other leukocytes are responsible of the 
production of reactive oxygen and nitrogen species, whose persistence in the 
tissue is dangerous, since they may generate mutagenic agents able to react 
with DNA.
44
 Furthermore, the release of tumor necrosis factor-α (TNF-α) and 
macrophage migration inhibitory factor contribute to the damage, determining 








Figure 2 Cancer-related inflammation: intrinsic and extrinsic pathways. 
 
A description of the key regulatory molecules involved in the conversion 
from chronic inflammation to cancer is useful for understanding some 
mechanisms. Key endogenous (intrinsic) factors can be defined, such as 
transcription factors (NF-κB, STAT3) and cytokines (IL-1β, IL-6, IL-23 and 
TNF-α named above). TNF-α was discovered first as a mediator locally 
expressed by cells of the immune system, with a therapeutic role.
25
 Moreover, 
it was demonstrated that TNF-α is also involved in most of the processes for 




and it is produced by tumoral cells, performing the role of an endogenous 




Also, NF-κB is an endogenous mediator involved in the promotion of 
cancer and the progression. It is a coordinator of innate immunity and 
inflammation, and it operates downstream, in the Toll-like receptor (TLR)-
MyD88 signaling pathway. In both tumor and inflammatory cells, NF-κB is 
responsible for the expression of genes which encode cytokines, angiogenic 
factors, enzymes involved in the synthesis of prostanoids (COX-2) or 
inducible nitric oxide synthase (iNOS). In light of this, NF-κB is an important 




A list of mediators that take part in the key molecular mechanisms of 
connection between the two pathological states is reported below. In 
conclusion, molecular and cellular components of the inflammatory response 
are crucial in cancer development. 
 
Potential linkers Functions in linking inflammation to cancer 
IL-6 Promotion of tumor growth 
TNF-α 
Induction of DNA damage and inhibition of  DNA repair 
Promotion of tumor growth 
Induction of angiogenic factors 
Chemokines 
Promotion of tumor growth 
Invasion and metastasis by directing tumor cell migration and 
promoting basement membrane degradation 
NF-ΚB 
Inflammation progress, promoting chronic inflammation 




Protection of transformed cells from apoptosis 
Promotion of tumor invasion and metastasis 
Feedback loop between proinflammatory cytokines 
iNOS 
Induction of DNA damage and disruption of DNA damage 
response 
Regulation of angiogenesis and metastasis 
COX-2 
Production of inflammation mediator prostaglandins 
Promotion of cell proliferation, antiapoptotic activity, 
angiogenesis, and metastasis 
HIF-1α 
     Promotion of chronic inflammation  
     Involved in angiogenesis, tumor invasion, and metastasis by 
transactivating VEGF 
STAT3 
Promotion of proliferation, apoptosis resistance, and immune 
tolerance 
Nrf2 
Anti-inflammatory activity  
Protection against DNA damage 
NFAT 
Regulation of proinflammatory cytokine expression  
Involved in cell transformation 
 
Table 1 Molecular connection between inflammation and cancer. 
 
1.5 Aim and outline of this thesis  
According to the importance and relevance of the described related 
pathologies, the aim of this research project was the identification of new 
potential anti-inflammatory and anti-tumor molecules. The side effects of the 
well-known non-steroidal anti-inflammatory drugs (NSAIDs), for example on 
the gastrointestinal tract and the cardiovascular system, require the discovery 






 especially for long term therapies.
47
 Prostagrandin E2 Synthase (PGES) 
is an enzyme involved in the inflammatory response, since it catalyzes the 
conversion of the unstable peroxide intermediate prostaglandin H2 (PGH2) in 
its isomer prostaglandin E2 (PGE2) (Figure 1). In particular, the enzyme is 
placed downstream in the inflammatory cascade, performing its function in a 
specific step which follows the upstream COX activity (Figure 1).23 The 
increase of the level of PGE2 in several types of cancer
19
 and its support in 
cancer cell proliferation and tumor growth
13
 are fundamental factors to 
consider the inhibition of the activity of PGES as a promising method for the 
development of novel anti-cancer drugs.
48
 Herein, it is important to stress the 
existence of three different isoforms of PGES: the cytosolic cPGES and the 
microsomal mPGES-1 and mPGES-2. This project is mainly focused on the 
discovery and the design of novel mPGES-1 inhibitors, since it has been 
demonstrated in recent studies an up-regulation of this specific isoform in 
concert with COX-2 after exposure to various inflammatory stimuli and 
mediators,
49
 whereas a constitutively expression of mPGES-2 and cPGES, and 
ubiquitous mPGES-1 at low concentration have been confirmed. 
Basing on the objectives above, the research group in which the entire 
project was developed follows a specific multitasks protocol (Figure 3) as a 
guideline for the identification of new mPGES-1 inhibitors. A detailed 
description of its application to this research work will be reported in chapter 
3.  
Computational chemistry techniques have been a handy and powerful tool 
in the development and the progress of the project. The study of ligand-protein 
interactions played a fundamental role in the design of promising compounds, 




chemical stereotypes for the individuation of new hits. Furthermore, the 
experimental part was essential to confirm in silico developed studies. 
Versatile and fast synthetic methods were performed for the generation of the 




Figure 3 General Workflow. 
 
The whole project has been founded by AIRC (Associazione Italiana per la 
Ricerca sul Cancro, Italian Association for Cancer Research).*  
Furthermore, a second part of the project was the identification of novel 




progression, belonging to the family of heat shock proteins (HSPs). Molecular 
chaperone activities of these proteins is noteworthy, since they are involved in 
the mechanisms of proteostasis in both physiological and stressful 
conditions.
50
 The regulation of three-dimensional folding, assembly and 
disassembly, translocation and degradation of macromolecular protein 
structures during normal cellular growth and development are examples 
among many activities for which they are responsible.
50
 Also, the members of 
this family take part in the refolding and reactivation of unfolded and 
misfolded proteins, damaged by stress conditions.
51
 Hsp90 clients include 
different classes of protein macromolecules involved in signal transduction, 
such as kinases and many steroid hormone receptors.
51
 In the last years, 
research on Hsp90 has been relevant, considering that most of Hsp90 clients 
are agents active in cancer progression.
51, 52
 Also, Hsp90 is an interesting 
target for our purposes, since it is over-expressed in many tumors (breast and 
lung cancers).
53, 54
 In the last years, the campaign of the discovery of Hsp90 
inhibitors led to the identification of many inhibitors able to interact with the 
N-terminal domain of the protein,
55
 whereas a few C-terminal inhibitors 
exist.
56-59
 A detailed description of the protein and its conformational cycle 
associated with its chaperone activity,
50
 and the importance of the 
individuation of C-terminal binders in comparison to N-terminal inhibitors
60
 
will be stressed below in this thesis
1
.  
                                                 
*AIRC IG 2012-ID 1277: Design, Virtual screening, and Synthesis of mPGES-1 inhibitors 
as new Anti-Inflammatory and Anti-Cancer drugs – Giuseppe Bifulco. 
*AIRC IG 2015-ID 17440: Identification and biological evaluation of optimized mPGES-
1 inhibitors as Anti-Inflammatory/Anti-Cancer drugs – Giuseppe Bifulco. 
*AIRC IG 2019-ID 21397: Inhibition of mPGES-1 and modulation of PGE2 biological 


























2.1 Computational Chemistry in Drug Discovery 
In the last three decades, computational chemistry techniques have played a 
major role in the development of therapeutically important small molecules.
61
 
A brief description of the adopted methods is reported in the next sections.  
Computer-aided drug discovery (CADD) is employed for the exploration of 
the molecular basis of bioactive compounds pharmacological activity as well 
as for the development of derivatives with improved activity. Three main aims 
of CADD in drug discovery campaign are noteworthy: 
1. the filtration of large libraries of compounds in order to select a 
small promising set for the biological evaluation; 
2. the optimization of hit compounds, increasing the affinity for the 
protein target or optimizing the pharmacokinetic parameters 
(absorption, distribution, metabolism, excretion, and the potential 
for toxicity) at least from a calculate perspective; 
3. the design of novel compounds, using "growing" strategies of 








Figure 4 CADD in drug discovery/design pipeline. 
 
2.2 Drug design 
Drug design, also named rational drug design or rational design,
62
 is a 
convenient method for the research of compounds targeting biological 
macromolecules. This approach appreciates a detailed knowledge of the 
targets involved in the pathology of interest, in order to decide the most 





1. its importance and its involvement in the pathology. 
2. the druggability,63 its ability to bind a small molecule able to change 
its physiological activity. Hopkins and Groom introduced the term 
druggable
64
. They wanted to identify a set of about 3,000 genes in 
the human genome which encode proteins related to the disease for 
which it is possible to develop drug-like compounds.
65
 Therefore, 
the previous definition of druggability included those 
macromolecules capable of binding the molecules that comply with 
the Lipinski rule.
66
 Today, a druggable structure is a protein which 
is implicated in the pathways involved in the pathology, whose 
activity can be modulated by drug-like molecules. 
63
 
It is also essential the knowledge of the existent modulators of the selected 
macromolecule, in order to define the chemical-physical properties and to 
compare them with the designed molecules, since the main aim of drug design 
is to generate compounds with an improved biological activity on the target. 
In the last few years, computational modeling techniques were used for the 
drug design.
67
 They consist of the application of molecular mechanic 
methods
68
 to perform computational simulations of the binding between a 
ligand and a macromolecule. As a crucial component in pharmaceutical 
research, CADD reduced costs and time of screening significantly without 
compromising the quality of the lead compound discovery. 
2.2.1 Structure-based Drug Design (SBDD)  
Structure-based drug design (SBDD) approach
69
 is based on the 
requirement that the 3D structure of the macromolecule is available. Protein 




proteins, determined by NMR, X-ray crystallography or homology modeling
70, 
71
 methods, have been deposited since 1976.  
As the design of the molecules is performed starting from the 3D structure of 
the protein, the active site is identified. Two cases are possible: 
1. a co-crystallized ligand, known inhibitor, is placed in the active 
site. The entire process of calculation is carried out in the ligand 
binding site (LBS). 
2. It is necessary to determine the possible binding sites using 
specific software, such as SiteMap
72







 analyzes several chemical-
physical parameters of the protein (volume, solvent exposure, 
hydrophobic and hydrophilic spaces, individuation of acceptor 
and donor hydrogen bonds) in order to calculate Site Score 
(SScore) and Druggability Score (DScore). 
The compounds or the fragments of compounds are located in the active 
site and a score is assigned, according to the analysis of the interactions with 
the receptor counterpart. Based on the methodology applied to perform the 
structure-based drug design, two approaches can be used: 
1. de novo approach, in which new ligands are tested into the 
binding site. A preliminary analysis of volume and shape of the 
site and the study of the key interactions for the determination of 
the biological activity are critical in this methodology. 
Fragments of molecules with specific functional groups are 
placed in the active site in order to establish the key interactions, 




2. virtual screening approach, in which several sized libraries of 
compounds are docked onto the LBS (Ligand Binding Site) in 
order to select the most promising. The libraries can be 
commercially available or built starting from the synthons of a 
synthetic accessible route.  
2.2.2 Ligand-based Drug Design (LBDD) 
If the three-dimensional structure of the protein is not available, the ligand-
based drug design approach
75
 is used in drug design. Basically, it consists of 
starting from the information obtained from known binders of the biological 
target of interest, in order to indentify novel modulators. The identification of 
a pharmacophore as a model is fundamental in this approach. Pharmacophore 
screening aims to identify compounds containing different scaffolds, but with 
a similar three-dimensional arrangement of key functional groups.
76
 In light of 
this, 3D-QSAR (3D structure-activity relationship) and shape similarity are 
both important tools in the ligand-based drug design. 
2.3 Methodologies employed 
In the next sections, the computational methodologies applied in this 
research work are briefly described. 
2.3.1 Molecular docking 
One key methodology is the molecular docking that estimates conformation 
and orientation of molecules within a targeted binding site. Many different 











 and Glide 
83-87
 are among the most popular. 




comes with its own set of strengths and weaknesses. However, the placing of a 
flexible ligand into a rigid binding site is a feature common to most of docking 
software. The use of a rigid macromolecule in the docking calculations 
reduces the number of freedom degrees, as only conformational changes of 
docked compounds are considered.  
Most molecular docking software has two key parts: 
1) a search algorithm 
2) a scoring function.88, 89 
The highest efficiency of the calculation is reached if both these parts are 




2.3.1.1 Conformational search 
The search algorithm is involved in the sampling of conformations and 
orientations of ligands in the binding site of the macromolecule. In light of 
this, it is possible to stress that the number of degrees of freedom of the 
docked small molecule influences the difficulty of this step. Three different 
categories of search methods can be identified: systematic methods, random or 
stochastic methods (Monte Carlo and genetic algorithms), and simulation 
methods (molecular dynamics, energy minimization). 
In the systematic search algorithms, all the degrees of freedom in a 
molecule are explored, generating a considerable number of conformations.
92
  
The random methods or stochastic methods perform random changes of a 
single ligand or a population of ligands. At each step, the variations of energy 




molecular space of the available conformations is explored. A pre-defined 
probability function is used for the examination of the obtained ligand.  
Molecular dynamics (MD)
93, 94
 is currently the most popular simulation 
method for the rationalization of the biological activity of macromolecules, 
calculating the time-dependent behavior of a molecular system. Detailed 
information about conformational changes of proteins and nucleic acids, and 
the nature and stability of binder-protein complexes can be provided by means 




The determination of protein motions requires the description of quantum-
mechanical motions and chemical reactions, that are too complex for even the 
best supercomputers. Molecular dynamics simulations were developed in the 
late 1970s
96
 and they were able to overcome this limitation, as simple 
approximations based on Newtonian physics are used for the calculations. 
Position and moment of each particle belonging to a molecular system are 
important for the determination of the state of the system. In detail, 6 
coordinates (3 for the position and 3 for the moment) for each particle occupy 
the so-called phase space. The initial instant is the minimized state of the 
molecule. Then, a moment with random direction is applied, whose intensity 
depends on the temperature of the system. The collection of a subsequent 
series of points in specific intervals of time provides a trajectory which is an 
estimation of the natural situation.  
Since only local energy minima can be reached using energy minimization 





2.3.1.2 Scoring function 
After the conformational search by means of search algorithms, the scoring 
function evaluates the results predicting the affinity for the biological target. 
Several factors influence this function, such as enthalpic and entropic 
components, limited resolution of X-ray crystals, induced fit or other adopted 
conformational changes, the presence of water-bridge molecules in 
macromolecule–ligand interactions. It is possible to group the scoring 
functions in three categories: force field (FF),
97
 empirical and knowledge-
based.  
In the force fields there is the contribution of two energetic components, the 
protein–ligand interaction energy and the internal ligand energy, as a single 
conformation of the protein is considered and the calculation of the internal 
protein energy can be omitted.  
The sum of electrostatic and van der Waals terms, and the hydrogen bonds 
established between ligand and biological target contribute to the 
determination of the enthalpic value. The van der Waals potential energy for 
the general treatment of non-bonded interactions is often modeled by a 
Lennard–Jones 12–6 function (Equation 1): 
 
            
 
   
 
   
  
   




   






where ε is the well depth of the potential and σ is the collision diameter of 




repulsion, whereas the exp(6) is related to an attractive term which approaches 
zero as the distance between two atoms increases (Equation 2).  
The Lennard–Jones 12–6 function is also used to describe the hydrogen 
bond in macromolecule-ligand complex, but is less smooth and angle 
dependent if compared to the Van der Waals function (Figure 6) 
 
 
Figure 5 Schematic representation of functions used to model pair-wise interactions that 
contribute to binding. Interactions are calculated as a function of the distance (rij) between 
two atoms i and j. A) van der Waals interaction given by a 12–6 Lennard–Jones potential. B) 
hydrogen bond potential given by a ‘harder’ 12–10 Lennard–Jones potential. C) electrostatic 
potential for two like (blue) or opposite (black) charges of same magnitude calculated using a 
distance dependent dielectric constant. 
 
The electrostatic potential energy is represented as the sum of Coulombic 
interactions, as described in equation 2: 
 
           
    
       
  
   
  




where N is the number of atoms in molecules A and B, respectively, and q 




to the protein–ligand interaction energy. Its value, in fact, is given by van der 
Waals contributions and/or electrostatic terms. 
The empirical scoring function considers the sum of a set of weighted 
empirical energy terms, (Van der Waals, hydrogen bonding and electrostatic 
energies, etc.):  
 





where ΔG is the summation of the individual empirical energy terms 
multiplied by the corresponding coefficients, which are determined by 
reproducing the binding affinity data of a training set of protein-ligand 
complexes with known three-dimensional structures, using least squares fitting 








2.3.1.3 Glide: an overview 
The named Glide
83-87
 software was used in this research work for docking 
analysis. It searches for possible locations of the test compound in the active-
site of the crystal structure of the protein, using a hierarchical set of filters 
(Figure 6). A grid determines shape and properties of the receptor, defined by 
a series of fields. A broad conformational search and a heuristic screen are 
both main actors in the removal of unsuitable conformations. Each ligand is 
divided into a core and rotamer groups, which are attached directly to the core 






), located at the end of a rotamer group are not considered 
rotatable. In the generation of conformers, core conformations are generated, 
generally fewer than 500. The number is related to the quantity of rotatable 
bonds, the presence of conformationally labile rings and asymmetric 
pyramidal trigonal nitrogen centers. The core and all possible conformations 
of rotamer groups are docked as a unique object. 
 
Figure 6 Glide docking hierarchy. 
 
The research of the possible locations and orientations of each conformer is 
carried out following a set of stages. The first consists of the calculation of a 




distances from the site point to the receptor surface is performed, which are 
sorted into distance ranges of width 1 Å. The same way, the distances between 
the ligand center and the ligand surface are calculated and sorted as described. 
A comparison between the distance ranges from the site point to the receptor 
surface and those from the ligand center to the ligand surface is carried out. 
The selection is based on the evaluation of the match between the ligand 
center and the site point. 
A second stage is divided in several steps. The diameter test (2a) focuses on 
the calculation of the distances between the most separated atoms inside the 
conformer (ligand diameter). The specific orientation is skipped if there are 
many steric clashes with the receptor. In the next step (2b), ligand diameter is 
considered rotatable and a first evaluation of the scoring deriving from the 
interactions of a subset of atoms able to establish hydrogen bonds or ligand-
metal interactions with the receptor is carried out, and if the calculated value is 
good, all the interactions with the receptor counterpart are inclused in the score 
(2c). Schrödinger’s ChemScore
100
 empirical scoring function is involved in 
these three tests. It is an algorithm which recognizes favorable hydrophobic 
interactions, hydrogen bonds and metal-ligations, whereas penalizes steric 
clashes. In this case, score evaluation for each atom depends on its position 
onto the receptor, but also on the best possible score which it may present by 
changing its position ±1 Å in x, y or z (greedy scoring). The final step 
provides a re-scoring of the top poses deriving from the previous step using a 
refinement procedure, in which the test compound may move rigidly ±1 Å in 
x, y or z.  
Only a few poses (100–400) enter the third stage, in which an energetic 




smoothed in order to reduce the wide energy deriving from too-close 
interatomic contacts. Then, a sampling of the top-ranked poses is performed, 
in which local-minima core and the torsion angles of rotamer groups are 
evaluated, with the aim of improving the score. 
A re-scoring of the minimized selected poses is the last stage. GlideScore
83-
87
 is the main actor of this phase. It is based on ChemScore, 
100
 but includes a 
series of other terms decribed in the equation 4. 
 
                                                        
                         
Equation 4 
 
where vdW and Coul are the van der Waals and coulomb energy 
respectively, Lipo, Hbond and Metal are the lipophilic, hydrogen-bonding and 
metal-binding terms. It also evaluates rewards and penalties, such as buried 
polar terms, hydrophobic enclosure terms, amide twist penalties. Emodel
83-87
 
is engaged in the final choice of the best poses for each ligand, and considers 
the energy grid score and the binding affinity provided by GlideScore. Herein, 




2.3.2 A flexible docking: Induced Fit Docking 
A more detailed computational protocol for docking experiments is the 
Induced Fit Docking (IFD), 
103-105
 as the flexibility of the amino acids placed 
in the binding site of the protein is considered in the calculations. The classical 
molecular docking described above, in fact, consists of placing flexible ligands 




site of a protein induces conformational changes and resolving the X-ray 
structure of the complex protein-ligand is frequently infeasible. The IFD 
protocol is one of the most useful instrument to overcome this limitations. The 
workflow is composed by a job sequence in which ligands are docked with 
Glide (first step)
103-105
, then Prime Refinement is used to allow the receptor to 
relax (second step),
105, 106
 and the ligands are redocked onto the relaxed 
receptor with Glide (third step). 
2.3.3 Ligand-based approach: Shape similarity 
The evaluation of the shape similarity between designed molecules and 
known inhibitors of the biological target is another fundamental component 
for the generation of promising libraries.
107
 The shape filter allows to take into 
account for the next steps only the structures showing a specific binding mode. 
Among different shape-based research software, Phase
108, 109
 is one of the most 
famous for ligand-based design. The determination of the three-dimensional 
disposition of the functional groups of active compounds by analyzing the 
chemical properties that confer activity against the target is the tool that the 
approach is based on. Then, Phase searches for novel structures with a similar 
shape from an internal database that can be updated or modified. Overlapping 
two structures A and B, the volume occupied by both structures (VA∩B) is 
normalized by the total volume (VAUB) to obtain SimAB, whose value is 
from a minimum of 0.00 to a maximum of 1.00, according to the similarity 
grade (Equation 5). 
               
Equation 5 
 




of pharmacophore sites that encode the positions of acceptor and donors 
hydrogen bonds, hydrophobic regions, positive and negative ionizable 
functions and aromatic rings. Another tool of Phase software is the Isosteric 
matching of the Core hopping software, useful for the research of bioisosters 
of a specific chemical item.
108, 109 
2.3.4 Calculation of pharmacokinetic parameters and filters 
application 
Pharmacokinetic parameters have fundamental importance to evaluate if a 
molecule is a right candidate to become a drug, or if its properties are not 
appropriated to consider it in the development of new hit compounds. With a 
prediction of these properties, it is possible to select exclusively drug-like 
compounds by discarding the remaining compounds from the calculation. 
In this field, the hydrophobic/hydrophilic balance in a compound influences 
its intestinal adsorption, or the distribution in the several compartments of the 
organism, the metabolism (higher hydrophobic properties make more difficult 
the metabolic processes) and the elimination.  
QikProp
110, 111
 is a module of Schrödinger LLC for the prediction of ADME 
(adsorption, distribution, metabolism, elimination) properties of molecules 
(e.g. belonging to a combinatorial library obtained with CombiGlide
112, 113
, 
described above) applying filters that eliminate the compounds unable to 
comply with some important rules and parameters. With the in silico 
prediction, it is possible to exclude not-drug-like molecules before the 
synthesis, reducing the time and the costs needed. 
QikProp
110, 111
 uses similarity in property space to increase the accuracy of 




database of known drugs. The similarity can be from a value of 0.0 (no 
similarity) to a value of 1.0 (maximum similarity). 
The software considers three cases: 
1. A similarity less than 0.9: the QikProp prediction is used. 
2. A similarity greater than or equal to 0.9: the predicted property 
(Ppred ) is:  
                          
Equation 6 
 
where S is similarity, Pexp the experimental prediction, PQP the QikProp 
prediction. 
3. A similarity of 1.0: the software reports the experimental value. 
In addition, it takes into account 30 different reactive functional groups, 
which could be responsible for false positives in high throughput screening 
(HTS) assays, instability and toxicity of the molecules. 
In the calculation of the pharmacokinetic parameters, the rule of Lipinski 
(also called the rule of 5)
114
 is one of the most important in order to estimate 
the adsorption of valid candidates. The researcher Christopher Lipinski in 
1997
66
 defined this rule according to which a molecule must: 
- not have a molecular weight higher than 500 (MW <500); 
- have no more than 5 hydrogen bond donors; 
- have no more than 10 hydrogen bond acceptors;  




There are extensions of the Rule of 5
115
 such as the "Rule of 3", used for the 
construction of fragment libraries for lead generation.
116
 These are generalized 
rules for assessing drug-likeliness and bioavailability of compounds.  
QikProp
110, 111
 can perform the calculation in two different modes: normal 
and fast (fast mode). The fast mode calculates fewer properties, in particular 
omits the PM3 calculation, which determines the dipolar moment, the 
ionization potential and the electron affinity, and is particularly suitable when 
a large number of molecules is available. 
Some of the properties calculated by the software are:  
 QPlogBB, an index of the permeability of the blood-brain barrier 
(BEE); 
 QPlogPo/w, the octanol / water partition coefficient; 
 QPlogS, predicted aqueous solubility; 
 QPPC which indicates the permeability through the Caco-2 cells, as 
a model of human intestinal barrier; 
 QPPMDCK indicates permeability through MDCK cells; QikProp 
predictions consider non-active transport;  
 QPlogHERG, predicts IC50 value for blockage of HERG K
+ 
channels; 
 RtvFG, the number of reactive functional groups;  
 SASA, the surface accessible to the solvent, expressed in Angstrom 
(Å); 
 FISA, a hydrophilic component of the solvent-accessible surface 




 HumanOralAbsorption, predicts human oral absorption, with values 
1 (low), 2 (medium) and 3 (high), which can also be expressed as a 
percentage. 
At the end of the calculation, only drug-like molecules are selected from the 





 is applied. This is a function of Maestro
117, 118
 through 
which you can set precise values for pharmacokinetic parameters and filter the 
libraries basing on these (for example molecular weight, logS, logP, FISA). 
2.4 Application of combinatorial chemistry to 
computational chemistry 
Combinatorial chemistry techniques have made possible the synthesis of 
large libraries of compounds and revolutionized the process involved in the 
discovery of new bioactive compounds.
119
  
The assumption that maximizing structural diversity would increase the 
chances of finding new hits has led to the design of libraries characterized by 
different compounds. However, in the design of a library other factors have to 
be considered, such as chemical-physical properties of molecules, costs, 
availability of reagents and synthetic accessibility. The techniques developed 






Reagent-based. This approach does not provide the use of a scaffold, but it 
starts from the available reagents, which are synthons of a synthetic strategy, 




physical diversity in order to obtain the most representative molecules of all 
the possible synthesizable compounds.
120
 
Product-based. Generally, it is used for the development of scaffolds. It 
consists of the use of a genetic algorithm (GA) which starts from a set of 
several scaffolds and alters atoms and molecular fragments in order to 
generate molecules that adapt to the indicated constraints. This algorithm can 
generate and optimize a large number of hits, taking into account weight and 
molecular volume, number of stereogenic centers, number and type of bonds, 
and other parameters.
121
 Combinatorial chemistry Lab (CCLab)
122
 is one of the 
software which uses this algorithm. 
2.4.1 Reagent Preparation 
Reagent Preparation is a function which provides the preparation of several 
fragments for the decoration of the core. It works by the generation of 
SMARTS (representation of chemical structures through text string), and 
defines precisely the fragment and the functional group that will be removed 
with Combiglide (Schrödinger, LLC) 
112, 113
 in the next step, to perform the 
connection to the core. Using the SMARTs it is possible to determine the 
breaking point of the collection of reagents, indicating the atom of the 
molecule that has to be preserved (rpc1) and the one that has to be removed 





Figure 7 Commercially available compound and correspondents SMARTs for the two 
possible fragments. 
2.4.2 Combiglide and generation of libraries 
CombiGlide
112, 113
 allows the choice of the specific points on the scaffold 
for the addition of the prepared fragments, applying the interactive 
enumeration function. It works following a combinatorial chemistry approach 
to obtain all the possible combinations of the different reagents with the core, 
starting from the synthons of a selected synthetic strategy. The links scaffold-
fragments are not necessarily the bonds that are cleaved in the real chemical 
reactions, taking into account that Combiglide considers the final product 
synthetizable using the selected synthetic strategy, and generates all the 
possible final compounds. Then, this is an important tool for the design of very 
large libraries of molecules, all the possible compounds starting from all the 
commercially available reagents, synthons of the synthetic route. Anyway it is 
not possible to synthesize all the designed compounds, but with the use of 
appropriate filters the most synthetically accessible molecules can be selected.  
Finally, LigPrep (Schrödinger, LLC) 
123, 124
 software performs: 
1. energetic minimization of the whole library using Optimized 
Potentials for Liquid Simulations  (OPLS) 2005 force 
field,
1 2 5




2. preparation of each compound, by the calculation of the 
stereoisomers, the tautomeric and ionization states, and the 
determination of three-dimensional ring conformations at 
physiological pH. 
3. Application of rules to eliminate possible mistakes in the structures 
of the molecules. 
The described computational methodologies and approaches were widely 
applied in multi-step protocols adopted in this thesis, for the identification of 
new potent hits on the protein targets. A detailed description is reported in the 
next chapters. 
























-CHAPTER 3-  
Discovery of new inhibitors of 
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3.1 Microsomal Prostaglandin E2 Synthase (mPGES-1) 
Prostagrandin E2 Synthases (mPGES-1, mPGES-2, cPGES) are enzymes 
involved in the inflammatory response, since catalyze downstream the 
conversion of prostaglandin H2 (PGH2) in its isomer prostaglandin E2 (PGE2) 
(Figure 8), as described in the introduction of this thesis. Microsomal PGES-1 
is ubiquitous, but its concentration is up-regulated after exposure to various 
inflammatory stimuli and mediators, for example, cytokines (LPS, IL-1β and 
TNF-α).
126
 Different studies reported by Jackobsson et al.
127
 demonstrated its 
belonging to the superfamily of membrane-associated proteins involved in 
eicosanoid and glutathione metabolism (MAPEG),
128
 together with 5-
lipoxygenase-activating protein (FLAP), leukotriene C4 synthase (LTC4S) 





Figure 8 mPGES-1 in the inflammatory cascade. 
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3.1.1 Structure, Catalytic Mechanism and Binding Site 
The first structure was reported in 2008 by 3D-electron crystallography at 
low resolution,
130
 and Sjögren et al reported in 2013 the high resolution (1.16 
Å) X-ray crystal of mPGES-1 in the active conformation, in complex with its 
cofactor glutathione.
131
 Structurally, it is a membrane protein of 16 kDa with a 
total number of 153 amino acids in mouse and rat, and 152 amino acids in 
human because of the absence of the 11
th
 amino acid. The tridimensional 
disposition of the enzyme consists of a homotrimer in the endoplasmic 
reticulum membrane, and each monomer is organized in four helices, named 
TM1, TM2, TM3 and TM4. Three equivalent active sites are placed in the 
three monomers, within the membrane-spanning region at each monomer 
interface. Each active site is oriented towards the cytoplasmic part of the 
protein, between the N-terminal parts of TM2 and TM4 of one monomer and 









Figure 9 A) on the left, transparent molecular surface representation of mPGES-1, with chains 
A, B and C depicted in red, black, and blue ribbons, respectively; on the right, representation 
of the mPGES-1 binding site with the co-factor (GSH). B) on the left, mPGES-1 co-
complexed with LVJ inhibitor (PDB code: 4BPM, LVJ represented in sticks, C cyan, O red, N 
blue, polar H white, Cl green, F light green); on the right, 2D representation of LVJ and 
interactions with the residues in mPGES-1 binding site. 
 
According to Jegerschöld et al.,
130
 mPGES-1 has to perform a change from 
the closed to the open conformation in order to allow access of PGH2 to the 
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active site. In the last few years, the tridimensional X-ray structures of the 
enzyme have been crystallized in the open conformation. The investigation of 
the involvement of GSH cofactor in the catalytic mechanism by the replacing 
of cysteine residue by a serine residue in GSH molecule, confirmed the 
fundamental role of the thiol moiety in the conversion of PGH2 in PGE2.
132
 
The access of inhibitors is blocked by the so-called “gate keepers” (Thr131, 
Leu135 and Ala138, probably Arg52 and His53 too). Regarding Ser127 
residue, it was considered able to activate the thiol moiety of the cofactor for 
starting the catalytic cycle, but recent studies including a combination of site-
directed mutagenesis (Ser 127 has been replaced by an Alanine) and activity 
assays with a structural dynamics analysis, demonstrated Ser127 is not 
essential for catalysis.
132
 Conversely, similar investigations corroborated the 
crucial role of Arg126 and Asp49 in the catalysis. In details, the interaction 
between the positively charged Arginine and the negatively charged Aspartate 
is the key of the whole mechanism (Figure 10). Also, analysis of the active site 
showed that a water molecule forms a hydrogen-bonding network between the 
α-carboxylate and the thiol moiety of GSH, inducing the deprotonation of the 
latter and the formation of the thiolate which is stabilized by interaction with 
the guanidine moiety of Arg126. Two different mechanisms have been 
proposed (Figure 10): 
A. The thiolate attacks upon endoperoxide ring at the C-9 position, the 
O-O bond is cleaved, and S-O bond is formed. Simultaneously, 
Asp49 reduces the pKa of the C-9 proton, and this leads 
spontaneously to the yield of the PGE2 isomer. 
B. The thiolate as a base removes the C-9 proton, inducing the 
cleavage of the unstable O-O bond and the formation of the product. 









From a meticulous analysis of the binding site of the enzyme moving from 
the cytoplasmic to the opposite part of the membrane, three sub-regions 
including hydrophobic/polar residues have been identified: 
Results and Discussion 
47 
 
1. a groove between the GSH binding site and a region close to the 
cytoplasmic part (colored in green, Figure 9). Herein, mPGES-1 
known binders (co-crystallized LVJ, 4DV, 4DZ, 4U8, 4U9)
133
 
establish π-π contacts with aromatic residues, such as Phe44chain C, 
His53chain C. Polar interactions with Arg52chain C and Asp49chain C 
residues (the latter essential for mPGES-1 catalysis) located in this 
region, take part in the set of the key interactions with the enzyme.  
2. the cofactor binding region (colored in orange, Figure 9). In detail, 
the U-shape conformation of GSH stemmed from the interactions 
between its two terminal carboxylic functions and the positively 
charged residues Arg38 and Arg73 of chain C. Also, in this part of 
the protein is placed the Ser127 of chain A mentioned above. 
3. a binding groove between TM1 of chain C and TM4 of chain A 
(colored in yellow, Figure 9), with polar (Gln134ChainA), aliphatic 
(Val24ChainC) and aromatic residues (Tyr28ChainC and Tyr130ChainA). 
3.1.2 mPGES-1 inhibitors 
Considering the importance of the above described enzyme in the 
individuation of novel selective anti-inflammatory and anti-cancer drugs, 
several mPGES-1 inhibitors have been discovered and developed in the last 
years as result of long and difficult research works. Among these, only two 
inhibitors entered the clinical trials and none is in the market.  
Endogenous fatty acids (arachidonic acids, docosahexaenoic acid) and 
eicosanoids (leukotriene C4, PGJ2 and 15-deoxy-Δ12, 14-PGJ2) demonstrated 
in some studies the ability of weakly inhibit the activity of the enzyme,
134
 but 
the first synthetic inhibitor was the indole derivative MK-886 (Figure 11) 
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which has been discovered earlier as a FLAP inhibitor with an IC50 value of 
2.5 nM.
135
 Instead, the IC50 value presented in the cell-free assay on mPGES-1 
was higher (1.6 µM).
136
 Also, MK-866 inhibitor showed low activity in the 
whole blood assay and is able to interfere with the activity of COX-2 at higher 
concentration (8 µM). The MK-866 synthesized derivatives are more potent 
and selective than the starting compound. For example, the analogue reported 
in figure 10 showed an IC50 of 3 nM in the cell-free assay on mPGES-1, and a 










A chemical class of developed mPGES-1 inhibitors includes Phenanthrene 
imidazoles, characterized by a 2,6-dicyano-substituted phenyl ring at position 
2 of the imidazole. In detail, three inhibitors have been developed, presenting 
low values of IC50. Compound MF-63 (Figure 12) showed an IC50 of 0.42 μM 
in the A549 whole cell assay in the presence of 50% fetal bovine serum, and 
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an IC50 of 1.3 μM in human whole blood assay. Also, MF-63 inhibited the 
human mPGES-1 (IC50=1.3 nM) and presented a 1000-fold selectivity over 
mPGES-2, PGI2, PGD2 and TX synthases, and a similar selectivity was tested 
against COX-1, COX-2, 5-lipoxygenase (5-LO). It is also able to strongly 
inhibit guinea pig mPGES-1 (IC50=0.9 nM).
137
 Other inhibitors are 2,4 
biarylimidazoles (Figure 12, compound I) and trisubstituted ureas (Figure 12, 
compound II) that presented low IC50 value in both cell-free and whole blood 
assay. Compound AF3485 (Figure 12) is a benzoyl derivative of 3-
aminocarbazole. It showed promising value of IC50 in the in vitro assays 
versus human mPGES-1 expressed in bacterial membrane and microsomal 
PGES-1 in A549 cells, results confirmed by the cell-based assay. In the in vivo 
experimentation, its ability to contrast inflammatory pain in a dose-dependent 
manner in mice was demonstrated, and it presented high value of absorption 
by the intestinal barrier and high bioavailability. It is also able to reduce the 
level of PGE2 in A431 epithelial tumor cells, but the antitumor activity of this 
compound could be related to the inhibition of EGFR signaling.
138
 
Furthermore, the investigation of the activity of three imidazopyridine 
carboxamides led to the selection of compound III (Figure 12) as a very 
promising inhibitor, presenting an IC50 of 1 nM in the cell-free assay. Another 
important class of inhibitors consists of 2-arylamino benzimidazoles. This 
broad class of inhibitors includes a high diversity of the arylamino moiety. 
Unsuccessful, it was demonstrated that the compounds selected in the first step 
presented different results in the enzyme and cell-based assays, showing 
different potencies in the two tests. Thus, biological evaluation of another 
class of benzimidazole derivatives was carried out in 2012, and the most 
efficient inhibitors for mPGES-1 were discovered. The investigation of 
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derivatives bearing the 2,4-dichlorobenzyl pivalamide group (Figure 12, 
compounds IV and V) seems to have provided compounds presenting an IC50 
of 1 nM in the enzyme assay and IC50 less than 1 nM in the A549 cell-based 
assay. A further modification was the removal of the carboxamide residues of 
the benzimidazole ring, which afforded compound VI as an efficient mPGES-
1 inhibitor, showing an IC50 value of 1.3 nM. 
Considering another class of inhibitors, the introduction of the imidazole 
moiety on benzamides derivatives provided molecules with higher efficiency 
in the inhibition of the enzyme, as confirmed from different performed 
biological assays. Among these, compound VII (IC50=12 nM in ex vivo human 
whole blood assay) was submitted to the monoiodoacetate (MIA) in vivo 
model for knee pain in comparison with diclofenac, and both significantly 
reduced pain in a dose-dependent manner. It also presented absorption, 
distribution, metabolism and excretion properties and VII·H3PO4 was defined 
as proper for clinical development. Compound PF-4693627, a benzoxazole 
piperidine carboxamide, exhibited an IC50 value of 3nM in the cell-free assay 
and of 109 nM in the whole blood assay. This compound has been advanced in 
clinical studies for the treatment of rheumatoid arthritis and osteoarthritis.
139
 
Another interesting compound is the methyl-piperidine VIII in Figure 12, 
(IC50=1.93 nM in the cell-free assay, IC50=2 nM in human whole blood assay, 
IC50=4.71 nM in the cell-based assay). 
140
 
Bis-sulfonylamino derivatives were also developed for the target. In 









Figure 12 Known mPGES-1 inhibitors. 
 
Also, it is necessary to mention compound CAY10526 (Figure13), since it 
was used as a control in some biological assays performed on compounds 
developed in this thesis. It inhibits PGE2 production through the selective 








Figure 13 CAY10526 inhibitor. 
 
To date, two different compounds entered the clinical trials: 
1. GRC27864 (Figure 14) was developed by Glenmark and belongs to 
the substituted pyrimidine chemical class. It showed an IC50 value 
of 5 nM in the cell-free assay and 376 nM in human whole blood 
assay, and was able to interfere with the production of PGE2 in 
synovial fibroblasts and chondrocytes deriving from tissues affected 
by rheumatoid arthritis and osteoarthritis. Other biological assay 
demonstrated that it is also a potent inhibitor of recombinant guinea 
pig mPGES-1 enzyme (IC50=12 nM) and 1000-fold selective over 
COX-1, COX-2, mPGES-2, cPGES, PGI2, PGD2 and TXA2 
synthases and did not inhibit cytosolic phospholipase A2 
(cPLA2).
143
 It showed safety and no side effects in Phase 1 of the 
clinical trials, and is currently in phase 2. 
2. LY3023703, developed by Lilly, whose structure has not yet been 
disclosed. A group of 48 patients took part in the experimentation of 
the efficacy of the compound. In detail, mPGES-1 inhibitor, 
celecoxib (400 mg) or a placebo once a day for 28 days were 
administered. From the results, LY3023703 is more potent than 
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celecoxib in the inhibition activity of the enzyme. The identified 
side effects were diarrhoea, abdominal pain, and one of the patients 





Figure 14 GRC27864 mPGES-1 inhibitor. 
 
In this section only the most significant mPGES-1 synthetic inhibitors are 
reported.  
Regarding natural products (NPs), several compounds obtained from 
different plant species are able to inhibit the activity of mPGES-1. The 
suppression of PGE2 synthesis was observed in both cell-free and whole cell 
assay, with IC50 values close to low micromolar concentrations. Most of the 
reported natural mPGES-1 inhibitors also interfere with the activity of 5-LO at 
similar concentrations, confirming no selectivity for the enzyme. 145-148  
 














3.2 The importance of the research of new mPGES-1 
inhibitors 
The discovery of inhibitors of mPGES-1 is even more aimed, since its 
inhibition could be a new promising strategy for the treatment of inflammation 
in order to avoid the side effects connected to NSAIDs. Furthermore, the 












noteworthy. Considering its over-expression in a large number of tumors, it is 
















 etc.). For example, an important 
Results and Discussion 
56 
 
evidence of the involvement of mPGES-1 in cancer progression is its up-
regulation correlated with prognosis in late stages in colorectal cancer.
162
  
Moreover, a crucial point is the disclosing of selective inhibitors. Some 
binders, in fact, are endowed with a dual activity on both mPGES-1 and 5-
lipoxygenase (5-LO), the latter involved in the synthesis of leukotrienes. Also, 
quite few inhibitors present activity on other prostanoid synthases, such as 
mPGES-2, PGI2, PGD2 and TX synthases, or are able to interact and modulate 
the activity of COX-1 and COX-2. However, the dual activity on mPGES-1 
and 5-LO has been considered an innovative and effective strategy for the 
treatment of inflammation in the last few years.
163, 164
 
In the research group where this research work has been mostly carried out, 
several derivatives able to strongly inhibit the activity of the enzyme have 
been developed using computational chemistry techniques, whose grade of 
promiscuity demonstrates the key role of exploring different chemical items in 
order to increase the possibility of discovering new important hits (Figure 15).  
 
 
Figure 15 Examples of scaffolds of derivatives developed in the research group using 
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3.3 General workflow of the project and additional 
procedures 
The main part of the project is focused on a general workflow (Figure 16) 
which includes: 
1. The choice of a synthetic strategy, whose building blocks are used 
as a starting point for the in silico design of new large libraries of 
molecules, following a combinatorial chemistry approach. 
Afterwards, a multi-step computational protocol is applied to the 
generated libraries for the selection of the most promising according 
to the virtual docking studies on the protein target (phase 1). 
2. Synthesis of the molecules applying the selected synthetic route and 
purification of the crude by flash chromatography, HPLC (high 
performance liquid chromatography) and crystallization techniques; 
characterization of the synthesized molecules by nuclear magnetic 




C NMR, COSY 
experiments and by ESI-HRMS (high resolution electrospray 
ionization mass) and LC-MS (Liquid Chromatography Mass 
Spectrometry) (phase 2). 
3. Biological assays on the targets and cell line tests for the 
experimental evaluation and quantification of the activity of the 
synthesized molecules. If the compounds are able to interfere with 
the functions of the protein target, they are the starting point for an 
optimization step, with the goal of improving their pharmacokinetic 
properties or their performance in the modulation of the activity of 
the protein. This may include a second application of the multi-step 
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computational protocol using a combinatorial or a 3D-QSAR (three-
dimensional quantitative structure-activity relationships) 
approach
167
 for the generation of analogues of the new disclosed 
hits. Instead, if the results show an inability to inhibit the activity or 
a very low inhibition, the protocol foresees a “recycling” (namely a  
repurposing) of the synthesized compounds. A computational 
technique named Inverse Virtual Screening, 
168
 developed in the last 
years in the research group in which the whole research project was 
carried out, is very useful for the individuation of a specific target in 
a panel of targets. Briefly, Inverse Virtual Screening
168
 is an inverse 
screening in which a molecule or a small set of molecules are 
docked versus a panel of proteins involved in the development of 
cancer and inflammation. Thus, this approach is the opposite of the 
direct virtual screening in which a large library of compounds is  












Figure 16 General Workflow. 




Also, the workflow consists of the application of other specific multi-step 
computational protocols on large libraries of commercially available 
compounds in order to individuate interesting novel scaffolds involved in the 
inhibition of the enzyme (Figure 16, red box). A detailed example is reported 
in chapter 4 of this thesis. 
Finally, an important place in the computational developed studies was 
occupied by docking analysis of small libraries of commercially available 
compounds on the biological target (Figure 16, blue box) in order to 
rationalize the activity presented in biological assays (chapter 5). Also in this 
case, the research work continued with an optimization campaign on the 
disclosed novel biologically active compounds, as described previously.  
The reason for defining “additional procedures” the last two points (red and 
blue boxes) is not related to the importance of the discovery. This preference 
in the classification derives from a distinction between the main scheme which 
most of the research project was based on, and these second activities that 
gave very interesting results. 
3.3.1 Selection of the scaffold  
The design of new compounds potentially able to inhibit the activity of 
microsomal prostaglandin E2 synthase as a new promising anti-inflammatory 
and anti-tumor drugs started with the selection of “privileged scaffolds”. This 
definition was described by Evans in 1998 and indicates specific building 
blocks consisting of different ring systems (either heterocyclic or not, 
saturated or aromatic) as a source for an appropriate functionalization and 
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production of molecules targeting a broad variety of receptors, and that 
perform different biological activities.
164
 
A previous knowledge of existent modulators reported in literature and a 
detailed study of their pharmacodynamic and key interactions with the 
receptor counterpart are essential in the choice of new scaffolds as a starting 
point for the individuation of new hits. 
Since the large number of compounds targeting mPGES-1 developed so far 
is characterized by structural and pharmacokinetic properties with an extensive 
variability, this research project aimed to approach different categories of 
scaffolds to evaluate their ability to inhibit the activity of the protein. Also, 
this approach was employed to expand the probability to discover hits with a 
considerably increased activity in comparison to known inhibitors. According 
to the importance of heterocyclic compounds in medicinal chemistry in the last 
few decades, several heterocyclic cores have been considered.
169
 
3.3.2 Selection of the chemical route 
A study of the possible chemical routes for each scaffold was useful to 
select a very efficient and fast method for the synthesis of the final selected 
compounds and to individuate the commercially available synthons for the 
design phase. At this point, it is important to emphasize that the choice of the 
methods for the synthesis and the generation of libraries of molecules are 
strongly connected since the synthons of the synthetic strategy are the building 
blocks of each designed compound. 
3.3.3 Multi-step computational protocol 
Before starting the discussion concerning the obtained results, it is 
appropriate to introduce the adopted computational protocol which the main 
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part of the developed research project was based on. The aforementioned 
combinatorial computational approach allows the design of a large number of 
potentially biologically active compounds with a substantially lower time 
needed in comparison to the classical QSAR methods. However, a QSAR 
approach is also suitable in the optimization phase, in order to improve the 
biological activity of the new discovered hit compounds (see section 3.3). 
The applied computational method is represented in figure 17, and is based 
on a sequence of techniques described above (see chapter 2). In detail, two 
phases can be distinguished:  
1) Selection of the scaffold and generation of new libraries of 
molecules containing drug-like compounds. Combiglide
112, 113
 was 
used for the generation of all the possible compounds deriving from 
the combination of the commercially available reagents with the 
core, according to the selected synthetic route. LigPrep
123, 124
 
includes all protonated states at physiological pH, tautomers and 
stereoisomers. Regarding QikProp,
110, 111
 it was applied for the 
prediction of pharmacokinetic parameters, such as evaluation of 
Lipinski rule, logP, permeability through Caco-2 cell lines, toxicity 
against HERG K
+
 channel, permeability through the blood-brain 
barrier (BEE), in order to modify the number of all the possible 
synthesizable compounds to a lower number of synthesizable drug-
like compounds. LigFilter
117, 118
 was applied to define certain 
restrictions: 
 150 <= MW <= 500;  
 –3 <= logPo/w <= 6.5;  
 logS>= –7;  
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 reactive groups = 0 
2) Docking analysis on the built new libraries for the selection of the 
best candidates by means of virtual screening workflow (VSW, 
Glide software). 
83-87, 117, 118
 The latter is a computational method for 
the screening of large libraries of ligands versus one or more 
biological targets. Generally, the ligand files for the docking 
analysis is previously prepared using several software described 
above. If a file with 2D structures is used, it is possible to run the 
LigPrep to obtain the MAE format, since the workflow contains a 
Ligand Preparation and a Filtering part as well. Since in this case 
the preparation of the libraries and the application of filters was 
performed separately, the virtual screening workflow was restricted 
to the docking analysis. The docking path works at three different 
levels, which operate with a gradually increasing precision: 
 HTVS (high throughput virtual screening) 
 SP (standard precision) 
 XP (extra precision) 
For each level, it is possible to keep a percentage of top-ranked 
poses using docking score as a selection parameter. The selected are 
then submitted to the next docking step, which outperforms the 
previous for both sampling and scoring. The analysis of the final 
screened compounds is based on the interactions with the receptor 
counterpart, binding energy, superimposition with a known binder 
that is co-crystallized in the three-dimensional crystal structure of 
the protein available in the protein data bank (PDB) database. 
 





Figure 17 Multi-step computational protocol. 
 
3.3.4 Synthesis of the molecules selected via structure-based 
drug design 
The selected chemical routes were applied for the synthesis of the 
compounds generated and filtered via structure-based drug design. In some 
specific cases, the synthetic procedure has been slowed down by several 
issues, concerning the solubility or the reactivity of the involved reagents. 
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Based on the analysis of the specific chemical conditions, the reaction 
optimization was very useful to overcome the limitations and for the 
obtainment of the desired products. 
In total, 42 molecules have been synthesized as promising inhibitors of 
mPGES-1. 
3.3.5 Biological evaluation of mPGES-1 inhibition 
A cell-free assay was performed on the synthesized compounds in 
collaboration with Prof. Oliver Werz of the University of Jena (Germany).
170
 
For the performance of the enzyme assay, A549 human lung epithelial cancer 
cells are treated for 48 h with interleukin-1β (1 ng/ml) and the expression of 
mPGES-1 is induced. Centrifugation and resuspension in a buffer solution of 
the microsomal fraction are carried out, the total protein concentration are 
determined, and microsomes are diluted in potassium phosphate buffer (0.1 M, 
pH 7.4) containing 2.5 mM glutathione. Then, the test compounds are added 
and incubated at 4 °C for 15 min. A 20 µM PGH2 solution is used for starting 
the reaction, which is stopped after 1 min adding the stop solution (40 mM 
FeCl2, 80 mM citric acid, and 10 µM 11β-PGE2). Solid-phase extraction and 
RP-HPLC (reverse-phase high performance liquid chromatography) are used 
for the determination of the amount of PGE2 which defines the percentage of 
inhibition activity of the enzyme in the presence of the test compounds.
170
 
In order to deeply investigate and confirm the inhibition activity presented 
in the cell-free assay, the effect of the test compounds on PGE2 production in 
cells was evaluated. In details, interleukin-1β-treated A549 cells were 
incubated for 24 h with the test compounds and the amount of PGE2, secreted 
into the culture medium, was measured using ELISA assay. Furthermore, in 
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order to ensure that the PGE2 reduction of the active compounds derives from 
the inhibition of the activity of mPGES-1 and not from compound-induced 
cytotoxicity, the cell viability was examined using MTT assay. 
Also, the anti-proliferative or cytotoxic effects of the active compounds 
were evaluated on A375 human melanoma cells. It was demonstrated that in 
this cell line mPGES-1 is over-expressed, and its inhibition blocks the 
melanoma cell survival.
171
 The cells were incubated for 72 h with increasing 
concentrations (from 5 µM to 150 µM) of compounds and cell viability was 
investigated by means of MTT assay. The known inhibitor CAY10526, which 
is a selective modulator of mPGES-1 and does not interfere with COX-2 
activity,
142
 was used as a control in the experiments. Finally, the analyses of 
the cell cycle progression of A375 cancer cells was performed on the 
compounds able to inhibit cell proliferation or to induce cell death. The cell 
line was treated with concentrations close or higher to the IC50 values of the 
compounds, and the flow cytometry analysis was used for the determination of 
the cell cycle progression and the apoptosis induction. 
Detailed results of the mentioned performed biological assays on the 
synthesized molecules will be reported in the following sections, with explicit 
reference to the individual chemical class. 
3.4 Application of the protocol with 2-amino-1,3-
benzothiazole and 2-amino-1,3,4-thiadiazole items 
One of the scaffolds selected for the generation of new large libraries of 
molecules using a combinatorial approach is the 2-aminobenzothiazole 
building block (Figure 18), due to its incidence in antitumor, anti-
inflammatory and antibacterial agents and other biologically active 





 Furthermore, the synthetic versatility and accessibility of this 
scaffold is noteworthy, and a wide range of chemical routes for the generation 
of derivatives has been explored and optimized, taking into account the 
possibility to use it as both reactant and reaction intermediate; the presence of 
NH2 group and endocyclic N functions, in fact, may assist reactions with 
common bis electrophilic reagents to form a diverse fused heterocyclic 
scaffold.
169
 Also, other recent studies demonstrated that molecules with a 2-
aminothiazole moiety are able to inhibit the activity of the enzyme in vitro.
175
 
In light of this, the 2-aminobenzothiazole has been chosen to explore the 
ability of its derivatives to inhibit the activity of the enzyme, with the 




Figure 18 From 2-aminothiazole to 2-aminobenzothiazole. 
 
A compared rationalization was adopted in the choice of the 2-amino-1,3,4-
thiadiazole (Figure 19) according to the biological activity of 2-aminothiazole 
compounds. 





 (Figure 20) co-crystallized in 2016, it seemed appropriate to modify 
the disposition of the molecular moieties, in order to further optimize the 
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distances between the compound and the key amino acids of the active binding 
site.  
The translation of the aromatic moiety from position 4 to position 5 of the 
2-aminothiazole, and the insertion of the nitrogen on the aromatic ring at 
position 4 afforded the new scaffold for the design of new potential hits 
(Figure 19). In this way, the nitrogen could be potentially able to establish 
additional hydrogen bonds with the receptor counterpart and induce a three-
dimensional conformation such that the substituted aromatic ring gets able to 
interact with Tyr130 and Gln134 by π-π and other specific interactions, 
according to the importance of these amino acids in the binding mode of 
known inhibitors. 
 
Figure 19 From 2-amino-1,3-thiazole to 2-amino-1,3,4-thiadiazole. 
 





Furthermore, the broad diffusion of several isomers (Figure 21) of 1,3,4-
thiadiazole in the pharmaceutical field and the vast spectrum of 
pharmacological activities led to the selection of this scaffold for the 
application of the computational protocol used for the individuation of new 
hits. 
 
Figure 20 Binding mode of ligands 4UJ (A) and 4UK (B) in the binding site of mPGES-1. 





Thiadiazole scaffold is involved in analgesic, antidepressant and anxiolytic, 
antihypertensive, anticonvulsant, anti-inflammatory and anaesthetic 
activities.
177
 The pharmacological profile was attributed to the presence of the 
portion -N=C-S,
178
 but the isosterism is also noteworthy. The 1-3-4-
thiadiazole, in fact, is the bioisoster of pyridazine, which is implicated in 
different pharmacological activities. (Figure 22).
177
 In particular, the main 
reason for the choice of the thiadiazole instead of the pyridazine scaffold is 
focused on the lipophilicity-hydrophilicity balance, as the substitution of –
CH=CH moiety with –S increases the lipophilic properties. These 






Figure 22 Bioisosters. 
 
Figure 21 1,3,4-thiadiazole scaffold and its isomers. 
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An important factor is the possibility of 1,3,4-thiadiazole derivatives to 
produce mesoionic salts (Figure 23), which consist of a pentatomic 
heterocyclic ring endowed with a positive charge counterbalanced by a formal 
negative charge. The formation of these salts improves the ability of 
interaction with biological macromolecules (for example, DNA and proteins) 





Figure 23 Mesoionic salt. 
 
The 2-amino-1,3,4-thiadiazole derivatives are the most promising and 
studied, considering the experimented cytostatic activities of this core and the 
reactivity of the amine group.
177
 According to the considerations above, the 2-
amino-1,3,4-thiadiazole building block is an excellent candidate for the design 
of potential hit compounds.  
3.4.1 Synthetic strategy for 2-amino-1,3-benzothiazole and 2-
amino-1,3,4-thiadiazole derivatives 
For the synthesis of 2-aminobenzothiazole and 2-amino-thiadiazole 
derivatives, the same chemical route was selected. In both, a two steps strategy 
was chosen: a Suzuki-Miyaura reaction and a nucleophilic substitution, 
inverted on the case according to the synthetic accessibility. In particular, 
starting from 2-amino-5-bromobenzothiazole, 2-amino-6-bromobenzothiazole 
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and 2-amino-5-(4-bromophenyl)thiadiazole starting materials (Figure 24, A, B 
and C respectively) the strategy provided the coupling on the aromatic ring 
bearing the bromine using boronic acids and a nucleophilic substitution 
reaction on acyl chlorides with the amino group. 
 
 
Figure 24 A) 2-amino-6-bromobenzothiazole, B) 2-amino-5-bromobenzothiazole; C) 2-
amino-5-(4-bromophenyl)thiadiazole starting materials. 
 
The Suzuki-Miyaura reaction was first published in 1979 by Akira 
Suzuki,
179-181
 and improved in the following years modifying base, 
temperature and solvent conditions. It is a coupling reaction between an 
organohalide (alkenyl, vinyl, aryl halides) and a boronic acid (organometallic 
compound), catalyzed by a palladium (0) complex in basic conditions, which 
lays to the formation of C-C bonds (Figure 25). Considering the efficiency and 
versatility of this reaction, and the stability and low toxicity of the 
organometallic partner in comparison to others, it is often applied for the 




Figure 25 Suzuki reaction between boronic acid (R1-BY2) and halide (R2-X). 
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The use of palladium is related to its characteristics, as it has an 
electronegativity similar to the carbon. The bond C-Pd, in fact, is quite strong 
due to its poor polarity. In the Suzuki reaction, palladium (Pd) takes part in the 





Figure 26 Catalytic cycle of Suzuki reaction. 
 
The oxidative addition is the rate determining step of the reaction. During 
this step, palladium is oxidized from palladium (0) to palladium (II) and is 
coupled with the alkyl halide forming an organopalladium complex, in which 
it is placed between the halogen and the R2 group (Figure 27). The reaction 
time is determined by the halogen, according to the scale of halogen reactivity: 
I >OTF> Br >> Cl.  
 








The second step is the transmetalation, which consists of an exchange of 
ligands between two chemical species (Figure 28). In particular, in this case 
the organic moiety of the boronic acid switches to the organopalladium 
complex, giving the final R2-Pd
II
-R1. A detailed mechanism of the 
transmetalation phase is not known to date. Moreover, the presence of the base 
is essential, since it plays an important role in the activation of the 
organoboron compound as well as is involved in the formation of R2-Pd
ll
-
OtBu complex, from which the resulting complex is formed.  
 




The third step is the reductive elimination in which the palladium (II) 








Figure 29 Reductive Elimination and formation of the product (R1-R2). 
 
3.4.2 Generation of libraries of 2-aminobenzothiazole and 2-
aminothiadiazole derivatives 
Based on the application of the multi-step computational protocol, a set of 
different libraries was built starting from the selected cores.  
Benzothiazoles. Starting from the synthons of the selected synthetic 
strategy, Combiglide
112
 was used for the decoration of 2-amino-6-
bromobenzothiazole and 2-amino-5-bromobenzothiazole with 318 acyl 
chlorides at position 2 and 570 boronic acids at position 5 and 6 respectively. 
After the combination of the scaffold with the prepared reagents (Figure 30) 
two large libraries were obtained:  
1) 2-arylacylamino-6-arylbenzothiazoles (A) 
2) 2-arylacylamino-5-arylbenzothiazoles (B) 
each containing 181,260 molecules. Then, the libraries were processed with 
LigPrep,
123
 in order to generate all the possible stereoisomers, tautomers and 
protonation states at a pH of 7.4 ± 1.0. The application of QikProp
1 1 0
 
for the determination of pharmacokinetic parameters and 





 (150<MW<500, –3<=logPO/ W<=6.5, logS >= –7, 
reactive groups=0) afforded the final libraries A and B. 
 
 
Figure 30 Generation of two libraries: A)2-arylacylamino-6-arylbenzothiazoles from 2-
amino-6-bromobenzothiazole; B)2-arylacylamino-5-arylbenzothiazoles from 2-amino-5-
bromobenzothiazole. 
 
Thiadiazoles. The same reagents prepared for the generation of the 
previous libraries were used for the decoration of 2-amino-1,3,4-thiadiazole 
core. A library of 181,260 N-(5-(4-arylphenyl)-1,3,4-thiadiazol-2-





 calculations and the same filters enumerated above were 
applied, obtaining the resulting library C. 
 




Figure 31 Generation of a library of N-(5-(4-arylphenyl)-1,3,4-thiadiazol-2-
yl)arylcarboxamides starting from 2-amino-1,3,4-thiadiazole (C). 
 
3.4.3 2-aminobenzothiazole and 2-aminothiadiazole 
derivatives targeting mPGES-1 
The second phase was the structure-based virtual screening of the libraries 
on mPGES-1. Semi-flexible docking experiments were carried out on the three 
libraries of compounds. The screened molecules were analyzed considering 
docking score, binding mode and interactions established with the receptor 
counterpart, basing on the reported key interactions.
165, 182, 183
 In total, 13 
benzothiazole (Figure 32) and 9 thiadiazole (Figure 33) derivatives were 
chosen for the synthesis and the biological evaluation of their anti-
inflammatory/anti-tumor activity, inhibiting mPGES-1. 




Figure 32 2-amino-1,3-benzothiazole derivatives selected for mPGES-1 via structure-
based drug design. 
 
Figure 33 2-amino-1,3,4-thiadiazole derivatives selected for mPGES-1 via structure-based 
drug design. 
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Among them, a representative description of the binding mode in the active 
site of the novel ligands series is reported, taking into account the most 
promising compounds: compound 3 for the 2-aminobenzothiazole item and 
compound 18 for the 2-aminothiadiazole item.  
Considering compound 3, the 2-amino-6-bromobenzothiazole scaffold 
centers the ligand binding site along the three different regions (see section 
3.1.1), establishing contacts and interactions with aromatic and polar residues. 
For this specific molecule, the substituents decorating the scaffold perform 
peculiar contacts: a) bromine atom establishes halogen bonds with Thr34ChainC 
and Asn46ChainC (Figure 35); b) -OH group is able to interact with 
Gln134ChainA, Tyr130ChainA and Ile32ChainC by hydrogen bonds, while -NH 
group of the amide establishes hydrogen bond with Ser127ChainA; c) 
benzothiazole interacts with Tyr130ChainA and the other aromatic rings with 
Tyr130ChainA and His53ChainC respectively, all of them by π-π stacking 
interactions (Figure 34). 
 




Figure 34 2D panel representation of compound 3 in the ligand binding site of mPGES-1. 
Positive charged residues are colored in violet, negative charged residues are colored in red, 
polar residues are colored in light blue, hydrophobic residues are colored in green. The π-π 






Figure 35 Three-dimensional representation of compound 3 in the active binding site of 
mPGES-1. Purple lines represent specific halogen bonds with the receptor counterpart. A 
selective representation of halogen bond interactions is reported. 




Regarding the thiadiazole moiety of compound 18, it is placed in the middle 
of the ligand binding site and interacts with the closest key amino acids 
(Gly35ChainC, Ser127ChainA) by hydrogen bonds. The centered position is 
retained in all the selected compounds, with a peculiarity in the interactions of 
the substituents with the receptor counterpart. The aromatic rings are able to 
establish π-π stacking interactions with His53ChainC on the cytoplasmic region 
and with Tyr130ChainA on the other side. In this case, the bromine on the amidic 
moiety of the molecule establishes halogen bonds with Asn46chainC (Figure 
37), while the amino group interacts with Tyr130ChainA and Gln134ChainA by 
hydrogen bonds (Figure 36). 
 
Figure 36 2D panel representation of compound 18 in the ligand binding site of mPGES-1. 
Positive charged residues are colored in violet, negative charged residues are colored in red, 
polar residues are colored in light blue, hydrophobic residues are colored in green. The π-π 
stacking interactions are indicated as green lines, and H-bond are reported as dotted pink 
arrows. 
 





3.4.3.1 Pan-Assay Interference compounds (PAINS) screening 
A current problem in drug discovery is the existence of chemical species 
able to not specifically bind numerous biological macromolecules, thus giving 
false positives in high-throughput screens. A preliminary computational tool 
focused on the prediction of ADME parameters was used in order to avoid this 
specific issue. SwissADME
184
 web tool evaluates the presence of chemical 
moieties belonging to “Pan-Assay Interference Compounds” (PAINS) 
chemical class, implemented from the paper by Baell et al. 
185
  
Since the promiscuity of 2-aminothiazoles is well-known, selected 2-
aminobenzothiazole (1-13) and 2-aminothiadiazole (14-22) based compounds 
were analyzed with SwissADME in order to apply a further filter focused on 
PAINS identification. All the molecules belonging to the small library selected 
for the synthesis (1-22) passed the filter, as they do not contain PAINS. 
Figure 37 Three-dimensional representation of compound 18 in the active binding site of mPGES-1. 
Purple lines represent specific halogen bonds with the receptor counterpart. A selective 
representation of halogen bond interactions is reported. 
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3.4.4 Synthesis of 2-amino-1,3-benzothiadiazole derivatives 
It is possible to distinguish three different groups in the 13 benzothiazoles 
candidates for the synthesis, according to the chemical structure of the 
coupling partner. The first two groups are different for the position of the 3-
(hydroxymethyl)phenyl moiety on the benzothiazole since one shows the 
substituent at position 6, the other one at position 5 (Figure 38). The third 
class, instead, contains a 3-aminocarbonylphenyl substituent at position 5 
(Figure 38). 
In the synthesis of the 13 molecules, two different commercially available 
starting materials were used: 2-amino-6-bromo-1,3-benzothiazole for the first 
group, and 2-amino-5-bromo-1,3-benzothiazole for the second and third 
groups. Suzuki coupling reaction was performed at position 6 of the 
benzothiazole using 3-(hydroxymethyl)phenylboronic acid for the synthesis of 
compounds 1-6, and at position 5 for the synthesis of compounds 7-10 (Figure 
39). The cross-coupling was performed under standard conditions using 
Pd(PPh3)4 as catalyst (0.2 eq.) and aqueous carbonate as base (3.0 eq.) in a 
mixture of dioxane (80%) and water (20%) at 80 °C. Reactions afforded the 
product with good yields (75% and 88%). 
 
 





Figure 38 Three groups of selected compounds. 
 




Figure 39 Coupling reaction for the synthesis of 23 and 24; i: Pd(PPh3)4, K2CO3, H2O-Diox, 
80°C. 
 
Then, the proper acylation reaction was performed on the resulting 
intermediates 23 and 24 to obtain compounds 1-6 and 7-10 respectively. 
Moreover, the hydroxyl group of the two Suzuki intermediates could perform 
a substitution reaction on the acyl chloride. A transient protection by 
trimethylsilyl ether was performed in situ in dry acetonitrile with pyridine at 
room temperature, before adding the proper acyl chloride in the reaction 
mixture. The protective group was then removed with acidic work-up (Figure 
40). 




Figure 40 Acylation reaction for the synthesis of the final products 1-6 and 7-10; ii: 
pyridine, CH3CN dry, TMSCl, r.t. 
 
 
Compounds 11-13 belonging to the third group were synthesized inverting 
the sequence of the reactions, considering the less polarity of 25, 26 and 27 
intermediates and a consequent easier purification. The acylation reaction with 
the proper acyl chloride was the first step, conducted in dry acetonitrile with 
pyridine at room temperature. Then, a coupling with 3-aminocarbonylphenyl 
boronic acid was carried out on the acylated intermediates (Figure 41) to 
afford 11-13.  
All compounds were purified by reversed phase HPLC (high performance 
liquid chromatography) or by flash column chromatography, and were 
obtained with >98% purity. 
 




Figure 41 Suzuki reaction on the acylated intermediates 25, 26 and 27 for the synthesis of the 
final products 11-13; ii: Pd(PPh3)4, K2CO3, H2O-Diox, 80°C. 
3.4.5 Biological evaluation of benzothiazole derivatives 
The cell-free assay on mPGES-1 expressed in IL-β-treated A549 cells was 
performed on compounds 1-13.
170
 The benzothiazole derivatives bearing the 
(hydroxymethyl)phenyl moiety at position 5 (7-10) showed a residual activity 
higher than 30% at 10 µM. The replacement of the (hydroxymethyl)phenyl 
with 3-aminocarbonylphenyl group at position 5 of compounds 9 and 10 did 
not provide an improvement of the results, since compounds 11 and 12 
presented a comparable inhibitory activity. Conversely, the introduction of a 
4-fluoro-2-(trifluoromethyl)phenyl acyl group in compound 13 of this series 
showed better results, with an IC50 value of 1.7±0.2 µM. The introduction of 
the (hydroxymethyl)phenyl at position 6 afforded an improved inhibitory 
activity, as it was demonstrated in the cell-free assay on compounds 1 and 3. 
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Moreover, the presence of a pyridine acyl group provided a reduction of the 
activity in compounds 4 and 5, whereas the 2,5-dimethylfuran in compounds 6 
determined an IC50 value of 2.6±0.1 µM. Thus, compounds 1, 3, 6 and 13 
presented a promising inhibitory activity in the enzyme assay on mPGES-1. 
Selectivity studies are in progress for the most promising compounds, in 
order to investigate the possibility of modulating the activity of COXs and 5-
LO. 
According to the cell-based assay performed on IL-β-treated A549 cell 
lines, a reduction of PGE2 production into the culture medium was 
demonstrated with compounds 1, 3, 6 and 13, and interestingly with 
compound 9 in a concentration-dependent manner. The MTT assay confirmed 
the reduction of PGE2 is not dependent from compounds cytotoxicity, since 
there was not a significant difference in cell viability with respect to control 
group. Compound 9 showed inhibition of 20% of cell viability at 10 µM and 
the PGE2 production value was normalized taking into account the percentage 
of cell viability. 
In light of this, in order to deeply understand the activity of the test 
compounds 1, 3, 6, 9 and 13, their effect on cancer cell viability and on cell 
cycle progression were evaluated in A375 human melanoma cells (see section 
3.3.5, biological assay for details). All the compounds inhibited the cancer cell 
vitality according to the MTT proliferation assay. In detail, the compounds 1, 
3, 9 showed the best IC50 values of 18.3 ± 1.5, 12.1 ± 0.8 and 20.3 ± 1.1 µM, 
respectively, while IC50 value for CAY10526 under the same conditions was 
4.7 ± 0.5 µM.
148
 In the flow cytometry analysis for the investigation of their 
effects on the cycle progression, 1 and 9 displayed a cytostatic activity in time 
and dose-dependent manner with a G0/G1 or S phase arrest, respectively 
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(Figure 43, A and C). Compound 1 induced a modest apoptotic effect after 48h 
or after 72h at high concentration, whereas compound 9 did not induce cell 
death (Figure 43, A and C). Conversely, compound 3 caused both cytostatic 






























Table 3 IC50 values deriving from the cell-free assay. 
Figure 42 Cell-based assay on IL-β-treated A549 cell line. 





Compound IC50 ± SD (µM) 
1 18.3 ± 1.5 
2  98.2 ± 1.3 
3  12.1 ± 0.8 
6  90.5 ± 1.4 
7  46.0 ± 1.4 
8  42.5 ± 1.7 
9  20.3 ± 1.1 
10  97.5 ± 1.9 
12  31.3 ± 1.7 
13  41.7 ± 1.3 
CAY10526 4.7 ± 0.5 
 
Table 4 Anti-proliferative effect of mPGES-1 inhibitors in A375 human melanoma cancer cell 
line. 
 




Figure 43 Cell cycle progression analysis by flow cytometry. 
3.4.6 Synthesis of 2-amino-1,3,4-thiadiazole derivatives 
The 2-amino-1,3,4-thiadiazole derivatives selected in the virtual screening 
workflow can be classified into two different groups: the first one bearing a 2-
aminophenyl and the second one a 3-hydroxyphenyl as coupling partner 
moiety (Figure 44). In the second group, four acyl chlorides (R1) of the first 
group are involved in the substitution reaction. 





Figure 44 On the left, the group of selected compounds bearing the 2-aminophenyl moiety; on 
the right, the group bearing the 3-hydroxyphenyl moiety. R1=Acyl chlorides moiety. 
 
As in the synthetic procedure of 2-aminobenzothiazole derivatives, the 
synthesis adopted for the 9 thiadiazolic compounds consists of the same two 
main steps. Starting from 2-amino-5-(4-bromophenyl)thiadiazole, the general 
route provides the acylation reaction on the amino group, followed by the 
Suzuki-Miyaura coupling on the 4-bromophenyl ring (Figure 45). 
 
Figure 45 General synthetic route (compounds 14-17). 




Among the 9 selected compounds, 14-17 were synthesized retaining the 
same sequence of reactions. In the synthesis of the rest of the molecules, an 
inversion of the steps was adopted, performing the coupling in the first step 
and the acylation reaction in the second step. The halogens on the aromatic 
rings of the acylated intermediates, in fact, would have been able to interfere 
with the coupling on the phenyl ring of the 2-amino-5-(4-
bromophenyl)thiadiazole, considering mainly the high reactivity of bromine. 
Also, the nucleophilic groups (-OH, -NH2) of the two Suzuki intermediates 
may be involved in the substitution reaction of the acyl chloride. The use of 
protective groups, with a further step for the final deprotection, was essential 
to avoid this problem. For the analogues bearing an amino group, the tert-
butoxycarbonylamino (Boc) protected boronic acid, commercially available, 
was used in the first step (Figure 46). After the acylation step with the proper 
acyl chloride, the protecting group was removed with a mixture of DCM 
(50%) and TFA (50%) stirring over three hours at room temperature, and the 
final compounds were obtained. 
In the synthesis of the analogues with the hydroxyl group, the intermediates 
deriving from the coupling reaction were protected with TMSCl (trimethylsilyl 
chloride), and the acyl chlorides were added in situ. The following acidic 
work-up removed the trimethylsilyl protecting group, affording the desired 
products (Figure 46). 





Figure 46 Synthetic strategy for compounds 18-22. 
 
Another important problem observed in the synthesis of 2-aminothiadiazole 
derivatives is related to the tautomeric equilibrium (Figure 47). Amino-
heterocycles, in fact, may exist in two tautomeric forms: amino (A) and imino 
(B). In the last few years, different experiments demonstrated that the 
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tautomerism affects the orientation of the substitution and increases the 




Figure 47 Tautomeric equilibrium of 2-aminothiazole. 
 
In light of the peculiarity of this class of compounds, the acylation step in 
the synthesis of 2-amino-1,3,4-thiadiazole derivatives represented a limitation 
in the synthetic route. In this case, in fact, the reaction may afford two 
different products, as demonstrated by NMR and LC-MS analysis:  
1. The product bearing the amidic group at position 2 of the 
thiadiazole, deriving from the substitution of the amino group. 
2. A product deriving from a double acylation, in which a further 
substitution reaction on the nitrogen at position 3 of the thiadiazolic 
ring provides a di-amide. 
 
Figure 48 Tautomeric equilibrium leading to double acylation. 
 
For this reason, the reaction gave the product with low yields (10-20%). In 
order to optimize the yields, a reduction of reaction time was adopted, and a 
considerable increase of the desired product was observed. 
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3.4.7 Biological evaluation of thiadiazole derivatives 
Among the synthesized compounds reported above, the cell-free assay
170
 
was performed on 14 and 16-20, and is in progress for the remaining 
compounds. All test compounds presented a residual activity higher than 30% 
at 10 µM. Compounds 18-20 showed a promising IC50 value. Furthermore, the 
cell-based assay on A549 cell line was performed on 15 and 18-22. 
Compounds 18-20 confirmed the results of the cell-free assay, while 
compound 22 presented an interesting high inhibitory activity (Figure 49, A). 
A further performed analysis was the cell viability assay (MTT). Human 
fibroblast cells were incubated with DMSO or compounds 18-20 and 22 at 10 
µM or 50 µM for 24 hours. No cell viability inhibition was observed for all 







Table 5 IC50 values deriving from the cell-free assay. 
 
 








Figure 49 A) Cell-based assay on IL-β-treated A549 cell line; B) Cell viability assay on 
human fibroblast cells (10 µM or 50 µM). 
 
3.5 Application of the protocol with 2-carboxamide 
pyrrole 
A pyrrolic scaffold was also chosen as a new promising mPGES-1 targeting 










In a research work developed in 2012,
192
 a set of different pyrroles was 
synthesized and tested on mPGES-1. Starting from the 4-acylpyrrol-2-
ylpropionic acid (Figure 50), a known inhibitor of mPGES-1 with an IC50 
value of 0.80 M, the synthesis of analogues was carried out in order to obtain 
compounds with an improved activity on the enzyme. In details, the 
modifications provided the variation of the dodecanoyl residue, the 
substitution of the methyl groups with hydrogen, phenyl and benzyl, length 
modifications of the acid chain, and bioisosteric replacement of the carboxylic 
acid group. In spite of the large number of synthesized analogues, quite a few 
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of pyrrole derivatives were able to inhibit the activity of the target.
192
 Also, it 
was demonstrated that such flat structures are nuisance inhibitors of mPGES-
1, since they lost activity at 10 M in the presence of Triton X-100.  
In this research project, other modifications of the pyrrolic scaffold were 
explored in order to overcome the issues above, and a rationalization of the 
binding mode of the pyrrole alkanoic acid derivatives reported in Table 6 was 
carried out, in order to compare them with the new pyrroles selected via 
structure-based virtual screening. 
 
 
Figure 50 3-(4-dodecanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid, mPGES-1 
inhibitor (IC50 = 0.80 M). 
 
In particular, the 2-carboxamide pyrrole building block was considered for 
the design of derivatives, due to its incidence in a broad range of 
pharmacological activities, such as antimicrobial and antifungal.
188, 193, 194
 
3.5.1 Synthetic strategy for 1H-pyrrole-2-carboxamide 
derivatives 
The pyrrole analogues chemical route consists of a synthetic method 
developed by Prof. Anna Ramunno at the Department of Pharmacy of Salerno 
University.
191
 In detail, the reaction between (±)-serine methyl ester 
hydrochloride and p-toluenesulfonyl chloride affords the tosyl protected 
compound, which reacts in turn with tert-butyl pyrocarbonate, (Boc)2O, and a 
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catalytic amount of 4-dimethylaminopyridine (DMAP) to give the 
dehydroalanine. Then, β-diketones are used for the synthesis of pyrrole using 
Cs2CO3 as base and 10% THF in dichloromethane. The next hydrolysis of the 
methyl-ester and the amide formation provides the desired products (Figure 
51, A).
191
 β-diketones may be commercially available or synthesized starting 








Figure 51 A) Synthetic strategy for pyrrole derivatives; i=tosyl chloride, TEA, DMC, 0°C to 
rt, overnight,; ii= (Boc)2O, DMAP, CH3CN,rt; iii= Cs2CO3, dry CH3CN; iv=NaOH , MeOH; 
v=EDC, DMAP, DCM, rt.
191




3.5.2 Generation of libraries of 1H-pyrrole-2-carboxamides 
Two large libraries of molecules were prepared starting from two pyrrolic 
cores differentially substituted at position 5. Considering some structures of 
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the previously developed pyrrole derivatives include an alkylic moiety,
192
 a 
modification was its substitution with a bulky substituent as an aromatic ring. 
Also, the acidic group was functionalized to an amidic group. Two different 





Since the synthons of the synthetic method are methyl ketones and aromatic 
amines, commercially available reagents were used for the decoration of the 
scaffolds (Figure 52) using Combiglide.
112
 Starting from the two cores and the 
prepared reagents, two final libraries were generated: 
 
1) 4-aryl-5-methyl-N-aryl-1H-pyrrole-2-carboxamides 
2) 4-aryl-N,5 diaryl-1H-pyrrole-2-carboxamides 
 
each containing 11,312 compounds. To simplify, the two libraries are 
named respectively D and E. Again, LigPrep
123
 calculation was performed for 
the addition of all the tautomers, stereoisomers and protonation states at 
physiological pH, and QikProp
1 1 0
 for the estimation of pharmacokinetic 
parameters. Specific filters
1 1 7
 were applied (see section 3.4.2) and the final 
libraries D and E were determined.  
 





Figure 52 Generation of two libraries: D) 4-aryl-5-methyl-N-aryl-1H-pyrrole-2-
carboxamides; E) 4-aryl-N,5 diaryl-1H-pyrrole-2-carboxamides. 
 
3.5.3 Selection of the most promising 1H-pyrrole-2-
carboxamide derivatives 
An accurate analysis of the XP poses resulted from the screening, 
respectively 388 and 116 for the libraries of 5-methylpyrroles and 5-
phenylpyrroles derivatives, led to the selection of a total number of 24 
molecules from the first named library (D). 
As expected, the phenyl at position 5 of library E induces a shift of the 
molecules into the binding site, and some fundamental interactions are 
missing, such as the hydrogen bonds with Gln 36chainC and π-π interactions 
with His 53chainC and Phe 44 chainC (Figure 53). Considering these aspects, the 
compounds belonging to this structural class have been excluded in the 
selection. 





Figure 53 2D binding mode comparison of two similar compounds of libraries D and E. 
 
Based on the chemical structure of the methyl ketone moiety, it is possible 
to classify the selected compounds in 4 different categories: benzofuran-
methylketone, naphthalene methyl ketone, benzene or pyridine methyl ketone 
and pyrrole or furan methyl ketone derivatives. 
All the molecules presented a value of binding energy in the range of (–
8.5)–(–7.0) kcal/mol and demonstrated to be able to establish the key 
interactions with the receptor counterpart: in most of the compounds, the 
aromatic moiety deriving from the methyl ketone building block is involved in 
π-π interactions edge to face or face to face with His 53 chainC and Phe 44 chainC, 
while the amidic moiety interacts by specific hydrogen bonds and other π-π 
interactions with Gln134chainA, Tyr130chainA, Thr131chainA, Tyr28chainC. For the 
pyrrole-methyl ketone derivatives, a hydrogen bond interaction of the nitrogen 
of the pyrrole moiety with Gln134 chainA induces an overturning in the binding 
site, and the π-π interaction is established with the aromatic ring of the amidic 
moiety. A representative 2D binding mode of a compound for each class is 
reported below. 









Figure 54 Benzofuran derivatives. 
Figure 55 Naphthalene derivatives. 





















Figure 56 Phenyl-pyridil derivatives. 
 




Figure 57 Heterocycles-based derivatives. 
 
Finally, a binding mode comparison between the developed pyrroles 
alkanoic acid derivatives
192
 and the compounds selected through virtual 
screening workflow was performed. The docked molecules are reported in 
Table 6. The analysis of the XP poses of the reported compounds showed a 
different binding mode compared to the designed compounds. Most of the 
interactions are focused in a lower region of the binding site, since the 
carboxylic group establishes hydrogen bonds with Arg38chainC, Ala45chainC, 
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Figure 58 Representative examples of the binding mode of the reported pyrrole alkanoic 
derivatives. 
3.5.3.1 PAINS screening 
SwissADME
184
 web tool was used for the individuation of chemical species 
belonging to “Pan-Assay Interference compounds” chemical class. Among 
compounds 37-61, the pyridine derivative 53 did not pass the filter, since it 
was classified as belonging to PAINS. In light of this, 23 molecules were 
selected for the next step. 
3.5.4 Synthesis of 2-carboxamide pyrrole derivatives 
To date two among the 23 selected compounds have been synthesized in 
collaboration with Prof. Anna Ramunno (Figure 51). The applied synthetic 
strategy is previously reported. 
191
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3.5.5 Biological evaluation of 2-carboxamide pyrrole 
derivatives 
Compounds 45 and 47 were submitted to the cell-free assay.
170
 Both of 
them showed inhibitory activity on mPGES-1, with a better result for the 
molecule bearing a dimethyl substituted benzene ring as amidic moiety 
(IC50=5.5±0.7 µM).  
 














3.6 Application of the protocol with N-heterocycles 
In conclusion, a set of saturated N-heterocycles cores was chosen since they 
are very common in the preparation of bioactive small molecules and are 
useful to overcome the limitations in solubility, pharmacokinetic parameters, 
and bioavailability of high-aromatic-ring-count.
196, 197
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Furthermore, since a biological evaluation of mPGES-1 inhibitory activity 
of saturated heterocycles presented positive response,
140
 (Figure 59) it seems 
promising to consider this chemical class of molecules as building blocks of 
potential inhibitors of the enzyme. The co-crystallized ligand 6PW (Figure 
59), in fact, co-complexed with a crystal structure of the human protein 
released in 2016 (PDB code: 5K0I)
140
 is a 3,3-dimethyl substituted N-aryl 
piperidine, belonging to the saturated heterocyclic family. It presented an IC50 
of 7 nM in an ex vivo human whole blood (HWB) assay. In addition, it showed 
no activity in human COX-1 or COX-2 assays at 30 µM and in the inhibition 










According to these data, 4 different scaffolds were selected for our 
purposes: thiomorpholine, morpholine, piperazine, and ethyl thiomorpholine-
3-carboxylate. 
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3.6.1 Synthetic strategy for thiomorpholine, morpholine, 
piperazine and ethyl thiomorpholine-3-carboxylate derivatives 
Concerning the set of saturated heterocyclic scaffolds, the SnAP (Stannyl 
Amine Protocol) chemistry was selected as promising synthetic strategy. This 
approach was developed for the first time in 2013 from Jeffrey W. Bode et 
al.,
197
 and it is considered a very useful synthetic tool. 
Metal-catalyzed cross-coupling reactions have had a considerable role in 
organic chemistry in the last few decades. The application of cross-coupling 
synthetic strategies in the development of bioactive molecules induced the 
increase of aromatic-ring-count in the compounds, responsible for limitations 
such as solubility, pharmacokinetics and bioavailability. According to the 
considerations above, the use of saturated building blocks is getting privileged 
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Most of the heterocycles are functionalizated on the C-H bonds adjacent to 
nitrogen, due to their higher reactivity.
198
 Different α-arylation of N-
heterocycles have been proposed,
199-202 
but a common difficulty of these 
reactions was the removal of N-aryl substituents. Herein, the proposed SnAP 
chemistry is a synthetic approach able to play a crucial role in the overcoming 
of the lacks of the previously studied mechanisms. In particular, the method 
leads to the direct formation of N-unprotected heterocycles, and the introduced 
substituents derive from stable and broadly commercially available functional 
groups in comparison to others. In detail, in the reaction are involved an 
aldehyde and an amino-tributylstannane (SnAP reagent) and consists of the 







Figure 61 SnAP reaction; X=heteroatom. 
 
Considering that in the intermolecular addition of organostannanes to N-
phenyl imines reported by Kagoshima
203
 a stoichiometric amount of Cu(OTf)2 
is used, the same was kept in the seeking of the most optimized conditions for 
the cyclization of the pre-formed imine. Different situations were explored, 
modifying the nature of the solvent, temperature and additive in the 
cyclization step of a fixed imine. In the end, the most promising conditions 
were:  
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 A mixture 4:1 CH2Cl2:HFIP (hexafluoroisopropanol) as solvent. 
 Room temperature 




Figure 62 SnAP chemistry optimized conditions. 
 
A general mechanism was also proposed and presented with experimental 
data. Kagoshima et al. proposed a role for the Cu
II
 as a Lewis acid in the 
nucleophilic addition of α‐thioalkyl stannanes to N‐phenyl or 
N‐para‐methoxyphenyl imines. Experimentally, other metal salts (such as 
Zn(OTf)2 and BF3⋅OEt2) failed the cyclization, while the use of 2-
pydirylaldehydes showed a poor reactivity although they could chelate Cu
II
. 
Furthermore, with the addition of TEMPO (1.5 equiv.) in the reaction, no 
cyclization product was obtained, demonstrating the existence of a radicalic 
intermediate. In light of these considerations, it was hypothesized that Cu
II
 acts 
as an oxidant. Considering that organostannanes are able to form carbon-
centered radicals under oxidative conditions, the mechanism below (Figure 
63) was reported. 
197
 









Iminotributylstannane is protonated in acidic conditions (HFIP). The 
one‐electron oxidation with Cu(OTf)2 gives Cu
I
 and the radical cation, which 




The first reactions were performed using the Thiomorfoline SnAP reagent 
(SnAP-TM),
197
 but the same approach was applied to others 
aminotributylstannanes belonging to the family of SnAP reagents, such as 
Morpholine (SnAP-M)
196, 204
 and Piperazine (SnAP-PIP).
196, 204
 Furthermore, 
more-substituted SnAP reagents were considered,
197









Figure 64 On the left, SnAP-Cys. On the right, SnAP-Pen, and the favored cis-products 
(A=SnAP-Cys, B=SnAP-Pen). 
 
In particular, for the disubstituted SnAP-Cys and SnAP-Pen (Figure 64) 
was confirmed by X-ray crystallization a high diastereoselectivity (20:1) of the 
reaction for the cis-product, thermodynamically favored. 
197
  
Based on the considerations above, this is a widely efficient synthetic 
strategy for the generation of N-unprotected saturated heterocycles under mild 
conditions. For our purpose were considered Thiomorpholine (SnAP-TM), 
Morpholine (SnAP-M), Piperazine (SnAP-PIP) and ethyl thiomorpholine-3-
carboxylate (SnAP-Cys). 
3.6.2 Generation of libraries of thiomorpholine, morpholine, 
piperazine and ethyl thiomorpholine-3-carboxylate derivatives 
Starting from the SnAP synthetic approach, morpholine, thiomorpholine, 
piperazine and ethyl thiomorpholine-3-carboxylate were decorated with 
commercially available aldehydes to obtain 4 final libraries of saturated N-
heterocyclic derivatives. After the application of the filters mentioned above, 
the molecules which were undergone to docking analysis were 13,625 for the 
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morpholine, 13,625 for thiomorpholine and 26,578 for piperazine, 14,182 for 
ethyl thiomorpholine-3-carboxylate scaffolds. 
 
Figure 65 Generation of 4 libraries: F) Piperazine derivatives; G) Morpholine derivatives; H) 
Thiomorpholine derivatives; I) ethyl thiomorpholine-3-carboxylate derivatives. 
 
3.6.3 Selection of the most promising thiomorpholine, 
morpholine, piperazine and ethyl thiomorpholine-3-
carboxylate derivatives 
In total, 17 SnAP-molecules have been selected from the 4 libraries for the 
synthesis (Figure 66), basing on a detailed in silico analysis of the binding 
mode and the interactions in the active site of the crystal structure of the 
enzyme. In particular, according to the small size of the scaffold compared to 
the other cores explored in this thesis, compounds bearing high molecular 
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weight aldehydic substituents presented the most promising results. All the 
selected compounds, in fact, center the binding site interacting with most of 
the key amino acids. In details, their saturated heterocyclic moiety establishes 
specific hydrogen bonds with Gln134chainC, Tyr28chainA, Tyr130chainC. 
Moreover, a further binding mode is observed among the poses, in which the 
heterocyclic scaffold is oriented along the cytoplasmic region ( section 3.1.1) 
and interacts by hydrogen bonds with Ser127chainC and Arg52chainA (see Figure 
68). Interestingly, SnAP-Cys derivatives bearing the ethyl-ester group at 
position 3 interact by specific hydrogen bonds with the receptor counterpart, 
established between the ethyl-carboxylate moiety and Arg52chainA, Ser127chainC 
and Arg126chainC residues. Also, this class of selected compounds present a 
good superimposition with the co-crystallized 6PW inhibitor
140
 (Figure 69). 
An advantage of the use of this specific scaffold is the possibility of a 
functionalization, for instance with commercially available aromatic amines.  
Considering the susceptibility of the ester group to hydrolysis, a further 
docking analysis was performed on the acid analogues of the selected 
molecules. Specifically, 4 hydrolyzed compounds (Figure 67) are able to 
reproduce a similar binding mode onto the crystal structure of the enzyme, 
retaining the specific interactions reported above. Thus, in order to investigate 
the inhibitory activity on mPGES-1 of the acid analogues and to compare them 
with the biological results deriving from the assays performed on the esters, 
the 4 promising compounds were selected for the synthesis. In conclusion, 21 
SnAP-molecules entered the next synthetic step. 
 




Figure 66 Selected SnAP-molecules. 




Figure 67 Selected acidic analogues. 
 
Figure 68 Two different binding modes (A and B) of compound 64. 





Figure 69 A) 3D superimposition of the co-crystallized ligand 6PW
140
 ( colored in light blue) 
and the selected compound (colored in pink); B) 2D representation of 6PW inhibitor in the 
binding site of mPGES-1; C) 2D representation of the 3D reported selected molecule in the 
binding site of mPGES-1. 
3.6.3.1 PAINS screening 
Each selected compound was submitted to SwissADME
184
 analysis, with 
the purpose of identifying possible PAINS moieties in the structures. 
Compounds 62-82 passed the filter in this preliminary phase. 
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3.6.4 Synthesis of saturated N-heterocycles 
The synthesis of the selected N-heterocycles was performed using the 
above described SnAP chemistry.
197-202
 The whole synthetic project was 
carried out in the research group of the author of this approach, Prof. Jeffrey 
W. Bode, at the Department of Chemistry and Applied Biosciences of ETH. In 
the last few years, the group has had a lot of experience with SnAP chemistry, 
reaching important results that confirmed the versatility and utility of the 
chemistry in a broad range of applications. For the synthesis, the 
thiomorpholine (TM), morpholine (M), piperazine (PIP) and ethyl 
thiomorpholine-3-carboxylate (Cys) SnAP reagents were used as starting 
materials. The first three were synthesized previously in the group, while 
SnAP-Cys was synthesized by a one-step reaction
197
 starting from 
tributyl(iodomethyl)stannane.
206
 In the synthesis of SnAP-Cys reagent was 
performed a substitution reaction on tributyl(iodomethyl)stannane with L-
ethyl-cysteine. In detail, an ethanol-water solution of 
tributyl(iodomethyl)stannane (83) and L-ethyl-cysteine hydrochloride (84) 
was stirred and refluxed at 70 °C for 4 hours in the presence of K2CO3. 
Purification via flash chromatography gave compound 85 (Figure 70). 
 
 
Figure 70 Synthesis of ethyl 2-amino-3-(((tributylstannyl)methyl)thio)propanoate; i: K2CO3, 
4:1 EtOH:H2O, 70°C, 4 hours. 
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For the synthesis of compounds 62-78 the optimized SnAP chemistry 
conditions were applied in the performance of the two steps reaction. 
The imine formation was carried out between the amino group of the 
tributylaminostannane (SnAP reagent) and the proper aldehyde in dry CH2Cl2 
in presence of 4Å MS, stirring overnight at room temperature. A filtration of 
the mixture through a short layer of Celite afforded the pure imine products. 
For the cyclization step, a suspension of anhydrous Cu(OTf)2 in HFIP was 
prepared, and 2,6-lutidine was added in one portion. Then, a solution of the 
imine intermediate in CH2Cl2 was added to obtain a final solution 4:1 
DCM:HFIP, and the resulting mixture was stirred overnight at room 
temperature. Schlenk techniques were applied to all reactions.  
 
 
Figure 71 Application of SnAP chemistry. 
 
Boc protective group of SnAP-PIP is useful to avoid the imine formation on 
the amine group close to tributyl stannyl moiety. Thus, the synthesis of SnAP 
products 69-71 required a third deprotection step, which was carried out using 
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a mixture 1:1 TFA:DCM (Figure 72). After work-up and purification, the final 





Figure 72 Deprotection of SnAP-PIP derivatives. 
 
Also, for the synthesis of the acid analogues 79-82, the hydrolysis of 
compounds 72-75 was performed, using a mixture 10% NaOH solution (50%) 






Figure 73 Synthesis of compounds 79-82. 
 
Some reactions were tried with electron-rich aldehydes, but because of their 
limited reactivity the imine formation was not complete, showing 50% of 
aldehyde by 
1
H NMR analysis. An increase of the temperature gave an 
improvement of the yields, avoiding the use of carbonyl group activants such 
as titanium isopropoxide. This is the example of the imine precursor of 
compounds 64, 71 and 74, whose aldehyde is the 3-methoxy-4-((3-
methoxybenzyl)oxy)benzaldehyde. 
  




Figure 74 Failed synthesis of compound 68. 
 
Regarding the synthesis of compound 68, (Figure 74) which involves the 
mentioned aldehyde and the SnAP-M (morpholine), it was possible to identify 
the signals of the product by 
1
H NMR analysis carried out on the crude of the 
reaction. Purification by flash column chromatography did not afford the 
product. Again, the reaction was performed applying the same general 
conditions and a variation in the purification step. Silica column, in fact, was 
replaced with a small column of propyl sulfonic acid supported on silica 
(SCX2), but the product was not isolated.  
 
 
Figure 75 Test reaction. 
 
In addition, in order to further investigate SnAP chemistry limitations, test 
reactions were carried out with SnAP-M (morpholine). Experimentally, the 
SnAP reactions with adehydes bearing cathecol did not work. Thus, the 
Results and Discussion 
127 
 
reaction with –MOM (methoxymethyl) protected vanillin (Figure 75) was 
carried out, in order to analyze the reaction with less bulky substituent in 
comparison to compound 68. Also in this case, the reaction did not work. 
Therefore, among the SnAP reagents used for the synthesis of promising 
mPGES-1 inhibitors, the use of SnAP-M presented more problems from a 
synthetic point of view, especially when combined with electron-rich 
aldehydes. 
Other limitations included the purification of the crudes. Generally, flash 
chromatography was performed, using different mixtures of hexane-ethyl 
acetate as eluent and a solution 0.1% Et3N in the solvent mixture was prepared 
for the most polar compounds. In many cases, traces of Tin were identified. 
For the removal of Tin, the product was dissolved in acetonitrile and washed 
with hexane. Traces of aldehyde (2-5%) in the product after flash 
chromatography were removed using SCX2 for not basic aldehydes. 
In conclusion, the SnAP chemistry was useful to synthesize most of the 
desired compounds, but with different yields based on the nature of the 
aldehyde moiety. 
3.7 Generation of a database of compounds starting 
from the SnAP chemistry 
The versatility and applicability of SnAP chemistry gave inspiration for the 
preparation of a database of synthetically accessible compounds.  
Developments of the SnAP chemistry
197, 198
 led to the generation of iSnAP 
(Iterative Stannyl Amine Protocol) reagents (Figure 76), organostannanes 
bearing ketones or amine groups potentially useful for further 
functionalization. Practically, a reductive amination on the ketone could be 
Results and Discussion 
128 
 
carried out, or a substitution reaction of alkyl or acyl halides could be 
performed by the amino group. In this specific case, the synthetic route 
selected for the generation of the database is as follows: 
1) The application of the classic SnAP chemistry between the involved 
amino-organostannane and the aldehyde; 
2) Substitution reaction of acyl or alkyl halides on the amino group;  
Therefore, the multi-step computational protocol was applied for the 
generation of the database. Starting from a library of 33 iSnAP-scaffolds, all 
possible diastereoisomers were generated for each item and a total of 98 
scaffolds were prepared. At the same time, two large libraries of commercially 
available aldehydes and alkyl/acyl halides were divided into clusters according 
to 2D ligand properties, and for each class a representative reagent was 
selected.
207, 208
 After this filtration, 129 aldehydes and 97 halides were selected 
for the next steps. Herein, using a combinatorial chemistry approach, the main 
tool of this research work, 98 iSnAP-molecules libraries were generated 
combining each scaffold with the aldehydes and the halides. A small sub-
library of about 20,000 compounds was built for each isomer, considering all 
possible tautomers and protonation states at physiological pH. After the 
application of various filters, a database of 1,277,744 drug-like molecules 
synthesizable using SnAP chemistry was obtained, which can be subjected to 
virtual screening on biological targets. As proof of concept, virtual screening 
workflow was performed onto the crystal structure of mPGES-1 (PDB code: 
4YL0),
133
 and 38 molecules were selected. In details, 15 of the 98 iSnAP-
scaffolds involved in the calculation showed promising results on the enzyme 
in the in silico docking analysis. Similar studies may be applied for the 
Results and Discussion 
129 
 
individuation of iSnAP-derivatives in the database potentially able to interfere 
with the activity of pharmacologically interesting targets. 
The structures of iSnAP-cores and the selected compounds are not reported 
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4.1 Multi-step computational protocol 
Another computational protocol (Figure 77) adopted for the discovery of 
novel mPGES-1 inhibitors involved both ligand and structure based methods. 
A library of molecules containing 310,657 compounds, commercially 
available in Otava Ltd. (www.otavachemicals.com) and endowed with high 
chemical variability, was selected for the computational processes. The library 
above consists of both small fragments and high in weight compounds (16 Da 
≤ molecular weight (MW) ≤ 1307 Da), presenting a broad range of hydrogen 
bond donors (HBD) and acceptors (HBA) (0 ≤ HBD ≤ 8; 0 ≤ HBA ≤ 16). 
Herein, the high degree of promiscuity is certainly useful for the individuation 
of new hits.  
In the next sections, a detailed description of each step of the applied 
workflow is reported (Figure 77). 
 
 
Figure 77 Protocol applied for the identification of the novel mPGES-1 inhibitors. 
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4.1.1 Ligand-based shape similarity screening 
The starting library of compounds was obtained from the Otava Chemicals 
database. In order to reduce the number of the molecules, a preliminary 
analysis was carried out for the selection of the best candidates for the 
molecular docking experiments. The known potent inhibitor LVJ, co-
crystallized in the crystal structure with the PDB code 4BPM
209
, was chosen 
for a shape alignment study. Briefly, using a free conformational sampling for 
the alignment, the chemical shape of every molecule was compared to that of 
LVJ (Phase software, Schrodinger, LLC)
210
. This analysis stemmed from the 
demonstration, in several virtual screening studies,
211, 212
 that similar 
molecules could bind the receptor counterpart in a similar way, thus showing a 
similar binding mode. In details, two steps can be distinct: conformational 
search and alignment of the resulting conformers with LVJ reference 
compound, calculating the similarity with the arithmetical parameter “shape 
similarity”. The sampling was performed allowing the conformers around the 
amide bond to vary freely, and finally, 1000 maximum number of conformers 
were considered for the shape analysis. The shape similarity value can shift 
from 0 (no overlap between screened and reference compound) to 1 (all the 
atom overlap perfectly). Based on it, a ranking from the best to worst values 
was obtained, and a threshold of 0.627 was chosen reducing of 0.100 the best 
value (0.727).  
After the application of this filter, the number of molecules was reduced to 
7,220 items. Here, the new library featured only the most promising 
compounds, showing intrinsic conformational and pharmacophoric features, 
with high compatibility with LVJ reference compound. 
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4.1.2 Molecular docking and structure-based shape 
similarity screening 
The 7,220 compounds were prepared using LigPrep software (Schrodinger 
Suite).
213
 All the possible stereoisomers, tautomers, and protonation states at 
pH=7.4±1.0 were generated for each compound, and an energetic 
minimization was performed using OPLS 2005 force field. 
Structure-based molecular docking experiments were carried out on the 3D 
crystal structure of mPGES-1 (PDB code: 4BPM), using Glide software
214
.  
In particular, the High-Throughput Virtual Screening (HTVS) was used for 
the first analysis. A maximum of 10 poses for each compound was generated, 
and a ranking based on docking score value was established. The first 10,000 
ranked poses were selected, corresponding to 4546 different compounds. The 
second set of docking experiments provided the Standard Precision (SP) Glide 
precision mode. A maximum number of 10 poses for each of the 4,546 
compounds was identified, and each of them was submitted to an “in place” 
shape screening against LVJ. This study is a shape comparison between the 
structure-based docking poses and the LVJ pose co-crystallized with the 
protein. Thus, in this case the shape similarity is performed on predefined 
poses of the molecules, and not on different conformers. The choice of a 
threshold of 0.400 led to the selection of 4,120 compounds. The third and last 
docking round was the Extra-Precision (XP) Glide mode which is more 
accurate in comparison to the SP mode for both sampling and scoring. A 
number of 100 maximum poses for each compound was saved and the “in 
place” shape similarity with the LVJ co-crystallized structure was performed. 
Considering a threshold of 0.500, 914 final molecules were selected for the 
next steps. 
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4.1.3 Evaluation of the key interactions 
Starting from the selected promising molecules, presenting an elevated 
shape similarity to LVJ co-crystallized pose after docking experiments, an 
evaluation of the binding mode was useful to deeply screen the best items for 
the biological assays. A visual analysis of the key interactions in the presence 
of the cofactor was performed, in order to confirm the respect of those 
established between the reference compound and the receptor counterpart. 
In details, the set of optimal interactions includes:  
 edge-to-face π-π interaction with Phe44 and/or His53 of chain C; 
 contacts with Pro124, Thr131 of chain A and with Asp49 of chain 
C; 
 interactions with Tyr130 of chain A (hydrogen bonds or edge to 
face π-π contacts), which interacts with glutathione co-factor; 
 contacts with glutathione. 
As a result of this study, 296 poses were selected, corresponding to a total 
of 50 compounds. 
4.1.4 Pan-Assay Interference compounds (PAINS) screening 
A further evaluation of the 50 selected compounds was provided. 
SwissADME
184
 web tool (section 3.4.3.1) was used in order to evaluate the 
presence of chemical moieties belonging to “Pan-Assay Interference 
Compounds” (PAINS) chemical class. The application of this added filter 
along with the preservation of the chemical variability and the optimal XP 
GlideScore value (Table 8) led to the selection of 8 final promising 
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compounds, that were subjected to biological assays with the goal of 
confirming the in silico predictions. 
4.1.5 Biological assessment of mPGES-1 and 5-LO inhibition 
The cell-free assay described above, which provides the use of the 
microsomal fractions of IL-1β-treated A549 cells (as source for mPGES-1), 
170
 
was applied to demonstrate the ability of compounds 86-93 (Table 8) to 
interfere with the activity of mPGES-1.  
In a first screening campaign, a solution 10 μM of each compound in 
DMSO was prepared for the biological test. From the preliminary results, the 
most promising compounds were those bearing a 3-hydroxy-3-pyrrolin-2-one 
(87 and 88), as presented from ~70 up to ~80% of mPGES-1 inhibition 
activity. Since this chemical core is endowed with a broad spectrum of 
biological activities (for instance anticancer and antiviral) and several 
chemical strategies have been reported for the synthesis of derivatives using 
multi-component reactions, the identification of these novel hits provided the 




Also, compounds 90 and 93 showed a moderated activity, with a percentage 
from ~30 up to ~40% of inhibition activity. In light of this, additional 
investigations are helpful for the identification of the minimal pharmacophoric 
moieties in order to provide more potent derivatives. 
A further investigation of the activity of compounds 87 and 88 afforded the 
determination of the IC50 values. Both the compounds are able to inhibit the 
activity of mPGES-1 in the low micromolar range (IC50 = 3.7± 2.7 μM for 87; 
1.9± 1.5 μM for 88). In order to evaluate their selectivity, the two compounds 
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were tested at 10 μM concentration against 5-LO, another key enzyme 
involved in the AA cascade,
218
 since a dual inhibition activity of both mPGES-
1 and 5-LO was demonstrated for several kinds of compounds. From the 
results, compound 87 presented no inhibitory activity, while a modest 
inhibition was performed by compound 88 (See Table 8). 
4.2 Analysis of the binding mode of compounds 87 and 
88 
The 3D representation of molecular docking poses of compounds 87 and 88 
define their good accommodation onto the mPGES-1 binding site. Both of 
them establish specific hydrogen bonds and polar interactions with Gln36chainC 
by means of the 2-keto-3-hydroxy moiety, and the fundamental π-π 
interactions between Tyr130chainA and the aromatic ring of the keto-portion at 
position 4 of the pyrroline-based scaffold are noteworthy. Furthermore, it is 
important to highlight a variable set of interactions with the key amino acids: 
polar interactions with Asp49chainA, Ser127chainA, Thr131chainA, Arg38chainC, 
His53chainC, H-bonds with Ser127chainA, Thr131chainA, Arg52chainC, and π-π and 
π-cation contacts with Phe44chainC, His53chainC, Arg52chainC (docking poses 
featuring the highest shape similarity with LVJ reported in Figure 79 and 80).  
 





















activity at 10 
μM) 
86 -7.462 0.506 80.1 ± 3.9 - - 
87 -6.494 0.585 30. 5 ± 3.4 3.7± 2.7 92.5 ± 10.0 
88 -6.406 0.538 25.0 ± 6.5 1.9± 1.5 56.6 ± 8.5 
89 -6.323 0.657 86.8 ± 4.2 - - 
90 -6.284 0.660 72.1 ± 4.1 - - 
91 -6.241 0.517 88.6 ± 3.7 - - 
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92 -6.193 0.515 82.6 ± 2.4 - - 
93 -6.155 0.507 65.3 ± 11.1 - - 
 
Table 8 Glide XP Score, best shape similarity value (related to LVJ reference crystallized 
conformation), mPGES-1 and 5-LO residual activities tested at 10 μM ligand concentration, 








Figure 79 A) Selected 3D pose of 87 (colored by atom types: C, ochre; N, blue; O, red; S, 
yellow; polar H, light grey; Cl, light green) featuring the highest shape similarity to LVJ, in 
docking with mPGES-1 (chains A, B and C depicted in red, black, and blue ribbons, 
transparent molecular surface on the binding site colored in yellow, orange, and green, see text 
for details, glutathione (GSH) cofactor and key residues in the mPGES-1 binding site are 
represented in sticks, C grey, O red, N, blue, polar H white); B) related two-dimensional panels 
representing interactions.  
 
 






































Figure 80 A) Selected 3D pose of 88 (colored by atom types: C, indigo blue; N, blue; O, 
red; S, yellow; polar H, light grey; Cl, light green) featuring the highest shape similarity to 
LVJ, in docking with mPGES-1 (chains A, B and C depicted in red, black, and blue 
ribbons, transparent molecular surface on the binding site colored in yellow, orange, and 
green, see text for details, glutathione (GSH) cofactor and key residues in the mPGES-1 
binding site are represented in sticks, C grey, O red, N, blue, polar H white); B) related two-
dimensional panels representing interactions. 
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5.1 Heat shock proteins 
Heat shock proteins (Hsps) is a family of ubiquitous proteins named 
according to the specific molecular weight (kilodaltons), which cells product 
in response to exposure to high temperatures
219
 or to a variety of physiological 
and environmental insults (cold, UV light, bacterial or viral infections, 
oxidative stress or during wound healing and tissue remodeling).
220-222
 
According to their several and dynamic roles in protein homeostasis, many of 
the Hsps are mainly located in the cytoplasm, but also in other organelles such 
as the endoplasmic reticulum, mitochondria, and nucleus. Hsps are involved in 
the correct three-dimensional folding, assembly and disassembly of 
macromolecular protein structures, and in their translocation and degradation 
during ordinary cellular growth and development,
221, 223
 performing molecular 
chaperone function. Also, the members of this family take part in the refolding 




The five major families of HSPs are Hsp100 (in plants), Hsp90, Hsp70, 
Hsp60, and small HSP (sHSP, 15-30 kDa) which include Hsp27.  
Clp/Hsp100 (casein lytic proteinases/heat shock proteins 100) are 
chaperones belonging to the larger AAA+ family of proteins (ATPases 
Associated with various cellular Activities) that act to remodel/disassemble 
protein complexes and/or protein aggregates using the energy of ATP. This 
substrate remodeling may serve many functions, including regulating the 
activity of protein complexes, unfolding proteins for presentation to proteases 
or facilitating the refolding of denatured protein aggregates. 
226, 227
 Hsp90 (heat 
shock protein 90) proteins interact with the protein substrate after binding with 
Hsp70. They do not act in nascent protein folding, but at a later stage of 





 Hsp70 (heat shock protein 70) is a class of chaperone system 
involved in different functions, such as import of proteins into cellular 
compartments (mitochondria, endoplasmic reticulum), folding of proteins in 
mitochondria and of a subset of proteins in the endoplasmic reticulum and the 
cytosol, disassembly of protein complexes, degradation of unstable proteins 
and the bacterial heat shock transcription factor, control of the activity of 
regulatory proteins such as heat shock transcription factors and the initiator 
protein of plasmid replication. Critical drivers of the activities of these 
proteins are Hsp40 family proteins.
229-231
 Considering Hsp60 (heat shock 
protein 60) or chaperonins, they are key components of cellular chaperone 
machinery. Chaperonins form a part of the elaborate, co-operative network of 
chaperones that ensure correct folding of newly synthesized or stress-
denatured proteins. The primary sequence of several polypeptides in the cell 
consists of multiple domains with α/β fold. Such proteins with complex 
topologies require the assistance of these specialized folding machines. 
Chaperonins form oligomeric, high molecular weight complexes of ~800 kD. 
It forms a large cage-like structure formed by two heptameric rings, each 
enclosing a central cavity. The heptamer is made of similar subunits, each 
having a molecular weight of 57 kD 
228
 Finally, sHSP (small heat shock 
proteins), also induced in stress conditions, are a very diverse group of 
chaperones that play an important role in maintaining the protein quality 
control in the cell. One of the most important protein which belongs to this 
family is Hsp27. The affinity of small HSPs for the target is not modulated by 
ATP binding, but it is determined by their oligomerization status. Only large 
oligomers (up to 1000 kDa) of Hsp27 have a chaperone activity and confer 
thermoprotection. Hsp27 oligomerization is a dynamic process that depends, 
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in part, on the phosphorylation status (it could be phosphorylated at three 
serine residues) of the protein and exposure to stress.
232 
5.2 Heat shock protein 90 
Hsp90 family is one of the most investigated from both industry and 
academic research institute, as it is the most conserved and represents 1-2% of 
the total cytosolic proteins in non-stressed conditions, with an increase to 4-
6% in stress-conditions, such as in tumoral states.
233-235
 Two major isoforms 
have been found in the cytosol: the constitutive Hsp90β and the inducible 
Hsp90α.
236
 Also, there are two non-cytosolic isoforms: the Hsp75/tumor 
necrosis factor receptor associated protein 1 (Trap1)
237
 that is located in the 
mitochondrial matrix and is implicated in the oxidative cell death, and the 
endoplasmic reticulum resident Hsp90 isoform, 94 -kDa glucose-regulated 
protein (Grp94),
238
 which plays a crucial role in cell adhesion, immune 
response, Ca
2+
 balance and folding of proteins.  
Hsp90 inhibitors with cytotoxic effects induce the degradation of client 
proteins (to date, the maturation of more than 300 proteins is regulated by 
Hsp90) that are then submitted to ubiquitinylation-mediated proteasomal 
degradation.
239, 240
 Compounds endowed with these features are excellent 
potential anticancer drugs,
241
 while non-cytotoxic compounds able to block the 
functions of the chaperone are responsible of an up-regulation of HPSs levels 
and a subsequently solubilization of protein aggregates, suggesting application 
as neuroprotective agents.
242-244
 Hsp90 chaperone is overexpressed in cancer 
cells, with an increase up to 10-fold than in normal cells, and takes part in the 
progression of malignancy,
245
 since it prevents the aggregation and regulates 
the folding of client oncoproteins, such as ErbB2, Akt, p53, Bcr-Abl, Her-2, 
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Cdk4, Cdk6, Raf-1, v-Src, MET, telomerase and survivin.
246, 247
 Furthermore, 
the interference with Hsp90 machinery activity affects all hallmarks of cancer, 
blocking the maturation of oncoproteins associated with each hallmark.
248
 In 
light of this, the chaperone is interestingly a significant and promising target 
for cancer therapy. 
241
 
Also, Hsp90 is involved in the biogenesis, homeostasis and activation of 
IκB kinase (IKK) connected to the transcription factor NF-κB.
249
 
Experimentally, the inhibition of NF-κB pathway was observed after treatment 
with the N-terminal Hsp90 inhibitor geldanamycin.
250, 251
 This may suggest a 
potential in the prevention of cancer-related inflammation. Several 
experimental data
252
 confirmed a connection between inflammation and 
chaperones, as Hsp90 is involved in different kind of inflammatory responses, 












5.2.1 Structure and conformational cycle of Hsp90 
Structurally, it is a homodimer whose conformation plays a crucial role in 
the activity of the protein. The monomer is organized in three highly 
conserved domains: amino-terminal (NTD), middle (MTD) and carboxy-
terminal (CTD), which are active components of the conformational cycle.
258
 
The ATP hydrolysis in the N-terminal site is the starting point for the 
conformational change of the protein, and provides the energy needed for the 
chaperoning activities;
259
 the middle domain is responsible of the regulation of 
client proteins binding and interacts with the γ-phosphate of ATP;
260
 finally, 
the C-terminal contains a second nucleotide binding region, but is not 
endowed with ATPase activity,
261, 262
 and is involved in the regulation of 
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Hsp90 conformational rearrangement. The N-terminal and the middle domains 
are connected by a long and flexible linker which regulates the contacts 
between the two parts. Furthermore, an additional C-terminal motif could be 
identified which consist of the amino acid sequence Met-Glu-Glu-Val-Asp.
263
 
Heat shock proteins bind co-chaperones to perform most of their functions. 
Specifically, the C-terminal motif of Hsp90 chaperone is involved in the 







Figure 81 A) Hsp90 domains; B) Equilibrium between open and closed conformation of 
Hsp90 upon ATP binding; the C-terminal domain is colored in red, the middle in green, and 
the N-terminal in blue. 
 
The ATPase activity is the key of the open-closed-open conformational 
changes of the chaperone and, as a consequence, of the total functions that the 
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protein plays in the organism. A 15 Å deep pocket region in the N-terminal 
domain is involved in the binding of the ATP/ADP molecule. As a member of 
the gyrase, Hsp90, His kinase and Mutl superfamily of “split ATPases”, the 
association between the N-terminal and the middle domains is crucial for the 
ATP hydrolysis.
258
 In details, the binding of two molecules of ATP, one for 
each monomer, induces a rearrangement in which a loop of conserved amino-
acids, called lid region, closes over the bound ATP affording the intermediate 
state.
258, 264
 The dimerization of the two NTDs leads to the closed 1 state, and 
the association between the NTDs and the MTDs induces the closed 2 state, 
which leads the repositioning of the catalytic group in the middle domain and 
the hydrolysis activity. After the release of ADP and inorganic phosphate, the 
protein returns to the open conformation. 
258, 265
 In general, the enzymatic 
activity of Hsp90 is very low, with a dissociation constant (KD) of 400 µM. 
The conformational rearrangements for the formation of the split ATPase 
domain are the rate-limiting steps of this slow reaction. In this process, Hsp90 








Figure 82 A) Open-closed-open conformational changes. B) Catalytic loop of Hsp90. The N-
terminal domain is represented in yellow, while the middle domain is shown by two 
superimposed molecules of Hsp90 (cyan and green), one in the closed inactive state (blue) and 
the other one in the open active state (red). In the latter, Arg380 of the catalytic loop 




5.2.2 Regulation of heat shock protein 90 function  
Expression. The heat shock factors (HSF-1, HSF-2 and HSF-4)
268-270
 are 
ubiquitous proteins in the human cells. They consist of a DBD (DNA-binding 
domain), a trimerization domain containing three leucine zipper repeats called 
HR-A/B, the HR-C region which leads the regulation of HR-A/B domain and 
a CTA (C-terminal transactivation) domain, controlled by the central RD 
(regulatory domain).
267
 The stress-related transcription factor HSF1 (heat 
shock factor 1) is mainly involved in the regulation of the expression of 
Hsp90. When the amount of the chaperone is sufficiently available for the 
functions of the cell, HSF1 becomes a client of the protein and the complex 
Hsp90-HSF1 inhibits its activity.
271
 Stress conditions induce the release of 
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HSF-1 from its repressed association with Hsp90, the homotrimerization of the 
protein and the translocation to the nucleus. After the binding of HSF-1 to the 
heat shock promoter element (HSE), a series of phosphorylations transforms 
the HSF1 trimer into an active transcription factor, which stimulates the 
expression of responsive genes and the increase of heat shock proteins in the 
cytosol.
272




















 are the most 
significant post-transcriptional modifications in which Hsp90 is involved.
273
 
Hyperphosphorylation and hyperacetylation slow down the conformational 
cycle and regulate negatively the interaction with co-chaperones. S-
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nitrosylation of cysteine residue in the C-terminal domain interferes with both 
the chaperone and the ATPase activities and, interacting with endothelial nitric 
oxide synthase (eNOS), inhibits its activation.
279
 Summarily, the PTMs 
regulate the accessibility of binding sites and the interdomain communication 
across the Hsp90 homodimer. 
273
 
5.2.3 Heat shock protein 90 inhibitors 
Based on the position of the binding site of the ligands in the protein, three 
different classes of inhibitors are known: N-terminal, middle and C-terminal. 
In recent years different structurally unrelated natural or synthetic N-
terminal inhibitors have been disclosed. Some of them perform an excellent 
antitumor activity and have entered clinical trials. One of the most famous is 
Geldanamycin
280, 281
 (Figure 84), a 1,4-benzoquinone ansamycin antibiotic 
product in the organism of Streptomyces hygroscopicus. This natural 
compound is endowed with a great ability to inhibit the activity of Hsp90 and 
leads to the degradation of its client proteins (p53, Raf-1, Akt, ErbB2) by 
binding the ADP/ATP pocket of the chaperone. However, in spite of the anti-
cancer activity on the animals demonstrated in the pre-clinical phase, the 
limitation in solubility and the hepatotoxicity prevented the selection of 
Geldanamycin as a drug candidate.
282
 In light of this, some analogues have 
been developed in order to overcome the above mentioned limitations 
increasing the hydrophilicity.
280







which the methoxy group at position 17 is substituted respectively from an N-
allylamino and a dimethylamino group. Both the named derivatives have 
Results and Discussion 
150 
 
completed phase I of the clinical trials and are entering phase II, for the 
evaluation of the anti-cancer activity on solid tumors. 
Radicicol (RDC) is another known binder of the N-terminal domain of the 
chaperone, which interferes with its functions at nanomolar concentration and 
induces the following degradation of the client proteins. Structurally, it 
represents the first and unique non-benzoquinone ansamycin capable of 
binding Hsp90 in the same region of Geldanamycin and inducing the same 
responses, such as the inhibition of the maturation of oncogenic proteins.
286
 
Also, the studies concerning the effects of the purine-scaffold on the protein 
occupied a fundamental role in the discovering of new hits. Several purine 
derivatives have been developed in the last years, and some of them showed 
nanomolar potency (IC50 = 50 nM) in both cellular and animal models of 
cancer, entering the clinical trials.
287, 288
 A representative example is reported 
below. Other chemical items able to inhibit the activity of Hsp90 interacting 
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Moreover, although some N-terminal inhibitors are still in the clinical 
trials,
290, 291
 many have failed due to toxicity issues and to the occurrence of 
heat shock response (HSR) associated with resistance.
292
 
Concerning C-terminal inhibitors, only a few compounds have been 
developed in the last years, since the lack of structural information represented 
a limitation. The first identified C-terminus inhibitor was the natural antibiotic 
Novobiocin,
56
 from which chlorobiocin and coumermycin A1 analogues were 
developed.
293
 Its binding site includes amino-acids 538-728 in the C-terminal 
region. Experimentally, the binding of Novobiocin induces a conformational 
rearrangement such that the cleavage with proteolytic enzymes in 
correspondence of Arg400 and Lys615/Arg620 in the C-terminus is blocked, 
294
 and the binding of TPR of co-chaperones to the MEEVD motif is 
prevented.
295
 Since Novobiocin presented a weak interaction with Hsp90 (IC50 
= 700 μM in SKBr-3 breast cancer cells), several more potent analogues were 
synthesized (Table 9).
296-298







 and Sansalvamide A
302
 derivatives are able to inhibit the 
activity of the chaperone interacting with the C-terminus domain (Table 9). 
 
Table 9 C-terminal Hsp90 inhibitors. 
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Epigallocatechine-3-gallate299, 303, 304 
IC50 (MCF-7): 74.40 µM 
IC50 (SKBr3): 100.16 µM 
 
 
IC50 (MCF-7): 13.10 µM 
IC50 (SKBr3): 15.42 µM 
IC50 (MCF-7): 3.99 µM 
IC50 (SKBr3): 21.45 µM 
 






IC50 (SKBr3): 700 µM  
Chlorobiocin 




IC50 (SKBr3): 70 µM 
 
 
       
 






Sansalvamide A (Hsp90 allosteric 
modulator) 





5.2.4 C-terminal inhibitors vs N-terminal inhibitors 
Stressing the difference between N-terminus and C-terminus inhibitors of 
Hsp90 is important to understand why the latter class is more promising and 
preferred for cancer therapy. N-terminal modulators, in fact, presented several 
problems in clinical investigation (high concentration for a biological effect, 
poor aqueous solubility and hepatotoxicity) and induce heat shock response 
(HSR) related to cancer resistance.
55, 291, 292
 Conversely, the C-terminal 
inhibitors do not induce resistance mechanism and may be an alternative 
therapeutic strategy for the treatment of malignant cancers.
292
  The described 
HSR mechanism ensures the survival of cells in stressful conditions such as 
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exposure to heat, oxidative stress, toxins, bacterial infections and heavy 
metals.
270
 Specifically, N-terminal Hsp90 inhibitors induce the dissociation of 
HSF-1 from Hsp90, and the heat shock factor triggers its response. The 
increase of HSPs levels helps cancer cells to avoid the cytotoxic effect.
305
 In 
contrast, C-terminal Hsp90 inhibitors lock HSF-1 into its inactive Hsp90-
bound state and promote its degradation via the proteasome.
306-308
  
According to the importance of the discovery of novel C-terminal 
inhibitors, a purpose of this research work was the identification of new hits. 
However, the broad conformational space of this flexible chaperone is still a 
strong limitation.  
5.3 Discovery of new molecular entities able to 
strongly interfere with Hsp90 C-terminal domain 
In light of the above considerations, a specific protocol was applied in order 
to identify new inhibitors from commercially available structural unrelated 
small compounds. The purpose of expanding the number of molecules able to 
inhibit the activity of Hsp90 interacting with the C-terminal domain is the 
reason for which variability in the chemical structure of the selected small 
candidates was adopted. The exploration of the chemical space encoded by 




















5.3.1 Biological screening of a small library of molecules on 
Hsp90 
Considering that only a few C-terminal domain inhibitors 
56-59
 have been 
disclosed so far, a set of 48 compounds was undergone to the mentioned 
workflow (Figure 85). As a starting point, the biophysical surface plasmon 
resonance (SPR) assay
57-59, 310
 was performed on recombinant Hsp90α with the 
aim of screening the compounds and testing their ability to bind to the 
immobilized protein. Based on these analyses, 16 molecules (Figure 87) were 
selected for their ability to bind the molecular chaperone with high affinity and 
low KD values (Table 10). In the next step, the anti-proliferative activity was 
evaluated, in particular against Jurkat (human T-lymphocyte) and U937 
(human monocyte form histiocytic lymphoma) cell lines. The cells were 
exposed to increasing concentrations of the 16 selected compounds or the well 
known C-terminal inhibitor Novobiocin for a duration of both 24 and 48 
hours, and the MTT assay was carried out to measure the cell viability. The 
IC50 values listed below confirm compounds 100 and 103 as the best 
Figure 85 General workflow for the individuation of new C-terminal Hsp90. 
inhibitors 
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candidates for the following analysis. The evaluation of their anti-proliferative 
activity against non-tumor cell line PHA-stimulated human peripheral blood 
mononuclear cells (PBMC) demonstrated that both 100 and 103 compounds 
are not able to increase the non-viable cells percentage after 24 or 48 h, in 
comparison to the percentage observed in DMSO treated control cells. The 
experimental data show the following values of percentages: about 6 ± 1.8%, 8 
± 1.5% and 7 ± 1.3%, 9 ± 1.8% respectively for the compounds 100 and 103 at 
25 µM for 24 and 48 h, and 5 ± 0.9% for the control. Then, an elucidation of 
their mechanism in the cell cycle was very useful to confirm the anti-
proliferative activity. Jurkat (human T-lymphocyte) cell lines were used to 
perform the additional analysis for the characterization of the mechanism, 
since they were two-fold more susceptible than U936 (human monocyte form 
histiocytic lymphoma). The biological test provided the incubation of the cells 
with a concentration of compounds 100 and 103 close to their IC50 values or 
two and four times higher for 24 or 48 h. A comparison with Novobiocin was 
carried out, performing the test at the same conditions with concentrations 
close to its IC50 value (200 μM) or at lower doses (50 or 100 μM). 
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Figure 86 Library of 48 molecules screened for the individuation of Hsp90 
inhibitors. 




Figure 87 Chemical structures of the selected compounds with high affinity 
for Hsp90 from SPR screening. 
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Compound KD(nM) ± SD 
94 1.5 ± 0.5 
97 3.2 ± 1.1 
98 14.7 ± 9.4 
100 5.2 ± 3.8 
101 2.4 ± 0.6 
102 20.9 ± 9.5 
103 20.8 ± 8.7 
104 79.3 ± 7.2 
105 95.1 ± 5.7 
106 300 ± 19.3 
107 260.2  ± 8.4 
108 4.8 ± 2.9 
113 14.2 ± 4.9 
114 13.2 ± 2.3 
115 4.1 ± 2.6 
118 25.7 ± 8.4 
 
Table 10 SPR (Surface Plasmon Resonance) assay results of the 16 compounds able to bind 
Hsp90. 
 
Based on the results, compounds 100 and 103 demonstrated a cytostatic 
activity at concentration close to their IC50 values, since the cells blocked their 
growth in G0/G1 or S phase respectively without any significant increase of 
subG0/G1 cell fraction, for a duration of both 24 and 48 h. At 100 µM for 48 
h, the compounds were able to exhibit a cytotoxic activity. From a comparison 
of these results to the anti-proliferative activity of Novobiocin, which was able 
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to induce cell death at high concentration (200 µM), with a loss of the activity 
at lower concentration (50 and 100 µM), it is possible to confirm that 
compounds 100 and 103 perform improved cytostatic/cytotoxic effects. A 
monitoring of the expression levels of cell cycle cyclin-dependent kinases is a 
further demonstration of the above biological results. Cyclin D and CDK4, 
which regulate the G0/G1 phase cycle, were slightly down-regulated in Jurkat 
cells with the exposure to compound 100, in the other hand Cyclin A and 
CDK2, involved in normal S-phase progression, decreased with compound 
103 treatment.  
Western Blot was another deeper analysis to confirm that cell death was 
determined by Hsp90 activity inhibition. The lysates of Jurkat cells treated 
with compounds 100 and 103 were analyzed to determine the levels of some 
representative oncogenic Hsp90-client proteins, discovering a significant 
degradation (50–60%) of Hsp90-dependent client proteins Raf-1, p-Akt, p-Erk 
and p53 in a concentration-dependent way, without affecting actin levels, 
which is not dependent upon Hsp90, and a minimal reduction of Hsc70 (15–
20%). The expression of ER chaperone grp94 was not observed. Finally, 
limited proteolysis experiments were performed with the purpose to 
individuate the region of the C-terminal domain in which the compounds are 
placed in the inhibitory activity of the chaperone. It is possible to identify the 
binding site through the differences in the proteolytic patterns observed in 
presence or in absence of putative protein ligands.
311, 312
 The experiments were 
carried out on Hsp90α, Hsp90α/100 and Hsp90α/103 complexes, and on 
Hsp90α/Novobiocin, the positive control.
59
 
Based on MALDI analysis of the digestion mixtures of the several 
complexes, exposed to trypsin and chymotrypsin, a reduction of the cleavage 
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of Lys484, Lys498 and Lys656 was individuated in the complexes of the 
chaperone with both the compounds. Thus, the middle and C-terminal 
domains of Hsp90α are preferentially involved in the molecular binding.  
 
Compound 
IC50±SD (µM) (on Jurkat 
cell lines) 
IC50±SD (µM) (on 
U937 cell lines) 
100 25.1 ± 0.4 51.0 ± 0.7 
103 26.1 ± 0.7 50.0 ± 0.7 
 
Table 11 IC50 values of compounds 100 and 103, from cells viability assay on human 




Figure 88 A) Limited proteolysis experiments on compounds 100 and 103; B) Western blot 
analysis. 
5.3.2 Computational rationalization 
In this thesis, a detailed description of the final docking experiments for the 
rationalization of the activity of compounds 100 and 103 is reported. Several 
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computational experiments were performed to investigate the inhibitory effect 
at a molecular level. Molecular docking experiments were performed. Since 
the X-ray structure of human Hsp90 is not available in the protein data bank 
(PDB) database, the selection of a substitutive homologue crystal structure 
was essential to start the calculation. A research work published in 2011
313
 
reports the structure-based sequence alignment between the yeast Hsp82 (PDB 
code: 2CG9)
266
 and the human Hsp90α. In the comparison between the middle 
and the C-terminal domains of the two chaperones, they showed about 60% 
identity in 438 residues, and the superimposition reported an rmsd of 0.91 Å 
for 219 Cα atoms. 
313
 A similar comparison was also applied with the canine 
GRP94 (PDB: 2O1V),
314
 but lower values of identity and superimposition 
were identified (about 49% identity in 414 residues and a rmsd of 1.02 Å for 
241 Cα atoms). 
313
 For this reason, the Hsp82 X-ray structure was chosen as 
the best candidate for the computational experiments. The selected 3D 
structure of the protein, complexed with the co-chaperone Sba1 in the active 
closed conformation, was deposited in 2006 and is characterized by a 
resolution of 3.1 Å. 
266
 
After applying the Protein Preparation Wizard Workflow, 
117
 in which 
water molecules were removed, all hydrogen atoms were added, and the bond 
orders were assigned, the PDB file was converted to the Maestro (MAE) 
format. Starting from the results of limited proteolysis experiments reported 
above, the region including the Arg 670 of Hsp82, which corresponds to the 
Lys 656 of Hsp90 involved in the binding site, was considered during the 
conformational searches. The 16 compounds screened by SPR experiments 
were docked onto the close active crystal structure of Hsp82, using the 
Induced Fit Docking Protocol (Schrödinger Suite),
103, 104
 to account for 
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flexibility of ligands and receptor.
315
 Considering that compounds 100 and 103 
were disclosed as two novel Hsp90 C-terminal inhibitors, a comparison of the 
binding mode between the active compounds and the structural analogues of 
the tested commercially available library was crucial for a detailed 
investigation at a molecular level. Specifically, compound 100 was compared 
with its structurally related compounds 101 and 102, and 103 with respect to 
104–107.  
Considering the group of molecules 100-101, the different biological 
activity has been attributed to the substituents at C-5 of thiazole ring, from the 
structural point of view. The main force of the interactions which the three 
compounds establish with the receptor counterpart is the pattern of H-bonds 
between their phenylamino acetamide and Leu671 and Leu674 of both the 
chains A and B in a specific site of the C-terminal domain. In spite of the three 
compounds occupy the same region of the protein, only the 3,4-dichlorobenzyl 
moiety of 100 is involved in a peculiar halogen bond with the side chain of 
Arg670 ChainA.  
On the other hand, for the second group of molecules (103–107), the 
quinazolinedione moiety is able to establish H-bond contacts with Leu674, 
Leu676 and Ile672, as well as the substituted N-hexanamide portion with 
Asp641ChainA. Also, compound 103 shows an additional docking pose deriving 
from the inversion of the N-(4-bromo-2-fluorophenyl)hexamide and 
quinazolinedione moiety. This orientation of the molecule in the binding site 
leads to several hydrogen bonds between Leu674ChainB, Leu671ChainA, 
Gly675ChainB and amide group of N-hexanamide, and between the fluorine 
atom of bromofluorophenyl and Leu676ChainA. Other additional bonds were 
observed: a halogen bond between its bromine and the CO of Thr638ChainB  
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and a hydrogen bond between the quinazolinedione and Arg670ChainA and 
Leu674ChainA. In light of this, the substitution on N-hexanamide is crucial for 
the biological activity of this set of molecules, due to additional interactions of 
this moiety with the receptor counterpart are essential for the inhibition of the 
conformational cycle of the protein. From the considerations above, the 
placement of compound 100 and 103 at the interface of the two Hsp90 A and 
B chains is induced by the precise pattern of hydrogen bonds with the leucine 
amino acids (Leu671, Leu674, Leu676), and the halogen interactions with 
Thr638ChainB for 100 and Asp641ChainA for 103 have been confirmed as 









Figure 89 2D diagram interactions (panel A, B and C) of 100, 101 and 102 with C-terminal 
domain of Hsp82 yeast analogue of Hsp90α (PDB: 2CG9). Positive charged residues are 
colored in violet, negative charged residues are colored in red, polar residues are colored in 
light blue, hydrophobic residues are colored in green. H-bond (side chain) are reported as 
dotted pink arrows. 




Figure 90 Superimposition of 100 (light pink sticks), 101 (sky-blue sticks) and 102 (light 
green sticks) with C-terminal domain of Hsp82 yeast analogue of Hsp90α (PDB: 2CG9). The 
protein is depicted by purple (chain A) and green (chain B) sticks. 
 




Figure 91 2D diagram interactions (panels A, B, C, D and E) of 103, 104, 105, 106 and 
107 with C-terminal domain of Hsp82 yeast analogue of Hsp90α (PDB: 2CG9). Positive 
charged residues are colored in violet, negative charged residues are colored in red, polar 
residues are colored in light blue, hydrophobic residues are colored in green. The π-π stacking 








 Figure 92 2D diagram interactions of second binding mode of 103 with C-terminal 
domain of Hsp82 yeast analogue of Hsp90α (PDB: 2CG9). The positive charged residues are 
colored in violet, negative charged residues are colored in red, polar residues are colored in 
light blue, hydrophobic residues are colored in green. H-bond (side chain) are reported as 
dotted pink arrows.  
 
 
Figure 93 Superimposition of 103 (cyan sticks), 104(red sticks), 105 (yellow sticks),106 
(blue sticks),and 107 (grey sticks) with C-terminal domain of Hsp82 yeast analogue of 
Hsp90α (PDB: 2CG9).The protein is depicted by purple (chain A) and green (chain B) sticks. 





Figure 94 Three dimensional models of 100 (violet sticks, panel A) and 103 (cyan sticks, 
panel B) with the C-terminal domain of the Hsp82 yeast analogue of Hsp90α (chain A is 
depicted in red and chain B in yellow). 
 
With the aim of performing deeper computational analysis for the 
investigation of ligand affinity and selectivity towards the target,
317, 318
 and 
considering the flexibility and dynamicity of the chaperone, the best poses of 
the most active compounds 100 and 103 in complex with Hsp90 were used as 
a starting point for molecular dynamics (MD) simulations (100 ns) in explicit 
solvent (Desmond software).
319
 In particular, for the analysis of the trajectories 
we have used the simulation interactions diagram (SID) (Maestro version 
10.2)
94
 a tool for exploring protein-ligand interactions. The simulation showed 
compounds 100 and 103 at the interface of the two chains of the C terminal 
domain, maintaining a good number of interactions with the amino acids 
mentioned in the previous analysis. The driving force of compound 100-
Hsp90 complex consists of a pattern of hydrophobic contacts and hydrogen 
bonds with Leu671chainB, maintained for more than 80% of the simulation time, 
in addition to further interactions with Leu676, Glu624, Asp641 of chain B 
(≈50%). In compound 103-Hsp90 complex, most of the contacts are retained 
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with Leu674chainB (>70%). Thus, the dynamic nature of protein-ligand 
interactions is described from a detailed pattern of hydrogen bonds and 
hydrophobic contacts with the C-terminal domain (Figure 95). 
 
Figure 95 Bar Figure of the protein-ligand (P-L) contacts of 100 (panel A) and 103 (panel B). 
Hydrogen bonds are represented by green bars, hydrophobic as lilac bars, water bridges as 
blue bars, and ionic as fuchsia bars. The stacked bar charts are normalized over the course of 
the trajectory: for example, a value of 0.5 suggests that 50% of the simulation time the specific 
interaction is maintained. 
 
5.4 Design of new libraries starting from the N-
hexanamine quinazolinedione moiety of compound 103 
The computational method applied for the development of novel mPGES-1 
inhibitors was used in this case for the development of compound 103 
derivatives. Thus, a flexible synthetic strategy was selected and novel libraries 
of derivatives were created.  
5.4.1 Synthetic strategy for quinazolinedione derivatives 
In this case, the synthetic strategy for the generation of derivatives provides 
the reaction between the isatoic anhydride and the amino acid with 
triethylamine in formic acid at reflux.
320
 Then, the amide formation between 
the acidic group of the chain and an amine affords the final product. 





Figure 96 Synthetic strategy for quinazolinedione derivatives. 
 
5.4.2 Generation of libraries of quinazolinedione derivatives  
The design of libraries of compounds deriving from the novel disclosed hit 
was carried out basing on the reported chemical route. Specifically, in order to 
develop C-terminus Hsp90 inhibitors with an increasing activity in comparison 
to compound 103, different items were considered. Length modifications of 
the N-exanamidic chain afforded two different scaffolds bearing a 5 and a 7 
carbon chain respectively, in order to investigate the different binding modes 
onto the grid of the three-dimensional structure of the chaperone. Thus, a 
combinatorial approach was applied on three quinazolinedione items for the 
generation of three different libraries endowed with a 5, 6 or 7 carbon chain 
respectively. In particular, commercially available aromatic amines were 
combined with each selected scaffold, using Combiglide software. Then, 
LigPrep was applied for the generation of all possible tautomers, stereoisomers 
and protonation states at physiological pH, while QikProp determined 
pharmacokinetic parameters for each item of the libraries.  




5.4.3 Docking studies and selection of the best candidates 
Semi-flexible docking experiments were performed onto the close active 
crystal structure of yeast Hsp82. Starting from a detailed analysis of the 
interactions and the binding mode of compounds filtered via structure-based 
approach, 21 molecules were chosen from the three libraries for the next 
synthetic step. Most of the items present a halogen at position 4 of the benzene 
ring, according to the importance of the halogen bonds in the previously 
disclosed hits. Furthermore, based on the analysis of the docking score, 
compounds bearing a 7 carbon chain showed the best results. All the selected 
compounds present the typical pattern of hydrogen bonds with leucines 
residues previously reported. A representative example is reported below 
(Figure 98). Compound 157, in fact, is able to establish hydrogen bonds with 
Leu676chainA, Gly675chainA, Leu674chainB and Ile672chainB, and further hydrogen 
bonds with residues of chain A. Also, the iodide at position 4 interacts with 
Arg670chainA via halogen bond, a peculiarity of the hits reported above. 
 
 
Figure 97 Design and selection of the most promising analogues of compound 103 using the 
multi-step computational protocol. 


















Figure 98 2D panel representation of compound 157 in the C-terminal domain of the 3D 
crystal structure of Hsp82 (PDB code: 2CG9).
313
Positive charged residues are colored in 
violet, negative charged residues are colored in red, polar residues are colored in light blue, 
hydrophobic residues are colored in green. The π-π stacking interactions are indicated as green 





Figure 99 Three-dimensional representation of compound 157 in the C-terminal domain of 
the 3D crystal structure of Hsp82 (PDB code: 2CG9).
313
 Purple lines represent specific 
halogen bonds with the receptor counterpart. A selective representation of halogen bond 
interactions is reported. 
 





Figure 100 5 carbon chain selected compounds 
. 
 
Figure 101 6 carbon chain selected compounds. 




































The research work carried out in the frame of my three years PhD has been 
focused on the development and the identification of new molecular platforms 
for the treatment of inflammation and cancer. Among the proteins of interest, 
the inducible microsomal Prostaglandin E2 Synthase-1 (mPGES-1) was the 
main target, due to its biological importance in both the mentioned 
pathologies. Thus, the application of a protocol based on a combination of 
computational chemistry tools and experimental synthesis was for me very 
useful to identify different chemical items able to inhibit the activity of the 
synthase. In particular, benzothiazole 1, 3, 6, 9 and 13, thiadiazole 18-20 and 
22, pyrrole 45 and 47 based molecules presented promising results in the 
biological evaluation on mPGES-1 in both cell-free and cell lines tests. 
Furthermore, I applied my protocol to SnAP (Stannyl Amine Protocol) 
chemistry and I had the opportunity to move to the Department of Chemistry 
and Applied Biosciences at ETH for the synthetic part. Currently, biological 
tests are in progress for the 20 synthesized compounds.  
SnAP chemistry took place in the generation of a database of about 
1,300,000 synthetically accessible compounds. A new generation of SnAP 
reagents, called iSnAP (Iterative SnAP) reagents, provided for the possibility 
of further substitutions and functionalization of the saturated heterocyclic core. 
Also, computational chemistry techniques based on both ligand and 
structure based approaches were crucial for disclosing two novel 3-hydroxy-3-
pyrrolin-2-one-based hits (compounds 87 and 88). 
Another important protein target selected as a good candidate in this 
research project is the molecular chaperone Hsp90, whose inhibition is 




several cancers. A multidisciplinary approach was applied for the discovery of 
new C-terminus inhibitors, considering the numerous advantages in 
comparison to N-terminal inhibitors. Thus, two novel structurally unrelated 
hits (compounds 100 and 103) were identified among 48 commercially 
available compounds, with a high binding affinity for C-terminal Hsp90. A 
computational rationalization was very useful to understand the molecular 
fingerprints of the interactions between the new hits and the receptor 
counterpart. These findings gave the input for an optimization campaign, 
which was carried out following the multi-step computational protocol applied 
for the discovery of novel mPGES-1 inhibitors. Thus, 21 molecules were 
selected from three libraries of compounds derived from the new hit 103. 
All these promising results may stimulate further research towards the 
individuation of novel inhibitors or the optimization of the identified hits, 
considering the high potential that the inhibition of the activity of the two 






































-CHAPTER 6-  
Computational details and synthesis of 
2-amino-1,3-benzothiazole derivatives 









6.1 Computational details 
The structures of the reagents, namely all commercially available acid-
chlorides and boronates at Sigma Aldrich Company, were converted from 2D 
structures to 3D structures suitable for the docking stage of the process, using 
LigPrep software (v. 3.4; Schrödinger, LLC, 2015). Then, the compounds 
were prepared using Reagent Preparation: in the acyl chlorides, a cleavage 
between the chloride and the carbonyl group was applied in order to select the 
carbonyl moiety as building block, while the acidic moiety was removed in the 
boronic acids. The final .bld files were combined with the scaffolds obtaining 
the novel libraries (A and B). LigPrep performed calculation increased the 
number to 607,602 molecules for libraries A and B, and a final energy 
minimization of the two libraries with Optimized Potentials for Liquid 
Simulations (OPLS) 2005 force field was performed. After the application of 
QikProp
110
 and LigFilter, 
117
 the final libraries A+B contained 233,273. 
In the docking step, mPGES-1 three-dimensional crystal structure (PDB 
code: 4BPM)
209
 was used for the structure-based molecular docking 
experiments. The three-dimensional model of the protein was prepared using 
the Schrödinger Protein Preparation Wizard,
117
 starting from the 
aforementioned crystal structure co-complexed with the inhibitor LVJ (2-
[[2,6-bis(chloranyl)-3-[(2,2-dimethylpropanoylamino)methyl]phenyl]amino]-
1-methyl-6-(2-methyl-2-oxidanyl-propoxy)-N-[2,2,2-
tris(fluoranyl)ethyl]benzimidazole-5-carboxamide) (PDB code: 4BPM).
209
 The 
combinatorial libraries were submitted to structure-based molecular docking 
experiments on the mPGES-1 3D protein structure, using Glide software.
103, 104
 
Basically, the virtual screening workflow
117
 ( section 3.3.3) was used: a first 




Virtual Screening (HTVS) precision mode of Glide that allows a first 
enrichment from the starting library of compounds with a high fastness. The 
30% top-ranked poses, filtered according to docking score values, were then 
submitted to a second round of docking experiments, using the Standard 
Precision (SP) which outperforms the first step in both sampling and scoring 
performances. Again, the 30% top-ranked poses were then submitted to the 
Extra-Precision (XP) Glide mode experiment, the final and most accurate 
docking step. During the molecular docking calculation, the adopted receptor 
grid was focused onto the co-crystallized ligand binding site (LVJ) with inner- 
and outer-box dimensions of 18×18×18 and 34.7×34.7×34.7, respectively.  
6.2 General synthetic methods 
The compounds 2-amino-6-bromo-1,3-benzothiazole and 2-amino-5-
bromo-1,3-benzothiazole were purchased from Sigma Aldrich and used as 
received. All solvents used for the synthesis were of HPLC grade, and were 
purchased from Sigma-Aldrich and Carlo Erba Reagenti. NMR spectra were 
recorded on 300 or 400 MHz Bruker Avance instrument. All compounds were 
dissolved in 0.5 mL of the following solvents: chloroform-d (Sigma-Aldrich, 
99.8 Atom % D); methanol-d4 (Sigma-Aldrich, 99.8 Atom % D); 
dimethylsulfoxyde-d6 (Sigma-Aldrich, 99.8 Atom % D). Coupling constants 
(J) are reported in Herz, and chemical shifts are expressed in parts per million 
(ppm) on the delta (δ) scale relative to CHCl3 (7.19 ppm for 
1
H and 77.0 ppm 
for 
13
C) or CH3OH (3.31 ppm for 
1
H and 49.15 ppm for 
13
C) or DMSO (2.50 
ppm for 
1
H and 39.51 ppm for 
13
C) as internal reference. Multiplicities are 
reported as follows: s, singlet; d, doublet; t, triplet; m, multiplet; dd, doublet of 
doublets. 
13
C NMR spectra were obtained at 100 MHz and referenced to the 




were performed on a LCQ DECA TermoQuest (San Josè, California, USA) 
mass spectrometer. Reactions were monitored on silica gel 60 F254 plates 
(Merck), and the spots were visualized under UV light. Analytical and semi-
preparative reversed-phase HPLC was performed on Agilent Technologies 
1200 Series high performance liquid chromatography using a Synergi Fusion 
C18 reversed-phase column (250 x 4.60mm, 4μ, 80 Å, flow rate = 1 mL/min; 
250 x 10.00mm, 10μ, 80 Å, flow rate = 4 mL/min respectively, 
Phenomenex®). The binary solvent system (A/B) was as follows: 0.1% TFA 
in water (A) and 0.1% TFA in CH3CN (B); gradient condition: from 5% B  to 
100 % B in 50 min. The absorbance was detected at 240 nm. All tested 
compounds were obtained with high purity (> 98% detected by HPLC 
analysis) and were fully characterized by HRMS, and NMR spectra.  
6.3 General prodecure for the synthesis of 
compounds 1-3, 7-10 and 11-13 
 




The synthesis of benzothiazole derivatives was carried out according to the 
selected synthetic route depicted in scheme 1. Pd-catalyzed Suzuki-Miyaura 
cross-coupling was performed between 3-(hydroxymethyl)phenylboronic acid 
and 2-amino-6-bromobenzothiazole or 2-amino-5-bromobenzothiazole 
respectively. The Suzuki-Miyaura reaction was chosen for our purpose 
because it is an efficient and versatile method for highly functionalized biaryls 
synthesis, in good yields under mild conditions. For the preparation of our 
compounds, the cross-coupling was performed under standard conditions 
using Pd(PPh3)4 as catalyst and aqueous carbonate base in a mixture of 
dioxane (80%) and H2O (20%) at 80 °C. Reactions proceeded with good yields 
(75% and 88%). Since the (hydroxymethyl)phenyl portion presented a primary 
alcohol it was necessary the protection of hydroxyl group before acylation 
reaction. We opted for a transient protection by trimethylsilyl ether which was 
formed in situ in dry acetonitrile at room temperature with pyridine and 
removed with acidic work-up. Acylation of the protected aminobenzothiazole 
nucleus was then accomplished adding to the reaction mixture the proper acyl 
chloride (a-h, Table 12). Compound 1-6 and 7-10 were obtained with 
moderate to high yields (32–85%). For compounds 11-13 we opted for a 
different synthetic approach because acylation of 2-amino-5-
bromobenzothiazole gave less polar compounds with consequently easier 
purifications. Acylation reactions were conducted in dry acetonitrile with 
pyridine at room temperature, between 2-amino-5-bromobenzothiazole and the 
proper acyl chloride (f-h, Table 12). Compounds 25-27 were then subjected to 
Suzuki-Miyaura coupling with 3-aminocarbonylphenylboronic acid to give 11, 




purified by reverse phase HPLC or flash column chromatography using 
different EtOAc:hexane mixtures, and were obtained with >98% purity. 
 





















Table 12 List of acyl chlorides used for the synthesis of benzothiazole derivatives. 
6.3.1 Synthesis of 3[3-(2-Amino-benzothiazol-6-yl)-phenyl]-
methanol (compound 23) 
 
 
2-Amino-6-bromobenzothiazole (460 mg, 1.0 equiv.), 3-
(hydroxymethyl)phenylboronic acid (365 mg, 1.2 equiv.), and 
tetrakis(triphenylphosphine)palladium(0) (115 mg, 5 mol%), were sequentially 
added to a degassed mixture of 1,4-dioxane (80%) and water (20%) (10 mL) 
and the mixture was stirred at r.t. for 30 min. Degassed aqueous Na2CO3 
solution (1 M, 2 equiv.) was added and the reaction mixture was heated under 
argon at 80 °C for 16 h. The mixture was transferred to a separating funnel, 
ethyl acetate was added and the organic layer was washed with brine, 
separated, and dried over MgSO4. The solvent was removed under reduced 




with a mixture of ethyl acetate (70%) and hexane (30%) to give 0.365 g (75%) 
of compound 23 as a pale oil. 
1
H NMR (CD3OD, 300 MHz): δ 7.74 (d, J = 1.8 Hz, 1H), 7.50 (s, 1H), 7.42 
(dd, J = 8.4, 1.9 Hz, 1H), 7.39 (m, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.28 (t, J = 
7.6 Hz, 1H), 7.16 (dd, J = 7.6 Hz, 1H), 4.56 (s, 2H). 
6.3.2 Synthesis of [3-(2-Amino-benzothiazol-5-yl)-phenyl]-
methanol (compound 24)  
 
2-Amino-5-bromobenzothiazole (300 mg, 1.0 equiv.), 3-
(hydroxymethyl)phenylboronic acid (237 mg, 1.2 equiv.), and 
tetrakis(triphenylphosphine)palladium(0) (75 mg, 5 mol%), were sequentially 
added to a degassed mixture of 1,4-dioxane (80%) and water (20%) (50 mL) 
and the mixture was stirred at r.t. for 30 min. Degassed aqueous Na2CO3 
solution (1 M, 2 equiv.) was added and the reaction mixture was heated under 
argon at 80 °C for 16 h. The mixture was transferred to a separating funnel, 
ethyl acetate was added and the organic layer was washed with brine, 
separated, and dried over MgSO4. The solvent was removed under reduced 
pressure, and the residue was purified by flash chromatography on silica gel 
eluting with a mixture of ethyl acetate (70%) and hexane (30%) to give 0.278 





H NMR (CD3OD, 400 MHz): δ 7.49 (d, J = 1.7 Hz, 1H), 7.46 (s, 1H), 7.35 
(d, J = 8.1 Hz, 1H), 7.30 (dd, J = 7.6, 1.7 Hz, 1H), 7.19 (t, J = 7.5 Hz, 1H), 
7.14 (dd, J = 7.6, 1.6 Hz, 1H), 7.10 (dd, J = 8.2, 1.8 Hz, 1H), 4.51 (s, 2H). 
6.3.3 General procedure for acylation reactions (compounds 1-
10)  
 
To a solution of compounds 23 or 24 (50 mg, 1 equiv.) in dry acetonitrile 
(10 mL) and pyridine (0.49 mL, 30 equiv.) was added chlorotrimethylsilane 
(0.26 mL, 10 equiv.) at 0 °C. The resulting mixture was stirred at r.t. for 3 h, 
then the proper acyl chloride (Table 12) was added (1.5 equiv) and the 
reaction mixture was stirred overnight. The mixture was diluted with ethyl 
acetate, washed with 0.5 N HCl (10 mL x 3) and brine (10 mL) and dried 
(MgSO4). The solvent was removed under reduced pressure, and the residue 
was purified by flash column chromatography using different EtOAc:hexane 
mixtures or by semi-preparative reversed-phase HPLC, using a Sinergy 




mutigradient from 5% to 100% CH3CN over 50 min, flow rate = 4 mL/min, 
UV detector at 240 nm. Yields for each compound are reported below. 
2-chloro-4-fluoro-N-(6-(3-(hydroxymethyl)phenyl)benzo[d]thiazol-2-




was obtained by following the general procedure, using 2-chloro-4-
fluorobenzoyl chloride (a) (65% yield). 
1
H NMR (CD3OD, 400 MHz): δ 8.08 (d, J = 1.8 Hz, 1H), 7.73 (d, J = 8.4 
Hz, 1H), 7.64 (dd, J = 8.3, 2.1 Hz, 2H), 7.59 (s, 1H), 7.50 (m, 1H), 7.34 (t, J = 
7.5 Hz, 1H), 7.32 (dd, J = 8.4, 2.5 Hz, 1H), 7.26 (m, 1H), 7.16 (td, J = 8.4, 2.5 
Hz, 1H), 4.60 (s, 2H); 
13
C NMR (CD3OD, 100 MHz): δ 167.0; 165.3 (d, J = 
252 Hz), 160.0, 149.5, 145.3, 143.6, 142.3, 139.0, 134.3 (d, J = 13.8 Hz), 
132.6 (d, J = 9.6 Hz), 132.3 (d, J = 3.0 Hz), 130.1, 127.3, 127.1, 126.9, 126.9, 
122.3, 120.8, 118.9 (d, J = 25.0 Hz), 115.8 (d, J = 22.0 Hz), 65.31; ESI-HRMS 
calcd for C21H15ClFN2O2S [M+ H]
+










yl)benzamide (compound 2) 
 
 
was obtained by following the general procedure, using 2,5-difluorobenzoyl 
chloride (b). Purification was performed by semi-preparative reversed-phase 
HPLC, tR = 36 min. The pure product was obtained as a white solid. (72% 
yield). 
1
H NMR (CD3OD, 400 MHz): δ 8.20 (d, J = 1.8 Hz, 1H), 7.87 (d, J = 8.4 
Hz, 1H), 7.77 (dd, J = 8.4, 1.8 Hz, 1H), 7.71 (s, 1H), 7.65 (m, 2H), 7.47 (t, J = 
7.6 Hz, 1H), 7.40 (m, 3H), 4.72 (s, 2H); 
13
C NMR (CD3OD, 100 MHz): δ 
160.1 (d, J = 32.0 Hz), 157.6, 156.9 (d, J = 214.0 Hz), 156.5 (d, J = 228.0 Hz), 
147.4, 141.5, 140.9, 137.7, 129.8, 129.1, 126.6, 126.2, 126.2, 125.9, 122.1 (dd, 
J = 24.5, 9.8 Hz), 121.2, 120.1 (m), 119.8, 118.4 (d, J = 26.0 Hz), 118.1 (dd, J 
= 17.0, 8.0 Hz), 65.3; ESI-HRMS calcd for C21H15F2N2O2S 397.0822 [M+ 
H]
+
, found 397.08175.  
2-bromo-N-(6-(3-(hydroxymethyl)phenyl)benzo[d]thiazol-2-






was isolated by following the general procedure, using 2-bromobenzoyl 
chloride (c). Purification was performed by semi-preparative reversed-phase 
HPLC, tR = 41 min. The pure product was obtained as a colorless oil (78% 
yield). 
1
H NMR (CD3OD, 400 MHz): δ 8.19 (d, J = 1.8 Hz, 1H), 7.85 (d, J = 8.4 
Hz, 1H), 7.76 (d, J = 8.2 Hz, 2H), 7.71 (s, 1H), 7.62 (m, 2H), 7.54 (td, J = 7.5, 
1.2 Hz, 1H), 7.47 (m, 2H), 7.37 (d, J = 7.5 Hz, 1H), 4.72 (s, 2H); 
13
C NMR 
(CD3OD, 100 MHz): δ 168.7, 160.0, 149.5, 143.6, 142.2, 139.0, 138.0, 134.6, 
134.4, 133.7, 133.3, 130.4, 130.1, 128.9, 127.2, 127.1, 126.9, 126.9, 122.3, 





dimethylnicotinamide (compound 4) 
 
 
was isolated as a white solid using 2,4-dichloropyridine-3-carbonyl chloride 
(d) (51% yield). 
1
H NMR (CD3OD, 400 MHz): δ 8.48 (d, J = 5.5 Hz, 1H), 8.22 (d, J = 1.8 
Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.77 (dd, J = 8.5, 1.8 Hz, 1H), 7.71 (s, 1H), 
7.66 (d, J = 5.4 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 






methylisonicotinamide (compound 5) 
 
 
was isolated as a white solid using 2-chloro-6-methylpyridine-4-carbonyl 
chloride (e) (53% yield). 
1
H NMR (CDCl3, 400 MHz): δ 8.03 (d, J = 1.6 Hz, 1H), 7.87 (m, 3H), 7.80 
(dd, J = 8.5, 1.7 Hz, 1H), 7.59 (s, 1H), 7.51 (d, J = 7.5 Hz, 1H), 7.44 (t, J = 7.6 
Hz, 1H), 7.35 (d, J = 7.5 Hz, 1H), 4.77 (s, 2H), 2.63 (s, 3H). 
N-(6-(3-(hydroxymethyl)phenyl)benzo[d]thiazol-2-yl)-3,5-
dimethylfuran-2-carboxamide (compound 6) 
 
 
was obtained by following the general procedure, using 2,5-dimethylfuran-
3-carbonyl chloride (f). Purification was performed by semi-preparative 
reversed-phase HPLC, tR = 36 min. The pure product was obtained  as a 
colorless oil (80% yield). 
1
H NMR (CDCl3, 400 MHz): δ 7.96 (d, J = 1.6 Hz, 1H), 7.83 (d, J = 8.5 
Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.58 (s, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.42 
(t, J = 7.6 Hz, 1H), 7.34 (d, J = 7.5 Hz, 1H), 6.77 (s, 1H), 4.75 (s, 2H), 2.61 (s, 
3H), 2.27 (s, 3H); 
13




141.7, 140.3, 138.6, 129.9, 129.2, 127.1, 126.6, 126.3, 125.8, 120.0, 118.3, 
114.5, 113.9, 103.7, 65.1, 14.1, 13.3; ESI-HRMS calcd for C21H19N2O3S [M+ 
H]
+ 
379.1116, found 379.11122. 
2-bromo-N-(5-(3-(hydroxymethyl)phenyl)benzo[d]thiazol-2-
yl)benzamide (compound 7) 
 
 
was obtained by following the general procedure, using 2-bromobenzoyl 
chloride (c). Purification was performed by semi-preparative reversed-phase 
HPLC, tR = 36 min. The pure product was obtained as a colorless oil (78% 
yield). 
1
H NMR (CDCl3, 400 MHz): δ 7.89 (m, 2H), 7.77 (dd, J = 7.6, 1.8 Hz, 1H), 
7.61 (m, 3H), 7.53 (m, 1H), 7.44 (t, J = 7.6 Hz, 1H), 7.39 (m, 2H), 7.31 (td, J 
= 7.7, 1.8 Hz, 1H), 4.77 (s, 2H); 
13
C NMR (CDCl3, 100 MHz): δ 165.7, 161.0, 
144.9, 141.5, 140.6, 140.4, 134.1, 133.9, 132.9, 130.1, 129.1, 129.0, 127.7, 
126.7, 126.3, 125.9, 124.3, 121.8, 120.2, 117.5, 65.2; ESI-HRMS calcd for 
C21H16BrN2O2S [M+ H]
+ 
439.0116, found 439.01075. 
2-chloro-4-fluoro-N-(5-(3-(hydroxymethyl)phenyl)benzo[d]thiazol-2-






was obtained as a white solid using 2-chloro-4-fluorobenzoyl chloride (a) 
(82% yield). 
1
H NMR (CDCl3, 400 MHz): δ 7.85 (d, J = 8.3 Hz, 1H), 7.77 (dd, J = 8.7, 
5.9 Hz, 1H); 7.58 (m, 2H), 7.44 (m, 3H), 7.38 (m, 1H), 6.90 (dd, J = 8.3, 2.4 
Hz, 1H), 6.84 (td, J = 8.1, 2.4 Hz, 1H), 4.77 (s, 2H); 
13
C NMR (CDCl3, 100 
MHz): δ 164.5 (d, J = 255 Hz), 163.5, 161.4, 158.2, 141.8, 141.3, 140.0, 
134.4, 132.8 (d, J = 9.8 Hz), 129.6, 129.3, 127.2, 126.6, 126.6, 126.0, 125.0, 
122.2, 118.9 (d, J = 25.0 Hz), 117.0, 115.2 (d, J = 21.8 Hz), 65.18; ESI-HRMS 
calcd for C21H15ClFN2O2S [M+ H]
+ 
413.0527, found 413.05191. 
N-(5-(3-(hydroxymethyl)phenyl)benzo[d]thiazol-2-yl)-3,5-
dimethylfuran-2-carboxamide (compound 9) 
 
 
was isolated as a colorless oil using 2,5-dimethylfuran-3-carbonyl chloride 
(f) (65% yield). 
1
H NMR (CDCl3, 400 MHz): δ 7.83 (d, J = 8.2 Hz, 1H), 7.77 (d, J = 1.5 
Hz, 1H), 7.56 (s, 1H), 7.51 (dd, J = 8.2, 1.5 Hz, 1H), 7.48 (m, 1H), 7.42 (t, J = 
7.5 Hz, 1H), 7.35 (m, 1H), 6.28 (s, 1H), 4.76 (s, 2H), 2.63 (s, 3H), 2.17 (s, 
3H); 
13
C NMR (CDCl3, 100 MHz): δ 162.7, 161.4, 160.7, 151.5, 141.8, 141.7, 
139.8, 129.3, 129.1, 126.7, 126.5, 125.8, 125.0, 122.3, 115.7, 113.7, 113.7, 








yl)benzamide (compound 10) 
 
 
was obtained by following the general procedure, using 2,6-
dichlorobenzoyl chloride (g). The pure product was obtained as a white solid 
(85% yield). 
1
H NMR (CDCl3, 400 MHz): δ 7.83 (d, J = 8.3 Hz, 1H), 7.59 (s, 1H), 7.53 
(dd, J = 8.4, 1.4 Hz, 1H), 7.49 (m, 2H), 7.39 (m, 1H), 7.36 (s, 1H), 6.84 (m, 
2H), 6.77 (dd, J = 9.3, 6.6 Hz, 1H), 4.81 (s, 2H); 
13
C NMR (DMSO-d6 100 
MHz): δ 163.2, 157.9, 149.3, 143.3, 139.7, 139.0, 134.2, 132.3 (2C), 131.1, 
130.6, 128.8, 128.3, 125.6 (2C), 125.3, 125.0, 123.0, 122.3, 118.0, 62.9; ESI-
HRMS calcd for C21H15Cl2N2O2S [M+ H]
+ 
















To a solution of 2-amino-5-bromobenzothiazole (200 mg, 1 equiv.) in dry 
acetonitrile (20 mL) and pyridine (0.11 mL, 1.5 equiv.) the proper acyl 
chloride was added (1.2 equiv) and the reaction mixture was stirred overnight. 
The mixture was diluted with ethyl acetate, washed with water (10 mL x 2) 
and brine (10 mL) and dried over anhydrous MgSO4. The solvent was 
removed under reduced pressure, and the residue was purified by flash 






was isolated as a colorless oil using 2,5-dimethylfuran-3-carbonyl chloride 





H NMR (CDCl3/CD3OD 1:1, 300 MHz): δ 7.86 (d, J = 1.9 Hz, 1H), 7.69 
(d, J = 8.4 Hz, 1H), 7.37 (dd, J = 8.5, 1.9 Hz, 1H), 6.49 (s, 1H), 2.58 (s, 3H), 







was isolated as a colorless oil using 2,6-dichlorobenzoyl chloride (g) (75% 
yield).  
1
H NMR (CDCl3, 400 MHz): δ 8.69 (d, J = 1.7 Hz, 1H), 7.53 (dd, J = 8.3, 






was isolated as a colorless oil using 4-fluoro-2-(trifluoromethyl)benzoyl 





H NMR (DMSO-d6, 400 MHz): δ 8.28 (d, J = 1.8 Hz, 1H), 8.08 (dd, J = 
8.7, 5.2 Hz, 1H), 7.99 (d, J = 8.2 Hz, 1H), 7.88 (dd, J = 9.2, 2.5 Hz, 1H), 7.74 
(dd, J = 8.2, 1.8 Hz, 1H), 7.68 (m, 1H). 





Compounds 25-27 (1.0 equiv.), 3-aminocarbonylphenylboronic acid (1.2 
equiv.), and tetrakis(triphenylphosphine)palladium(0) (5 mol%), were 
sequentially added to a degassed mixture of 1,4-dioxane (80%) and water 
(20%) (50 mL) and the mixture was stirred at r.t. for 30 min. Degassed 
aqueous Na2CO3 solution (1 M, 2 equiv.) was added and the reaction mixture 
was heated under argon at 80 °C for 16 h. The mixture was transferred to a 




with brine, separated, and dried over MgSO4. The solvent was removed under 
reduced pressure, and the residue was purified by semi-preparative reversed-
phase HPLC. 
N-(5-(3-carbamoylphenyl)benzo[d]thiazol-2-yl)-3,5-dimethylfuran-2-
carboxamide (compound 11) 
 
 
was obtained by following the general procedure. Purification was 
performed by semi-preparative reversed-phase HPLC, tR = 38 min. The 
product was isolated as a white solid (32% yield). 
1
H NMR (CDCl3, 400 MHz): δ 8.08 (s, 1H), 8.00 (s, 1H), 7.91 (d, J = 8.3 
Hz, 1H), 7.84 (d, J = 7.7 Hz, 2H), 7.70 (d, J = 8.5 Hz, 1H), 7.59 (t, J = 7.9 Hz, 
1H), 6.81 (s, 1H), 2.65 (s, 3H), 2.31 (s, 3H); 
13
C NMR (DMSO-d6, 100MHz): 
δ 167.9, 162.1, 159.1, 158.0, 157.7, 149.8, 149.4, 140.2, 138.1, 135.0, 129.8, 
129.0, 126.6, 125.9, 122.7, 122.2, 118.4, 115.8, 104.8, 13.7, 13.1; ESI-HRMS 
calcd for C21H18N3O3S [M+ H]
+ 








was obtained by following the general procedure and isolated as a white 
solid (42% yield).  
1
H NMR (CDCl3, 400 MHz): δ 8.52 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 7.6 
Hz, 1H), 7.53 (dd, J = 8.5, 7.5 Hz, 1H), 7.44 (m, 1H), 7.14 (m, 3H), 6.98 (d, J 
= 8.4 Hz, 2H), 6.87 (dd, J = 8.8, 7.3 Hz, 1H); 
13
C NMR (CDCl3, 100MHz): δ 
174.0, 167.7, 164.4, 138.0, 137.2, 136.3, 133.5, 131.4 (2C), 131.0, 129.8, 
129.4, 128.6, 128.2 (2C), 127.3, 127.1, 126.5, 125.5, 122.6, 117.5; ESI-HRMS 
calcd for C21H14Cl2N3O2S [M+ H]
+
 442.0184, found 441.29757. 
N-(5-(3-carbamoylphenyl)benzo[d]thiazol-2-yl)-4-fluoro-2-
(trifluoromethyl)benzamide (compound 13) 
 
 
was obtained by following the general procedure. Purification was 
performed by semi-preparative reversed-phase HPLC, tR = 41 min. The 
product was isolated as a white solid (45% yield). 
1
H NMR (DMSO-d6 400 MHz): δ 8.27 (s, 1H), 8.14 (m, 3H), 7.95 (dd, J = 
8.6, 5.4 Hz, 1H), 7.86 (m, 2H), 7.72 (m, 3H); 
13
C NMR (DMSO-d6 100 MHz): 
δ 165.7, 162.5 (d, J = 250.0 Hz), 158.7, 157.8 (d, J = 30.7 Hz), 149.2, 141.1, 
136.5, 132.0 (d, J = 8.8 Hz), 131.8, 131.7, 131.1, 130.5, 130.2, 129.9, 128.7 
(dd, J = 32.6, 8.5 Hz); 122.9, 122.6 (q, J = 270.0 Hz), 122.5, 119.6 (d, J = 21.4 
Hz), 118.9, 118.8, 114.5 (dd, J = 26.0, 4.7 Hz); ESI-HRMS calcd for 
C22H14F4N3O2S [M+ H]
+ 
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7.1 Computational details 
The structures of the reagents, namely all commercially available acyl 
chlorides and boronates at Sigma Aldrich Company, were converted from 2D 
structures to 3D structures suitable for the docking stage of the process, using 
LigPrep software (v. 3.4; Schrödinger, LLC, 2015). Then, the compounds 
were prepared using Reagent Preparation: in the acyl chlorides, a cleavage 
between the chloride and the carbonyl group was applied in order to select the 
carbonyl moiety as building block, while the acidic moiety was removed in the 
boronic acids. The final .bld files were combined with the scaffolds obtaining 
the novel library (C). LigPrep performed calculation increased the number to 
424,202 molecules for library C, and a final energy minimization of the library 
with Optimized Potentials for Liquid Simulations (OPLS) 2005 force field was 
performed. After the application of QikProp
110
 and LigFilter, 
117
 the final 
library C contained 15,412 compounds  
In the docking step, mPGES-1 three-dimensional crystal structure (PDB 
code: 4BPM)
209
 was used for the structure-based molecular docking 
experiments. The three-dimensional model of the protein was prepared using 
the Schrödinger Protein Preparation Wizard,
117
 starting from the 
aforementioned crystal structure co-complexed with the inhibitor LVJ (2-
[[2,6-bis(chloranyl)-3-[(2,2-dimethylpropanoylamino)methyl]phenyl]amino]-
1-methyl-6-(2-methyl-2-oxidanyl-propoxy)-N-[2,2,2-
tris(fluoranyl)ethyl]benzimidazole-5-carboxamide) (PDB code: 4BPM).
209
 The 
combinatorial library was submitted to structure-based molecular docking 
experiments on the mPGES-1 3D protein structure, using Glide software.
103, 104
 
Basically, the virtual screening workflow
117
 ( section 3.3.3) was used: a first 




Virtual Screening (HTVS) precision mode of Glide that allows a first 
enrichment from the starting library of compounds with a high fastness. The 
30% top-ranked poses, filtered according to docking score values, were then 
submitted to a second round of docking experiments, using the Standard 
Precision (SP) which outperforms the first step in both sampling and scoring 
performances. Again, the 30% top-ranked poses were then submitted to the 
Extra-Precision (XP) Glide mode experiment, the final and most accurate 
docking step. During the molecular docking calculation, the adopted receptor 
grid was focused onto the co-crystallized ligand binding site (LVJ) with inner- 
and outer-box dimensions of 18×18×18 and 34.7×34.7×34.7, respectively.  
7.2 General synthetic methods 
The compound 2-amino-5-(4-bromophenyl)thiadiazole was purchased from 
Sigma-Aldrich and was used without any purification. All solvents used for 
the synthesis were of HPLC grade; they were purchased from Sigma-Aldrich 
and Carlo Erba Reagenti. NMR spectra were recorded on 300 or 400 MHz 
Bruker Avance instrument. All compounds were dissolved in 0.5 mL of the 
following solvents: chloroform-d (Sigma-Aldrich, 99.8 Atom % D); methanol-
d4 (Sigma-Aldrich, 99.8 Atom % D); dimethylsulfoxyde-d6 (Sigma-Aldrich, 
99.8 Atom % D). Coupling constants (J) are reported in Herz, and chemical 
shifts are expressed in parts per million (ppm) on the delta (δ) scale relative to 
CHCl3 (7.19 ppm for 
1
H and 77.0 ppm for 
13
C) or CH3OH (3.31 ppm for 
1
H 
and 49.15 ppm for 
13
C) or DMSO (2.50 ppm for 
1
H and 39.51 ppm for 
13
C) as 
internal reference. Multiplicities are reported as follows: s, singlet; d, doublet; 
t, triplet; m, multiplet; dd, doublet of doublets. 
13
C NMR spectra were 
obtained at 100 MHz and referenced to the internal solvent signal. High 




DECA TermoQuest (San Josè, California, USA) mass spectrometer. Reactions 
were monitored on silica gel 60 F254 plates (Merck), and the spots were 
visualized under UV light. Analytical and semi-preparative reversed-phase 
HPLC was performed on Agilent Technologies 1200 Series high performance 
liquid chromatography. using a Nucleodur C8 reversed-phase column (250 x 
10.00 mm, 5 µM, 110 Å, flow rate = 4 mL/min, UV detector at 240 nm). The 
binary solvent system (A/B) was as follows: 0.1% TFA in water (A) and 0.1% 
TFA in CH3CN (B). Specific solvent gradient was applied for each compound. 
All tested compounds were obtained with high purity (> 98% detected by 
HPLC analysis) and were fully characterized by HRMS, and NMR spectra.  




The synthesis of thiadiazole derivatives was carried out according to the 
selected synthetic route depicted in scheme 2. Acylation reactions were 
performed between 2-amino-5-(4-bromophenyl)thiadiazole and acyl chlorides 




b and i respectively (Table 13) to obtain the proper acylated intermediated 163 
and 164. The acylation was performed in dry acetonitrile at room temperature 
with pyridine. Reactions proceeded with good yields (74% and 92%). 
 Then, Pd-catalyzed Suzuki-Miyaura cross-coupling was performed 
between compound 163 and 2-aminophenylboronic acid or 3-
hydroxyphenylboronic acid respectively, to obtain the final products 14 and 
15, while the coupling between compound 164 and the boronic acids above, 
provided products 16 and 17. The cross-coupling was performed under 




catalyst and aqueous carbonate base in a mixture 7:3 dioxane:H2O at 80 °C.  
For compounds 18-22 we opted for a different synthetic approach, because 
halogens on the acylated intermediates could be involved in the coupling. 
Since the aminophenyl and the hydroxyphenyl portion presented an amine and 
a hydroxyl group respectively, it was necessary the use of protective groups. 
In the synthesis of compounds 18-20, the 2-(N-Boc-amino)phenylboronic acid 
was used, and the final deprotection step gave the desired products, while for 
compounds 21 and 22 chlorotrimethylsilane (TMSCl) was used for the 
protection of the hydroxyl group in situ during the acylation reaction, and the 
consequent removal with acidic work-up afforded the products. Suzuki 
reactions were carried out between 2-amino-5-(4-bromophenyl)thiadiazole and 
2-(N-Boc-amino)phenylboronic acid to give compound 30, and between 2-
amino-5-(4-bromophenyl)thiadiazole and 3-hydroxyphenylboronic acid to 
give compound 31. Acylation reactions were performed on compound 30 with 
the acyl chlorides c, d and e (Table 13) to obtain compounds 32, 33, and 34. 




afforded the final products 18-20. Finally, compound 31 was protected by 
trimethylsilyl  ether, formed in situ in dry acetonitrile at room temperature 
with pyridine. Acylation of the protected aminothiadiazole nucleus was then 
accomplished adding to the reaction mixture the proper acyl chloride (c, d).  
All compounds were purified by high performance liquid chromatography 
(HPLC) or by flash column chromatography using different petroleum 
ether:ethyl acetate mixtures. 
















7.3.1 General procedure for the synthesis of compounds 14 
and 15 
The common intermediate 163 was synthesized as reported below:  
 
To a solution of 2-amino-5-(4-bromophenyl)thiadiazole (100 mg, 0.39 
mmol) in dry CH3CN (5 ml) were added pyridine (1.5 eq., 47 μL, 0.586 mmol) 
and 2,5-difluorobenzoyl chloride (1.5 eq., 72 μL, 0.586 mmol) under dry 
conditions. The mixture was stirred for two hours at room temperature. Then, 
ethyl acetate was added and the resulting mixture was washed with aqueous 
HCl 0.5 N (x2) and brine (x2). The organic phase was dried over anhydrous 
Na2SO4 and evaporated, affording 179 mg of white solid. Purification by flash 
chromatography, using a mixture 7:3 PET:EtOAc provided the pure product 
(114.2 mg, yield 74%).  
1
H NMR (400 MHz, CD3OD): δ 7.92 (d, J = 8.3 Hz, 2H), 7.56 (d, J = 8.3 
Hz, 2H), 7.37 (m, 2H), 7.25 (m, 1H). 
N-(5-(2'-amino-[1,1'-biphenyl]-4-yl)-1,3,4-thiadiazol-2-yl)-2,5-







In a 25 mL flask were added compound 163 (40 mg; 0.10 mmol), K2CO3 (3 
eq.; 41.5 mg; 0.300 mmol), 2-aminophenylboronic acid (1.5 eq.; 26 mg; 0.150 
mmol) and Pd(dppf)Cl2 
.
CH2Cl2 (0.2 eq.; 16.3 mg; 0.02 mmol) and Schlenk 
techniques were applied. A degassed mixture (5 ml) of 1,4-dioxane (70%) and 
water (30%) was added and the mixture was stirred overnight at 80 °C. Ethyl 
acetate was added and the organic layer was washed with distilled water (x2) 
and brine (x2), separated, and dried over anhydrous Na2SO4. After 
concentration under reduced pressure, a brown solid was obtained (65.8 mg). 
A purification was performed by semi-preparative reversed-phase HPLC using 
the following conditions: gradient from 5% ending to 100% CH3CN over 50 
min, tR = 29.5 min. The pure product was obtained (21.7 mg, yield 53%) and 
characterized by ESI-MS and NMR spectra (purity grade >98%). 
1
H NMR (400 MHz, CD3OD) δ 8.14 (d, J = 8.2 Hz, 2H), 7.69–7.60 (m, 
3H), 7.47–7.35 (m, 4H), 7.33 – 7.24 (m, 2H); ESI-HRMS calcd for 
C21H14F2N4OS [M + H]
+
 409.0856, found 409.0947. 
 
2,5-difluoro-N-(5-(3'-hydroxy-[1,1'-biphenyl]-4-yl)-1,3,4-thiadiazol-2-
yl)benzamide (compound 15) 
 
 
In a 25 mL flask were added: compound 163 (57 mg; 0.144 mmol), K2CO3 




mg; 0.216 mmol) and Pd(dppf)Cl2 
. 
CH2Cl2 (0.2 eq.; 23.5 mg; 0.029 mmol), 
applying Schlenk techniques. A degassed mixture (5 ml) of 1,4-dioxane (70%) 
and water (30%) was added and the mixture was stirred overnight at 80 °C 
under nitrogen. After the addition of ethyl acetate, the mixture was washed 
with distilled water (x2) and brine (x2). The organic phase was dried over 
anhydrous Na2SO4 and evaporated. A brown solid was obtained (59.5 mg). 
Purification by semi-preparative reversed-phase HPLC was carried out, using 
a multigradient H2O:CH3CN (0.1% TFA solutions): from 20% to 65% CH3CN 
over 5 min, from 65% to 80% CH3CN over 35 min and from 80% to 100% 
CH3CN over 10 min, total time = 50 min; tR = 14.1 min. The pure product was 
obtained as a white solid (21.2 mg, yield 36%) and characterized by ESI-MS 
and NMR spectra (purity grade >98%). 
1
H NMR (400MHz, DMSO-d6): δ 7.92 (d, J = 8.3 Hz, 2H), 7.69 (m, 2H), 
7.61 (m, 1H), 7.27 (t, J = 7.9 Hz, 1H), 7.21 (m, 2H), 7.13 (d, J = 7.6 Hz, 1H), 
7.08 (s, 1H), 6.78 (dd, J = 8.2, 2.4 Hz, 1H); 
13
C NMR (100MHz, DMSO-d6): δ 
162.0, 160.1 (d, J=210 Hz), 158.9, 158.5, 155.8 (d, J=246 Hz), 150.9, 141.1, 
140.7, 130.4, 129.6, 127.7 (4 C), 124.7, 121.5, 120.1, 119.4 (dd, J=25.0, 8.4 
Hz), 118.8 (m), 118.4 (dd, J=24.3, 8.4 Hz), 118.3 (d, J = 25.9 Hz); ESI-HRMS 
calcd for C21H13F2N3O2S [M + H]
+
 410.0775, found 410.0209. 
7.3.2 General procedure for the synthesis of compounds 16 
and 17 






To a solution of 2-amino-5-(4-bromophenyl)thiadiazole (50 mg, 0.195 
mmol) in dry CH3CN (5 ml) were added pyridine (1.5 eq., 23.6 μL, 0.292 
mmol) and 3-methyl-2-furoyl chloride (1.5 eq., 34 μL, 0.292 mmol) 
respectively, and the mixture was stirred for two hours at room temperature 
under anhydrous conditions. After dilution with ethyl acetate, the organic 
phase was washed with aqueous HCl 0.5 N (x2) and brine (x2), separated, 
dried over anhydrous Na2SO4 and concentrated under vacuum. A white solid 
was obtained (128 mg). Purification by flash column chromatography 
(PET:EtOAc 7:3) afforded 65.4 mg of pure product (92% yield), characterized 
by 
1
H NMR.  
1
H NMR (400 MHz, CD3OD): δ 7.75 (d, J = 8.5 Hz, 2H); 7.59 (d, J = 8.4 
Hz, 2H); 7.53 (s, 1H); 6.44 (d, J = 1.6 Hz, 1H); 2.43 (s, 3H).  
 
N-(5-(2'-amino-[1,1'-biphenyl]-4-yl)-1,3,4-thiadiazol-2-yl)-3-
methylfuran-2-carboxamide (compound 16) 
 
In a 25 mL flask were added: compound 164 (40 mg, 0.11 mmol), K2CO3 
(3 eq., 45.6 mg, 0.33 mmol), 2-aminophenylboronic acid (1.5 eq., 28.6 mg, 
0.165 mmol) and Pd(dppf)Cl2·CH2Cl2 (0.2 eq., 18 mg, 0.022 mmol) and 
Schlenk techniques were performed. The mixture was dissolved in a degassed 
solution (5 ml) of 1,4-dioxane (70%) and H2O (30%), and stirred at 80 °C over 




water (x2) and brine (x2), separated, dried over anhydrous Na2SO4 and 
evaporated under vacuum, affording a brown solid crude (77 mg). A 
purification was performed by semi-preparative reversed-phase HPLC, using 
the following conditions: gradient from 5% ending to 100% CH3CN over 50 
min, tR = 27.0 min. The pure product was obtained as a white solid (10.8 mg, 
26% yield) and characterized by ESI-MS and NMR spectra (purity grade 
>98%). 
1
H NMR (400MHz, DMSO-d6): δ 8.04 (d, J = 8.0 Hz, 2H), 7.90 (s, 1H), 
7.62 (d, J = 8.0 Hz, 2H), 7.15 (m, 2H), 6.91 (d, J = 8.0 Hz, 1H), 6.81 (t, J = 
7.5 Hz, 1H), 6.68 (s, 1H), 2.40 (s, 3H); 
13
C NMR (100MHz, DMSO-d6): δ 
161.1, 158.3, 156.8, 145.6, 142.7, 141.5, 140.2, 131.3, 130.1. 129.6 (2C), 
128.8, 128.6, 127.3 (2C), 126.2, 118.6, 116.8, 116.0, 11.1; ESI-HRMS calcd 
for C20H16N4O2S [M + H]
+
 377.1072, found 377.0495. 
 
N-(5-(3'-hydroxy-[1,1'-biphenyl]-4-yl)-1,3,4-thiadiazol-2-yl)-3-
methylfuran-2-carboxamide (compound 17) 
 
 
   
In a 25 mL bottom flask were added: compound 164 (25 mg, 0.068 mmol), 
K2CO3 (3 eq., 28 mg, 0.204 mmol), 3-hydroxyphenylboronic acid (1.5 eq., 14 
mg, 0.102 mmol) and Pd(dppf)Cl2·CH2Cl2 (0.2 eq., 11.1 mg, 0.0136 mmol) 




degassed mixture (5 ml) of 1,4-dioxane (70%) and H2O (30%), and stirred at 
80 °C over night. Ethyl acetate was added and the organic layer was washed 
with distilled water (x2) and brine (x2), separated, dried over anhydrous 
Na2SO4 and evaporated under vacuum, affording a brown solid crude (33 mg). 
A purification was performed by semi-preparative reversed-phase HPLC, 
using a multigradient H2O-CH3CN (0.1% TFA solutions): from 5% to 50% 
over 5 min, from 50% to 70% over 30 min, from 70% ending to 100% over 10 
min, total time = 45 min; tR = 19,6 min. The pure product was obtained as a 
white solid (12.1 mg, 47% yield) and characterized by ESI-MS and NMR 
spectra (purity grade >98%). 
1
H NMR (400MHz, DMSO-d6): δ 8.03 (d, J = 8.1 Hz, 2H), 7.89 (d, J = 1.7 
Hz, 1H), 7.78 (d, J = 8.1 Hz, 2H), 7.30 (t, J = 7.9 Hz, 1H), 7.16 (d, J = 7.7 Hz, 
1H), 7.10 (s, 1H), 6.81 (dd, J = 8.1, 2.2 Hz, 1H), 6.67 (d, J = 1.7 Hz, 1H), 2.39 
(s, 3H); 
13
C NMR (100MHz, DMSO-d6): δ 158.3, 158.0, 157.9, 157.7, 157.4, 
145.6, 142.2, 140.4, 131.3, 130.1, 129.1, 127.4 (4C), 117.5, 116.0, 115.1, 




 378.0912, found 
378.0746. 
7.3.3 Synthesis of compounds 18-20 
The common intermediate 30 was synthesized as reported below: 
 
 
In a 25 mL flask were added: 2-amino-5-(4-bromophenyl)thiadiazole (300 




amino)phenylboronic acid (1.5 eq., 560 mg, 1.75 mmol) and 
Pd(dppf)Cl2·CH2Cl2 (0.2 eq., 191 mg, 0.234 mmol). Schlenk techniques were 
applied. The mixture was dissolved in a degassed mixture (10 ml) of 1,4-
dioxane (70%) and H2O (30%), and stirred at 80 °C over night. Ethyl acetate 
was added and the organic layer was washed with distilled water (x 2) and 
brine (x 2), separated, dried over anhydrous Na2SO4 and evaporated under 
vacuum, affording a brown solid crude (734 mg). Purification by flash column 
chromatography (PET:EtOAc 1:1) afforded 258.4 mg of pure product (60% 
yield). 
1
H NMR (CD3OD 400MHz): δ 7.82 (d, J = 7.9 Hz, 2H), 7.52 (m, 3H), 7.34 
(m, 2H), 7.26 (m, 1H), 1.35 (s, 9H). 
7.3.3.1 Synthesis of compound 18 
 
 
To a solution of compound 30 (40 mg, 0.109 mmol) in dry CH3CN (5 ml) 
were added pyridine (1.5 eq., 11 μL, 0.133 mmol) and 2-bromobenzoyl 
chloride (1.5 eq., 17.4 μL, 0.133 mmol) under anhydrous conditions. The 
mixture was stirred for two hours at room temperature and diluted with ethyl 
acetate. The organic phase was washed with aqueous HCl 0.5 N (x2) and brine 
(x2), separated, dried over anhydrous Na2SO4 and evaporated to obtain 65 mg 
of solid crude. A purification was performed by semi-preparative reversed-




100% CH3CN over 45 min, tR = 43.7 min. 
1
H NMR analysis confirmed that 
compound 32 was obtained (21 mg, 35% yield) as an orange solid. 
1
H NMR (400MHz, CD3OD): δ 8.08 (d, J = 7.9 Hz, 2H), 7.75 (d, J = 7.9 
Hz, 1H), 7.62 (d, J = 7.7 Hz, 2H), 7.50 (m, 3H), 7.23 (m, 2H), 6.98 (m, 2H), 
1.28 (s, 9H). 
N-(5-(2'-amino-[1,1'-biphenyl]-4-yl)-1,3,4-thiadiazol-2-yl)-2-




The deprotection of compound 32 (21 mg, 0.0381 mmol) was carried out. 
After dissolution in a mixture of DCM (50%) and TFA (50%) (2 ml), the 
solution was stirred over night. After concentration under vacuum, the crude 
was purified by semi-preparative reversed-phase HPLC using the following 
conditions: gradient from 5% ending to 100% CH3CN over 45 min, flow rate 
= 4 mL/min, UV detector at 240 nm; tR = 26.4 min. The pure product was 
obtained as a yellow solid (16.5 mg, 96% yield). The compound was 
characterized by ESI-MS and NMR spectra (purity grade >98%). 
1
H NMR (400 MHz, CD3OD): 8.13 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 7.9 Hz, 
1H), 7.62 (d, J = 8.0 Hz, 3H), 7.50 (m, 5H), 7.42 (d, J = 7.6 Hz, 1H); 
13
C 




133.6, 132.7, 131.7, 131.3, 130.8, 130.5, 129.1 (2C), 129.0(2C), 128.6, 123.6 
(2C), 120.8; ESI-HRMS calcd for C21H14BrN4O2S [M + H]
+
 451.0228, found 
450.9545. 




To a solution of compound 30 (20 mg, 0.0540 mmol) in dry CH3CN (5 ml) 
were added pyridine (1,5 eq., 66 μL, 0.0815 mmol) and 2,4-dichloropyridine-
3-carbonyl chloride (1.5 eq., 11.2 μL, 0.0815 mmol) under anhydrous 
conditions. The mixture was stirred for two hours at room temperature and 
diluted with ethyl acetate. The organic phase was washed with aqueous HCl 
0.5 N (x 2) and brine (x2), separated, dried over anhydrous Na2SO4 and 
evaporated to obtain 76 mg of crude. A purification was performed by semi-
preparative reversed-phase HPLC using the following conditions: gradient 
from 5% ending to 100% CH3CN over 45 min, flow rate = 4 mL/min, UV 
detector at 240 nm; tR = 39.8 min. 
1
H NMR analysis confirmed that compound 
33 was obtained (12.2 mg, 42% yield) as an orange solid. 
1
H NMR (400MHz, CD3OD): δ 8.48 (d, J = 5.5 Hz, 1H), 8.05 (d, J = 8.3 
Hz, 2H), 7.66 (d, J = 5.4 Hz, 1H), 7.58 (d, J = 8.3 Hz, 2H), 7.38 (m, 2H), 7.29 











The de-protection of compound 33 (12.2 mg, 0.0223 mmol) was carried 
out. After dissolution in a mixture of DCM (50%) and TFA (50%) (2 ml), the 
solution was stirred over night. After concentration under vacuum, the crude 
was purified by semi-preparative reversed-phase HPLC using the following 
conditions: gradient from 5% ending to 100% CH3CN over 45 min, flow rate 
= 4 mL/min, UV detector at 240 nm; tR = 32 min. The pure product was 
obtained as a yellow solid (9.2 mg, 93% yield). The compound was 
characterized by ESI-MS and NMR spectra (purity grade >98%). 
1
H NMR (400 MHz, CD3OD) δ 8.49 (d, J = 5.5 Hz, 1H), 8.13 (d, J = 7.8 
Hz, 2H), 7.66 (d, J = 5.5 Hz, 1H), 7.62 (d, J = 7.8 Hz, 2H), 7.45 (m, 2 H), 7.36 
(m, 2H); 
13
C NMR (100MHz, CD3OD): δ 165.6, 163.5, 160.3, 153.0, 150.1 
(2C), 145.1, 142.1, 134.9, 134.8, 132.9, 131.2 (2C), 131.7 (2C), 131.1, 129.5, 







7.3.3.3 Synthesis of compound 20 
 
To a solution of compound 30 (15 mg, 0.0410 mmol) in dry CH3CN (5 ml) 
were added pyridine (1.5 eq., 5 μL, 0.0615 mmol) and 4-carbonyl-2-chloro-6-
methylpyridine chloride (1.5 eq., 6 μL, 0.0410 mmol) under anhydrous 
conditions. The mixture was stirred for two hours at room temperature and 
diluted with ethyl acetate. The organic phase was washed with aqueous HCl 
0.5 N (x 2) and brine (x2), separated, dried over anhydrous Na2SO4 and 
evaporated to obtain 76 mg of solid. A purification was performed by semi-
preparative reversed-phase HPLC using the following conditions: gradient 
from 5% ending to 100% CH3CN over 45 min, flow rate = 4 mL/min, UV 
detector at 240 nm; tR = 40.2 min. 
1
H NMR analysis confirmed that compound 
34 was obtained (4.9 mg, 23% yield) as a orange solid. 
1
H NMR (400MHz, CD3OD): δ 8.03 (d, J = 7.9 Hz, 2H); 7.84 (d, J = 11.0 
Hz, 2H); 7.57 (d, J = 8.0 Hz, 2H); 7.50 (d, J = 8.0 Hz, 1H); 7.37 (m, 2H); 7.29 









methylisonicotinamide (compound 20) 
 
 
The de-protection of compound 34 (4.9 mg, 0.0116 mmol) was carried out. 
After dissolution in a mixture of DCM (50%) and TFA (50%) 1/1 (2 ml), the 
solution was stirred over night. After concentration under vacuum, the crude 
was purified by semi-preparative reversed-phase HPLC using the following 
conditions: gradient from 5% ending to 100% CH3CN over 45 min, flow rate 
= 4 mL/min, UV detector at 240 nm; tR = 29.1 min. The pure product was 
obtained as a yellow solid (4.7 mg, 96% yield). The compound was 
characterized by ESI-MS and NMR spectra (purity grade >98%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.06 (d, J = 7.9 Hz, 2H), 7.96 (s, 1H), 
7.91 (s, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.12 – 7.03 (m, 2H), 6.80 (d, J = 8.0 Hz, 
1H), 6.68 (t, J = 7.4 Hz, 1H), 2.59 (s, 3H); 
13
C NMR (100MHz, DMSO-d6): δ 
162.1, 160.4, 158.1, 157.7, 150.0, 144.4, 142.9, 142.2, 130.0, 129.6 (2 C), 
128.8, 128.3, 127.4 (2 C), 125.1, 121.0, 119.8, 117.4, 116.0, 23.7; ESI-HRMS 
calcd for C21H16ClN5OS [M + H]
+











In a 25 mL flask were added: 2-amino-5-(4-bromophenyl)thiadiazole (300 
mg, 1.17 mmol), K2CO3 (3 eq., 485 mg, 3.51 mmol), 3-hydroxyphenylboronic 
acid (1.5 eq., 243 mg, 1.75 mmol) and Pd(dppf)Cl2·CH2Cl2 (0.2 eq., 191 mg, 
0.234 mmol). Schlenk techniques were applied. The mixture was dissolved in 
a degassed mixture (10 ml) of 1,4-dioxane (70%) and water (30%) and stirred 
at 80 °C overnight. Ethyl acetate was added and the organic layer was washed 
with distilled water (x2) and brine (x2), separated, dried over anhydrous 
Na2SO4 and evaporated under vacuum, affording a brown solid crude (440 
mg). Purification by flash column chromatography (PET:EtOAc 8:2) afforded 
150 mg of pure product (48% yield). 
1
H NMR (400 MHz, CDCl3): δ 9.34 (s, 1H, OH); 7.56 (d, J = 8.4 Hz, 2H); 
7.43 (d, J = 8.4 Hz, 2H); 7.02 (t, J = 7.9 Hz, 1H); 6.85 (d, J = 7.7 Hz, 1H); 
6.80 (m, 1H); 6.53 (dd, J = 8.0, 1.6 Hz, 1H). 
7.3.5 General procedure for the synthesis of compounds 21 
and 22 
To a solution of compound 31 (40 mg, 0.148 mmol) in dry CH3CN (5 ml) 
was added pyridine (30 eq., 359 μL, 4.44 mmol). The mixture was cooled to 
0°C, and chlorotrimethylsilane (10 eq., 856 μL 1.48 mmol) was added. The 




acyl chloride (1.5 eq) was added and the resulting mixture was stirred for two 
hours. After dilution with ethyl acetate, the organic phase was washed with 
aqueous HCl 0.5 N (x2) and brine (x2), separated, dried over anhydrous 
Na2SO4 and evaporated. Purification by semi-preparative reversed-phase 
HPLC and flash chromatography afforded the products. 
2-bromo-N-(5-(3'-hydroxy-[1,1'-biphenyl]-4-yl)-1,3,4-thiadiazol-2-




was obtained as a brown solid by following the general procedure, using 
acyl chloride c. A purification was performed by semi-preparative reversed-
phase HPLC using the following conditions: a mutigradient from 5% to 40% 
CH3CN over 5 min, from 40% to 60% CH3CN over 30 min, from 60% ending 
to 100% CH3CN over 5 min (total time = 40 min), flow rate = 4 mL/min, UV 
detector at 240 nm; tR = 9.3 min. The pure product was obtained (38.9 mg, 
58% yield) as a white solid. The compound was characterized by ESI-MS and 
NMR spectra (purity grade >98%). 
1
H NMR (400 MHz, DMSO-d6) δ 9.66 (s, OH, 1H), 8.04 (d, J = 8.0 Hz, 
2H), 7.76 (m, 3H), 7.67 (d, J = 7.4 Hz, 1H), 7.49 (m, 2H), 7.30 (t, J = 7.9 Hz, 
1H), 7.16 (d, J = 7.7 Hz, 1H), 7.10 (s, 1H), 6.81 (d, J = 8.0 Hz, 1H); 
13
C NMR 




132.9, 132.2, 130.1, 129.9, 129.1, 127.7, 127.6 (2 C), 127.46 (2 C), 119.2, 









 was obtained by following the general procedure, using acyl chloride e. 
Purification by flash column chromatography using a mixture of PET (60%) 
and EtOAc (40%) afforded the pure product (49.4 mg, 79% yield) as a white 
solid. The compound was characterized by ESI-MS and NMR spectra (purity 
grade >98%). 
1
H NMR (400 MHz, DMSO-d6) δ 9.66 (s, 1H, OH), 8.07 (d, J = 8.3 Hz, 
2H), 7.96 (s, 1H), 7.91 (s, 1H), 7.80 (d, J = 8.4 Hz, 2H), 7.31 (t, J = 7.9 Hz, 
1H), 7.17 (d, J = 7.9 Hz, 1H), 7.12 (s, 1H), 6.84 (d, J = 6.5 Hz, 1H), 2.59 (s, 
3H); 
13
C NMR (100MHz, DMSO-d6): δ 161.4, 160.2, 157.9, 157.7, 149.9, 
143.9, 143.8, 142.2, 140.4, 130.1, 129.2, 127.4 (4 C), 121.0, 119.7, 117.5, 















-CHAPTER 8-  
Computational details and synthesis 
of substituted saturated N-











8.1 Computational details 
For the docking analysis a different X-ray structure of the protein was used, 
since the co-crystallized ligand 6PW,
321
 a 3,3-dimethyl substituted N-aryl 
piperidine, presents a saturated heterocycle moiety in its structure. 
Protein 3D input file of mPGES-1 was obtained from the Protein Data Bank 
database (PDB codes: 5K0I).
321
 The Schrodinger Protein Preparation Wizard 
Workflow (Schrödinger, LLC, NY, USA, 2013) was performed for the 
preparation of the protein, which provides the removal of water molecules, the 
addition of cap termini and all hydrogen atoms, the assignment of bond orders.  
The resulting PDB file was converted to the Maestro (MAE) format. The 
grid for the structure-based docking experiments was prepared in the ligand 





) was applied ( section 3.3.3). The three rounds of experiments (HTVS, SP 
and XP) were performed with a gradually increasing precision, keeping the 
30% top-ranked poses for each step. During the molecular docking 
calculation, the adopted receptor grid was focused onto the co-crystallized 
ligand binding site with inner- and outer-box dimensions of 10×10×10 and 
27.4×27.4×27.4, respectively.  
8.2 General synthetic methods 
Chemicals were purchased from ABCR, Acros, Alfa Aesar, Apollo 
Scientific, Fluorochem, Maybridge, Merck, Sigma-Aldrich, Strem, or TCI, and 
were used without further purification. Common organic solvents were used as 
supplied (ACS or HPLC grade). SnAP reagents starting materials were 
synthesized in the laboratory of Prof. Jeffrey Bode at the Department of 




propanol is abbreviated to HFIP. Thin layer chromatography (TLC) was 
performed for reaction monitoring and visualized by UV quenching and by 
staining with basic KMnO4, ninhydrin solution, or phosphomolybdic acid. 
Flash column chromatography
322
 was performed on silica gel (Silicycle 
SiliaFlash F60, 230–400 mesh) using a forced flow of eluent at 0.4–0.5 bar. 
NMR spectra were recorded on Bruker Avance 400 MHz, and Varian 
Mercury 300 MHz spectrometers. All compounds were dissolved in 0.5 mL of 
the following solvents: chloroform-d (Sigma-Aldrich, 99.8 Atom % D); 
methanol-d4 (Sigma-Aldrich, 99.8 Atom % D); dimethylsulfoxyde-d6 (Sigma-
Aldrich, 99.8 Atom % D), D2O (Sigma-Aldrich, 99.8 Atom % D). Coupling 
constants (J) are reported in Herz, and chemical shifts are expressed in parts 
per million (ppm) on the delta (δ) scale relative to CHCl3 (7.19 ppm for 
1
H and 
77.0 ppm for 
13
C) or CH3OH (3.31 ppm for 
1
H and 49.15 ppm for 
13
C) or 
DMSO (2.50 ppm for 
1
H and 39.51 ppm for 
13
C) or H2O (4.8 ppm for 
1
H) as 
internal reference. Multiplicities are reported as follows: s, singlet; d, doublet; 
t, triplet; m, multiplet; dd, doublet of doublets. 
13
C NMR spectra were 
obtained at 101 MHz and referenced to the internal solvent signal. High 
resolution mass spectra were measured by the Mass Spectrometry Service 
Facility of Laboratorium of Organic Chemistry at ETH Zürich on a Bruker 
Daltonics maXis for ESI-Qq-TOF spectrometer (ESI-MS) or Micromass 
(Waters) AutoSpec Ultima for EI spectrometer (EI-MS). All compounds were 
obtained with high purity (> 98% detected by HPLC analysis) and were fully 




8.3 Methods and materials 
SnAP-M (Morpholine), SnAP-TM (Thiomorpholine), SnAP-PIP (Piperazine) 
were available in the laboratory where the synthesis of compounds 62-78 was 
carried out. SnAP-TM was purified by flash chromatography before use. 
SnAP-Cys (Cysteine) was synthesized as follow. 
8.3.1 Synthesis of ethyl 2-amino-3-





To a solution of Tributyl(iodomethyl)stannane (83) (2.324 g, 5.38 mmol, 
1.00 equiv) in EtOH (40 mL) was added L-ethyl cysteine hydrochloride (84) 
(1 g, 5.38 mmol, 1.00 equiv), followed by a solution of K2CO3 (0.892 g, 6.456 
mmol, 1.20 equiv) in H2O (11 mL) at rt. The reaction mixture was refluxed at 
70 °C. After 4 h, the mixture was concentrated under reduced pressure to 
remove the solvent; the resulting residue was dissolved in H2O and extracted 
with EtOAc (x3). The combined organic solutions were dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. Purification by 
flash column chromatography (2:1 hexane:EtOAc) afforded 85 (2.102 g, 86% 





H NMR (400 MHz, CDCl3)  4.19 (q, J = 7.1 Hz, 2H), 3.67 (dd, J = 8.0, 
4.5 Hz, 1H), 2.89 (dd, J = 13.4, 4.5 Hz, 1H), 2.70 (dd, J = 13.4, 8.0 Hz, 1H), 
1.92 (dd, J = 35.0, 9.3 Hz, 2H), 1.69 (s, 4H), 1.58 – 1.44 (m, 5H), 1.38 – 1.23 
(m, 10H), 0.99 – 0.84 (m, 15H); 
13
C NMR (101 MHz, CDCl3)  174.6, 61.2, 
53.2, 43.9, 29.1, 27.4, 14.4, 13.8, 9.7, 9.2; ESI-HRMS calcd for 
C18H40NO2SSn [M + H]
+























8.3.2 General method for the preparation of the substituted 
saturated heterocycles 
The assigned name for each compound derives from the starting SnAP 
reagent (TM, M, PIP or Cys) and the aldehydes (a-g). 
 
 
Scheme 3. Synthetic method for the synthesis of 62-78; i) MS 4 Å, dry DCM, rt ii) Cu(Otf)2, 





The general procedure for the synthesis of compounds 62-78 is depicted in 
scheme 3 (SnAP chemistry). To a solution of the amino tributylstannane-SnAP 
reagent (0.1-0.3 mmol, 1.00 equiv) in CH2Cl2 at rt was added the proper 
aldehyde (a-g, 1.0 equiv) and MS 4 Å (150 mg/mmol). The reaction mixture 
was stirred at rt overnight, filtered through a short layer of Celite and 




A suspension of anhydrous Cu(OTf)2 (1.00 equiv) in HFIP 
(hexafluoroisopropanol) was prepared, and 2,6-lutidine (1.00 equiv) was 
added in one portion. The mixture was stirred for 1 h at rt, during which time a 
homogeneous green suspension was formed. The previous imine was 
dissolved in dry DCM and added to the solution in one portion, and the 
resulting mixture was stirred overnight at rt. Schlenk techniques were applied 
to all reactions.  
The reaction was quenched with 10% aq NH4OH, and stirred for 15 min. 
Then, the layers were separated and the aqueous layer was extracted with 
CH2Cl2 (3 x 3 ml). The combined organic layers were washed with H2O (3 x 5 
ml) and brine (5 ml), dried over Na2SO4, filtered, concentrated, and purified 
by flash chromatography using mixtures of hexane and ethyl-acetate in 
different proportions, to provide the desired substituted saturated heterocycles. 
Boc moiety of SnAP-PIP is useful to avoid the imine formation at the 
amine group close to tributyltin group. For the synthesis of compounds 69-71, 
a final deprotection step afforded the desired products. 




Concerning SnAP-Cys derivatives (72-78), experimental data demonstrated 
a diastereoselectivity of the reaction for the cis product (20:1). 
Notes about the purification:  
 Purification was performed by flash column chromatography using 
mixtures of hexane and ethyl acetate in different proportions.  
 0.1% of Et3N was added to the solvent mixture prepared for the flash 
chromatography for the most polar compounds. 
 Tin traces were removed applying this method: the product was 
dissolved in acetonitrile and washed a few times with hexane, and the 
combined hexane layers were extracted with a small amount of 
acetonitrile. The combined acetonitrile layers were concentrated under 
reduced pressure to provide the pure product. 
 Traces of aldehyde in the product after flash chromatography were 
removed using a small column of propyl sulfonic acid supported on 
silica (loading/capacity mmol/g 0.62) (SCX2) for not basic aldehydes. 
 
6-(4-(thiomorpholin-3-yl)phenyl)nicotinonitrile (compound 62, TMa) 
 
 
Was obtained by following the general procedure (scheme 3, 0.1 mmol). 
Purification by flash column chromatography (hexane-EtOAc 2:1 to 0:3) 





H NMR (400 MHz, CDCl3) δ 8.95 (dd, J= 2.2, 0.9 Hz, 1H), 8.06-8.01 (m, 
3H), 7.85 (dd, J= 8.3, 0.9 Hz, 1H), 7.55 (d, J = 8.3 Hz, 2H), 4.08 (dd, J = 10.7, 
2.3 Hz, 1H), 3.53-3.49 (m, 1H), 3.23 (td, J= 12.0, 2.4 Hz, 1H), 3.03-2.91 (m, 
2H), 2.58-2.46 (m, 2H); 
13
C NMR (101 MHz, CDCl3) δ 160.0, 152.5, 145.9, 
139.9, 137.0, 127.7 (2C), 127.4 (2C), 119.9, 117.0, 107.9, 62.5, 48.8, 34.4, 
27.0; ESI-HRMS calcd for C16H16N3S [M + H]
+
 282.1059, found 282.1060. 
 





Was obtained by following the general procedure (scheme 3, 0.3 mmol). 
Purification by flash column chromatography (EtOAc-hexane 1:1 to 2:0) 
afforded the pure product as an orange oil (38 mg, 44% of yield). 
Note: not stable at rt. Stored at  2ºC - 8ºC.  
1
H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 8.3 Hz, 2H), 7.74 (t, J = 7.7 Hz, 
1H), 7.62 (dd, J = 7.8, 0.8 Hz, 1H), 7.48 (d, J = 8.2 Hz, 2H), 7.18 (dd, J = 7.6, 
0.8 Hz, 1H), 4.81 (s, 2H), 4.02 (dd, J = 10.7, 2.3 Hz, 1H), 3.49 (dt, J = 12.0, 
3.1 Hz, 3H), 3.20 (td, J = 11.9, 2.3 Hz, 1H), 3.01 – 2.86 (m, 2H), 2.50 (ddt, J = 
26.4, 13.3, 2.3 Hz, 2H); 
13
C NMR (101 MHz, CDCl3) δ 158.7, 155.6, 144.7, 
138.4, 137.5, 127.2 (2C), 127.05 (2C), 119.0, 118.9, 64.0, 62.6, 49.0, 34.6, 
27.2; ESI-HRMS calcd for C16H19N2OS [M + H]
+









Was obtained by following the general procedure (scheme 3, 0.1 mmol). 
Purification by flash column chromatography (EtOAc-hexane 2:1 to 3:0) 
afforded the product as a yellow solid.  
Notes: Traces of Tin in the sample were removed following the described 
method (10 mg, 23% of yield). 
1
H NMR (400 MHz, CDCl3) δ 7.32-7.27 (m, 1H), 7.04-7.01 (m, 2H), 6.98 
(s, 1H), 6.87-6.84 (m, 3H), 5.14 (s, 2H), 3.93-3.89 (m, 4H), 3.83 (s, 3H), 3.45 
(d, J= 12 Hz, 1H), 3.18 (t, J= 11.8 Hz, 1H), 2.99-2.84 (m, 2H), 2.47 (dd, J= 
20.8, 13.2, 2H); 
13
C NMR (101 MHz, CDCl3) δ 159.8, 149.7, 147.7, 138.8, 
129.6 (2C), 119.4, 118.8, 113.9, 113.4, 112.7, 110.2, 71.0, 62.8, 56.1, 55.3, 
49.1, 34.7, 27.2; ESI-HRMS calcd for C19H24NO3S [M + H]
+













Was obtained by following the general procedure (scheme 3, 0.1 mmol). 
Purification by flash column chromatography (EtOAc-hexane 1:1 to 2:0) 
afforded the pure product as an orange oil (6 mg, 22% yield). 
Note: performed NMR analysis demonstrated  it is not stable at rt. Stored at 
2ºC - 8ºC. 
1
H NMR (400 MHz, CDCl3) δ 7.75 (d, J= 8.6 Hz, 2H), 7.69 (d, J= 8.7 Hz, 
2H), 7.59 (d, J = 8.3 Hz, 2H), 7.51 (d, J= 8.3 Hz, 2H), 4.04 (dd, J = 10.6, 2.3 
Hz, 1H), 3.51 (d, J = 11.8 Hz, 1H), 3.23 (td, J = 11.9, 2.3 Hz, 1H), 3.00 – 2.86 
(m, 2H), 2.52 (dd, J = 24.9, 13.2 Hz, 2H); 
13
C NMR (126 MHz, CDCl3) δ 
145.2, 144.6, 138.6 (2C), 132.6 (2C), 127.6 (2C), 127.5 (2C), 127.4, 118.9, 
111.0, 62.5, 49.0, 34.8, 27.4; ESI-HRMS calcd for C17H17N2S [M + H]
+
 
281.1107, found 281.1106. 






was obtained by following the general procedure (scheme 3, 0.1 mmol). 
Purification by flash column chromatography (EtOAc-hexane 2:1 to 3:0) 
provided the product as a white solid (11 mg, 41% of yield). Tin traces were 
removed as described previously. 
 1
H NMR (400 MHz, CDCl3) δ 8.96 (dd, J= 2.2, 0.9 Hz, 1H), 8.04 (ddd, J = 
8.4, 6.8, 2.0 Hz, 3H), 7.87 (dd, J = 8.4, 0.9 Hz, 1H), 7.58 (d, J= 8.1 Hz, 2H), 
4.04 (dd, J= 10.3, 3.2 Hz, 1H), 3.91 (ddd, J= 18.0, 11.3, 3.0 Hz, 2H), 3.70 (td, 
J = 11.3, 2.7 Hz, 1H), 3.44 (dd, J = 11.0, 10.0 Hz, 1H), 3.19 (td, J = 11.6, 3.3 
Hz, 1H), 3.06 (d, J = 11.7 Hz, 1H); 
13
C NMR (100 MHz, CDCl3) δ 160.0, 
152.5, 143.3 139.9, 136.8, 127.9 (2C), 127.5 (2C), 119.9, 117.0, 107.9, 73.5, 
67.2, 60.2, 46.4; ESI-HRMS calcd for C16H16N3O [M + H]
+
 266.1288, found 
266.1291. 
 




Was obtained by following the general procedure (scheme 3, 0.3 mmol). 
Purification by flash column chromatography (EtOAc-hexane 2:1 to 3:0) 
provided the pure product as an orange oil (55 mg, 68% of yield). 
1
H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 7.9 Hz, 2H), 7.74 (t, J = 7.7 Hz, 
1H), 7.61 (d, J = 7.8 Hz, 1H), 7.52 (d, J = 7.9 Hz, 2H), 7.19 (d, J = 7.6 Hz, 
1H), 4.81 (s, 2H), 4.02 (dd, J = 10.2, 3.1 Hz, 1H), 3.89 (td, J = 11.2, 2.9 Hz, 




(d, J = 11.8 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 158.9, 155.7, 140.7, 
138.6, 137.5, 127.7 (2C), 127.1 (2C), 118.9, 118.8, 73.0, 66.8, 64.0, 60.1, 
46.2; ESI-HRMS calcd for C16H19N2O2 [M + H]
+
 271.1441, found 
271.1445. 
 Ethyl (3R,5S)-5-(4-(4-hydroxybut-1-yn-1-yl)phenyl)thiomorpholine-3-




was obtained by following the general procedure (scheme 3, 0.3 mmol). 
Purification by flash column chromatography (hexane-EtOAc 3:2 to 0:3) 
provided the pure product as a yellow oil (54 mg, 56% of yield). 
1
H NMR (400 MHz, CDCl3) δ 7.42 (d, J= 8.5 Hz, 2H), 7.36 (d, J= 8.3 Hz, 
2H), 4.30-4.18 (m, 2H), 4.01 (dd, J= 10.7, 2.3 Hz, 1H), 3.86-3.78 (m, 3H), 
2.93-2.69 (m, 5H), 2.47 (dt, J= 13.2, 2.0 Hz, 2H), 1.31 (t, J= 7.1 Hz, 3H); 
13
C 
NMR (101 MHz, CDCl3) δ 171.0, 143.0, 132.0 (2C), 126.6 (2C), 123.0, 86.8, 
82.0, 63.1, 61.5, 61.1, 60.7, 34.2, 28.8, 23.8, 14.1; ESI-HRMS calcd for 
C17H22NO3S [M + H]
+













was obtained by following the general procedure (scheme 3, 0.2 mmol) as a 
yellow oil (24 mg, 63% of yield) 
1
H NMR (400 MHz, CDCl3) δ 7.71 (d, J= 8.3 Hz, 2H), 7.58 (d, J= 8.5 Hz, 
2H), 7.31-7.27 (m, 1H), 7.09-6.99 (m, 2H), 6.90 (ddd, J= 8.3, 2.7, 1.0 Hz, 1H), 
5.15 (s, 2H), 4.30-4.19 (m, 2H), 4.01 (dd, J=10.6, 2.3 Hz, 1H), 3.81 (dd, J= 
10.6, 2.7 Hz, 1H), 2.94-2.73 (m, 3H), 2.49 (dt, J= 13.1, 2.1 Hz, 1H), 1.31 (t, J 
= 7.1 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 171.0, 158.5, 145.2, 142.4, 
132.5 (2C), 130.0, 127.6 (2C), 125.5, 120.0, 118.7, 114.2, 111.7, 68.9, 63.4, 
61.5, 60.8, 34.4, 28.8, 14.2; ESI-HRMS calcd for C21H23N2O3S [M + H]
+
 
383.1424, found 383.1425. 
 
Ethyl (3R,5S)-5-(3-methoxy-4-((3-








was obtained by following the general procedure (scheme 3, 0.2 mmol). 
The imine formation required an increase of the temperature at 40 C. 
Purification by flash column chromatography (hexane-EtOAc 2:1) afforded 
the pure product as a yellow oil (29 mg, 35% of yield) 
1
H NMR (400 MHz, CDCl3) δ 7.32-7.27 (m, 1H), 7.05-6.96 (m, 3H), 6.89-
6.83 (m, 3H), 5.15 (s, 2H), 4.30-4.17 (m, 3H), 3.96-3.92 (m, 4H), 3.84-3.77 
(m, 4H), 2.92-2.73 (m, 3H), 2.46 (dt, J= 13.1, 2.0 Hz, 1H), 1.30 (t, J= 7.1 Hz, 
3H); 
13
C NMR (101 MHz, CDCl3) δ 171.0, 159.8, 149.7, 147.8, 138.8, 136.7, 
129.6, 119.4, 118.9, 113.9, 113.4, 112.6, 110.4, 70.9, 63.4, 61.4, 61.0, 56.1, 






yl)phenyl)thiomorpholine-3-carboxylate (compound 75, CYSb) 
 
 
was obtained by following the general procedure (scheme 3, 0.3 mmol). 
Purification by flash column chromatography (hexane-EtOAc 1:1) afforded 
the pure product as a yellow oil (52 mg, 48% of yield) 
1
H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.4 Hz, 2H), 7.77 (t, J = 7.7 Hz, 
1H), 7.65 (dd, J= 7.8, 0.9 Hz, 1H), 7.53 (d, J = 8.2 Hz, , 2H), 7.19 (dd, J = 7.6, 
0.9 Hz, 1H), 4.83 (s, 2H), 4.31-4.18 (m, 2H), 4.09 (dd, J = 10.6, 2.3 Hz, 1H), 
3.84 (dd, J = 10.5, 2.9 Hz, 1H), 2.96-2.76 (m, 3H), 2.52 (dt, J= 13.1, 2.1 Hz, 
1H), 1.31 (t, J = 7.1 Hz, 3H); 
13




155.7, 144.3, 138.6, 137.5, 127.2 (2C), 127.1 (2C), 119.0, 118.8, 63.9, 63.2, 
61.5, 60.8, 34.3, 28.8, 14.2; ESI-HRMS calcd for C19H23N2O3S [M + H]
+
 
359.1424, found 359.1419. 
 
Ethyl (3R,5S)-5-(4'-cyano-[1,1'-biphenyl]-4-yl)thiomorpholine-3-
carboxylate (compound 76, CYSd) 
 
 
Was obtained by following the general procedure (scheme 3, 0.2 mmol). 
Purification by flash column chromatography (hexane-EtOAc 1:1) provided 
the pure product as a yellow solid (21 mg, 30% of yield). 
1
H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.7 Hz, 2H), 7.70 (d, J = 8.7 Hz, 
2H), 7.60 (d, J = 8.5 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 4.30-4.21 (m, 2H), 
4.09 (dd, J = 10.6, 2.3 Hz, 1H), 3.84 (dd, J = 10.6, 2.7 Hz, 1H), 2.96 – 2.77 
(m, 3H), 2.53 (dt, J = 13.1, 2.1 Hz, 1H), 1.32 (t, J = 7.1 Hz, 3H); 
13
C NMR 
(101 MHz, CDCl3) δ 171.0, 145.1, 143.9, 138.8, 132.6 (2C), 127.7 (2C), 127.5 
(4C), 118.9, 111.0, 63.1, 61.5, 60.7, 34.4, 28.9, 14.2; ESI-HRMS calcd for 










carboxylate (compound 77, CYSa) 
 
 
Was obtained by following the general procedure (scheme 3, 0.1 mmol). 
The imine formation required an increase of both temperature and of reaction 
time to induce 97% of conversion. After the cyclization reaction, a purification 
by flash column chromatography (hexane-EtAOc 1:1) afforded the product. A 
crystallization by hexane-EtOAc 8:2 was useful to remove traces of aldehyde 
in the sample. The pure product was obtained as a yellow oil (27 mg, 76% 
yield).  
1
H NMR (400 MHz, CDCl3) δ 8.96 (dd, J = 2.2, 0.9 Hz, 1H), 8.08 – 8.01 
(m, 3H), 7.87 (dd, J = 8.3, 0.9 Hz, 1H), 7.58 (d, J = 8.3 Hz, 2H), 4.25 (qd, J = 
7.1, 3.8 Hz, 2H), 4.11 (dd, J = 10.6, 2.4 Hz, 1H), 3.84 (dd, J = 10.6, 2.7 Hz, 
1H), 2.97 – 2.75 (m, 3H), 2.53 (dt, J = 13.2, 2.1 Hz, 1H), 1.32 (t, J = 7.1 Hz, 
3H); 
13
C NMR (101 MHz, CDCl3) δ 170.9, 160.0, 152.5, 145.9, 139.9, 137.0, 
127.8 (2C), 127.4 (2C), 119.9, 117.0, 107.9, 63.1, 61.5, 60.7, 34.3, 28.8, 14.2; 
ESI-HMRS calcd for C19H20N3O2S [M + H]
+









hydroxyphenyl)thiomorpholine-3-carboxylate (compound 78, CYSg) 
 
 
Was obtained by following the general prodecure (scheme 3, 0.5 mmol). 
After the cyclization reaction, a purification by flash column chromatography 
(EtAOc-hexane 1:1) provided the pure product as a brown oil (99 mg, 60% 
yield). 
1
H NMR (400 MHz, CDCl3) δ 6.99 (s, 2H), 6.83 (d, J = 8.1 Hz, 1H), 6.44 
(t, JH-F = 73.9 Hz, 1H), 4.17 (m, 2H), 3.86 (d, J = 10.4 Hz, 1H), 3.71 (d, J = 
10.4 Hz, 1H), 2.84 - 2.51 (m, 3H), 2.36 (d, J = 13.0 Hz, 1H), 1.21 (t, J = 7.1 
Hz, 3H); ESI-HRMS calcd for C14H18F2NO4S [M + H]
+
 334.0919, found 
334.0924. 
8.3.2.1 Synthesis of compounds 69-71 
tert-butyl 3-(4-(6-(hydroxymethyl)pyridin-2-yl)phenyl)piperazine-1-






Was obtained by following the general procedure (scheme 3. 0.3 mmol). 
Purification by flash column chromatography (EtOAc-hexane 2:1 to 3:0) 
afforded the pure product as a yellow solid (76 mg, 68% of yield). 
1
H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 7.9 Hz, 2H), 7.73 (t, J = 7.7 Hz, 
1H), 7.62 (d, J = 7.8 Hz, 1H), 7.51 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 7.6 Hz, 
1H), 4.80 (s, 2H), 4.06 (s, 2H), 3.78 (d, J = 10.4 Hz, 1H), 3.27 (s, 2H), 3.10 (d, 
J = 9.9 Hz, 1H), 2.99-2.70 (m, 3H), 1.49 (s, 9H). 
 




To a solution of compound 165 (76.0 mg, 0.205 mmol) in DCM (3 ml) was 
added trifluoroacetic acid (3 ml). The mixture was stirred at room temperature 
for two hours and concentrated. NaOH aqueous solution (1 N) was added 
dropwise, and the mixture was extracted with EtAOc. The layers were 
separated and the organic layer was washed with aqueous NaHCO3 and with 
brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure to give compound 69 (97% yield). 
1
H NMR (400 MHz, D2O) δ 8.49 (t, J = 8.0 Hz, 1H), 8.04 (dd, J = 8.1, 1.2 




8.4 Hz, 2H), 4.96 (s, 2H), 4.84 (dd, J = 12.5, 3.4 Hz, 1H), 3.91 – 3.44 (m, 6H); 
13
C NMR (101 MHz, D2O) δ 156.0, 151.4, 147.1, 134.3, 133.1, 129.7 (2C), 
128.6 (2C), 125.3, 123.4, 59.7, 55.6, 44.4, 41.2, 39.7; ESI-HRMS calcd for 
C16H20N3O [M + H]
+
 270.1601, found 270.1602. 
tert-butyl 3-(4-(4-hydroxybut-1-yn-1-yl)phenyl)piperazine-1-




Was obtained by following the general procedure (scheme 3, 0.3 mmol). 
Purification by flash column chromatography (EtOAc-hexane 2:1 to 3:0) 
provided the pure product as a yellow solid (70 mg, 71% of yield). 
1
H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.4 Hz, 
2H), 4.05 (br s, 2H), 3.81 (t, J = 6.3 Hz, 2H), 3.73 (dd, J = 10.8, 3.1 Hz, 1H), 










4-(4-(piperazin-2-yl)phenyl)but-3-yn-1-ol (compound 70, PIPe) 
 
 
To a solution of compound 166 (70 mg, 0.212 mmol) in DCM (2.5 ml) was 
added trifluoroacetic acid (2.5 ml). The mixture was stirred at room 
temperature for two hours and concentrated. NaOH aqueous solution (1 N) 
was added dropwise, and the mixture was extracted with EtAOc. The layers 
were separated and the organic layer was washed with aqueous NaHCO3 and 
with brine, dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure to give compound 70 (92% yield). 
1
H NMR (400 MHz, D2O) δ 7.52 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 
2H), 3.86 – 3.44 (m, 9H), 2.60 (t, J = 6.3 Hz, 2H); 
13
C NMR (101 MHz, D2O) 
δ 132.7, 130.3 (2C), 127.6 (2C), 125.5, 90.0, 80.6, 59.86, 55.8, 44.4, 41.1, 
39.7, 22.4; ESI-HMRS calcd for C14H19N2O [M + H]
+












carboxylate (compound 170) 
 
Was obtained following the general procedure (scheme 3, 0.1 mmol). 
Purification by flash column chromatography (EtOAc-hexane 1:1) provided 
the product as an orange solid (15 mg, 35% of yield).  
Note: Traces of aldehyde were removed using a small column of propyl 
sulfonic acid supported on silica. 
1
H NMR (400 MHz, CDCl3) δ 7.32 – 7.27 (m, 3H), 7.06 – 6.98 (m, 3H), 
6.89 – 6.83 (m, 3H), 5.13 (s, 2H), 3.96 – 3.87 (m, 3H), 3.85 – 3.77 (m, 5H), 
3.17 – 2.90 (m, 5H), 2.78 (t, J = 11.3 Hz, 1H), 1.48 (s, 9H). 
2-(3-methoxy-4-((3-methoxybenzyl)oxy)phenyl)piperazine 
(compound 71, PIPc) 
 
 
To a solution of compound 167 (15 mg, 0.035 mmol) in DCM (2.5 ml) was 
added trifluoroacetic acid (2.5 ml). The mixture was stirred at room 




was added dropwise, and the mixture was extracted with EtAOc. The layers 
were separated and the organic layer was washed with aqueous NaHCO3 and 
with brine, dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure to give compound 71 (94% yield). 
1
H NMR (400 MHz, CDCl3) δ 7.33 – 7.27 (m, 3H), 7.06 – 6.98 (m, 3H), 
6.89 – 6.83 (m, 3H), 5.13 (s, 2H), 3.96 – 3.87 (m, 4H), 3.85 – 3.77 (m, 5H), 
3.17 – 2.90 (m, 5H), 2.78 (t, J = 11.3 Hz, 1H); ESI-HMRS calcd for 
C19H25N2O3 [M + H]
+
 329.1860, found 329.1856. 
8.3.3 General procedure for the synthesis of compounds 79-82  
A solution of 10 mg of compounds 72-75 in methanol (1 ml) was treated 
with 10% NaOH solution (1 ml). The resulting mixture was stirred for 3 hours 
at rt and concentrated under reduced pressure at 40 °C. The remaining aqueous 
solution was acidified with HCl 2N (pH=6) and extracted with EtOAc (10 x 
3). The organic layer was dried over Na2SO4 and concentrated to obtain the 
final products 79-82.  
(3R,5S)-5-(4-(4-hydroxybut-1-yn-1-yl)phenyl)thiomorpholine-3-
carboxylic acid (compound 79) 
 
 






H NMR (400 MHz, MeOD) δ 7.54 (d, J = 7.3 Hz, 2H), 7.48 (d, J = 7.5 Hz, 
2H), 4.63 (d, J = 11.7 Hz, 1H), 4.43 (d, J = 11.6 Hz, 1H), 3.75 (t, J = 6.0 Hz, 
2H), 3.30 – 3.12 (m, 3H), 2.92 (d, J = 14.9 Hz, 1H), 2.65 (t, J = 6.0 Hz, 2H); 
13
C NMR (101 MHz, MeOD) δ 167.8, 134.9, 132.3 (2C), 127.2 (2C), 125.3, 
88.9, 79.8, 62.3, 60.0, 59.8, 29.6, 25.9, 22.8; ESI-HRMS calcd for 
C15H18NO3S [M + H]
+
 292.1002, found 292.0999. 
(3R,5S)-5-(3-((4-cyanobenzyl)oxy)phenyl)thiomorpholine-3-carboxylic 
acid (compound 80) 
 
 
Was obtained by following the general prodecure as a white solid (95% 
yield). 
1
H NMR (400 MHz, MeOD) δ 7.92 (d, J = 7.6, 2H), 7.57 (d, J = 7.6, 2H), 
7.45 (t, J = 7.9, 1H), 7.22 (s, 1H), 7.14 (t, J = 7.3, 2H), 5.24 (s, 2H), 4.60 (d, J 
= 11.6, 1H), 4.40 (d, J = 11.5, 1H), 3.33 – 3.13 (m, 4H), 2.92 (d, J = 14.6, 1H); 
13
C NMR (101 MHz, MeOD) δ 170.4, 168.7, 159.4, 141.1, 137.3, 133.1, 
130.7, 127.6 (2C), 126.8 (2C), 118.9, 115.5, 113.8, 69.1, 62.7, 59.6, 29.9, 









carboxylic acid (compound 81) 
 
 
Was obtained by following the general prodecure as an orange solid (71.4% 
yield). 
1
H NMR (400 MHz, MeOD) δ 7.20-7.12 (m, 2H), 7.06 (s, 1H), 7.00-6.90 
(m, 3H), 6.76 (d, J = 7.5 Hz, 1H), 5.04 (s, 2H), 4.42 (d, J = 11.5 Hz, 1H), 4.24 
(d, J = 11.7 Hz, 1H), 3.79 (s, 3H), 3.68 (s, 3H), 3.25-3.01 (m, 3H), 2.78 (d, J = 
14.6, 1H); 
13
C NMR (101 MHz, MeOD) δ 168.0, 150.1, 149.2 (2C), 138.5, 
129.2, 128.9, 119.6, 119.2, 114.4, 112.9, 112.7, 110.9, 70.5, 62.7, 59.8, 55.4, 
54.2, 29.8, 25.8. ESI-HRMS calcd for C20H22NO5S [M - H]
-
 388.1297, found 
388.1212. 
(3R,5S)-5-(4-(6-(hydroxymethyl)pyridin-2-yl)phenyl)thiomorpholine-3-
carboxylic acid (compound 82) 
 
 
Was obtained by following the general prodecure as an orange solid (93% 
yield). 
1
H NMR (400 MHz, D2O) δ 8.55 (t, J = 8.1 Hz, 1H), 8.10 (dd, J = 8.1, 1.1 




8.5 Hz, 2H), 4.75 (dd, J = 11.9, 2.7 Hz, 1H), 4.36 (dd, J = 11.1, 3.9 Hz, 1H), 
3.40 – 3.10 (m, 3H), 2.94 (ddd, J = 14.8, 2.7, 1.6 Hz, 1H); 
13
C NMR (101 
MHz, MeOD) δ 167.6, 158.2, 151.9, 145.8, 139.4, 133.2, 129.3 (2C), 128.1 
(2C), 124.3, 122.7, 62.3, 60.2, 59.6, 29.6, 25.6; ESI-HRMS calcd for 






































9.1 2-Carboxamide pyrrole derivatives targeting 
mPGES-1  
9.1.1 Generation of libraries 
 Commercially available methyl ketones and aromatic amines were 
converted from 2D structures to 3D structures using LigPrep software (v. 3.4; 
Schrödinger, LLC, 2015). The methyl moiety in the ketones and the amine 
group in the amines were removed to provide the building blocks for the next 
step in the Reagent Preparation phase, and Combiglide was used for the 
generation of the final libraries D and E. LigPrep performed calculation 
increased the number to 57,541 for each library, and a final energy 
minimization of the three libraries with Optimized Potentials for Liquid 
Simulations  (OPLS) 2005 force field was performed. After the 
application of QikProp
1 1 0
 and LigFilter, 
1 1 7
 the number was 
reduced to 4,300 and 458 molecules for the libraries D and E respectively. 
9.1.2 Docking analysis 
 In the structure-based molecular docking experiments, the same mPGES-1 
three-dimensional crystal structure (PDB code: 4BPM)
209
 used for the 
calculation concerning 2-amino benzothiazole and thiadiazole derivatives was 
adopted (see section 3.4.3). Also in this specific case, Glide software
103, 104
 
was used for docking analysis and the virtual screening workflow
1 1 7
 was 
applied (see sections 3.3.3 and 3.4.3), in the same size receptor grid focused 
onto the co-crystallized ligand binding site (LVJ). 
For the calculation regarding reported pyrrole alkanoic acid derivatives 




Panel (v. 9.6; Schrödinger, LLC, 2015) and  processed with LigPrep, (v. 3.4; 
Schrödinger, LLC, 2013) in order to generate all the possible stereoisomers, 
tautomers and protonation states at a pH of 7.4 ± 1.0, and a final energy 
minimization with the OPLS 2005 force field. Then, the Ligand Docking was 
performed using the same crystal structure and the same grid adopted for the 
virtual screening workflow for libraries D and E. Glide software package 
(Standard Precision [SP] mode, version 6.1, Schrödinger package) was used in 
order to analyze the binding mode of the compounds into the crystal structure 
of the protein (PDB code: 4BPM). 
209
 For this step, an expansion of the 
sampling mode (2×) was set, keeping 10,000 poses in the starting phase of 
docking and selecting 800 poses for energy minimization. Specifically, one 
output structure was saved for each binder, with a scaling factor of 0.8 related 
to van der Waals radii with a partial charge cutoff of 0.15. Basing on a 0.5 
kcal/mol rejection cutoff for the obtained minimized poses, a maximum of one 
pose was chosen in the post-docking optimization phase. The selected outputs 
were then submitted to another docking round, the Extra Precision Glide mode 
(Extra Precision [XP] mode, version 6.1, Schrödinger package) setting the 
same parameters applied in the previous SP-docking experiments. In the 
output file, 20 poses for each compound were saved, and in the post-docking 




9.2 Discovery of novel 3-hydroxy-3-pyrrolin-2-one 
derivatives as mPGES-1 inhibitors 
9.2.1 Input files preparation for molecular docking 
The starting library of compounds was purchased from the Otava 
Chemicals database (~ 3.1 × 10
5
 compounds). LigPrep software (Schrodinger 
Suite) was used for the preparation of the library and all the possible 
stereoisomers, tautomers, and protonation states at physiological pH were 
added to each compound, and a minimization was performed using OPLS 
2005 force field. Protein 3D model was prepared using the Schrödinger 
Protein Preparation Wizard, 
117
 starting from the mPGES-1 X-ray structure in 
the active form co-complexed with the inhibitor LVJ (2-[[2,6-bis(chloranyl)-3-
[(2,2-dimethylpropanoylamino)methyl]phenyl]amino]-1-methyl-6-(2-methyl-
2-oxidanyl-propoxy)-N-[2,2,2-tris(fluoranyl)ethyl]benzimidazole-5-
carboxamide) (PDB code: 4BPM). 
209
The visual inspection of the protein 
crystal structure showed that the binding of LVJ inhibitor in the ligand binding 
site was not assisted by structural water molecules, the reason why they were 
removed. All hydrogen atoms were added, and bond orders were assigned. 
Docking calculations were performed on the protein structure in the presence 
of the cofactor GSH, whereas LVJ was removed. 
9.2.2 Molecular Docking and structure-based shape 
screening 
The molecular docking virtual screening campaign was performed using the 





 High-Throughput Virtual Screening scoring/sampling (HTVS): an 
input file containing 7,220 compounds, saved 10 maximum number 
of poses for each compound, saved first 10,000 ranked poses 
(selection filter: docking score) as output, corresponding to 4546 
compounds 
 Standard Precision scoring/sampling phase (SP), and structure-
based shape screening: 4,546 unique compounds from HTVS phase 
as input, saved 10 maximum number of poses for each compound. 
Each produced pose was submitted to an “in place” shape screening 
(See Results and Discussion) against LVJ. Choosing a threshold = 
0.400, 4120 unique compounds were selected for the subsequent 
step 
 Extra Precision scoring/ sampling phase (XP), and structure-based 
shape screening: 4,120 unique compounds from SP/shape screening 
step as input, saved 100 maximum number of poses for each 
compound. The produced poses were submitted to an “in place” 
shape screening (See Results and Discussion) against LVJ. 
Choosing a threshold = 0.500, 914 unique compounds were 
selected. The selected compounds were then further filtered 




9.3 Discovery of new molecular entities able to strongly 
interfere with Hsp90 C-terminal domain: 
rationalization 
9.3.1 Molecular docking studies. 
Schrödinger Protein Preparation Wizard workflow
117
 was used to prepare 
the ATP-bound active state of Hsp82, a yeast Hsp90α homologue (PDB code: 
2CG9)
313
 removing the water molecules that were found 5 Å or more and cap 
termini were included. Additionally, all hydrogen atoms were added and bond 
orders were assigned. Chemical structures of investigated compounds were 
built with Maestro’s Build Panel (version 10.2) 
117
 and subsequently processed 
with LigPrep (version 3.4)
123
 in order to generate all the possible tautomers 
and protonation states at a pH of 7.4 ± 1.0; the resulting ligands were finally 
minimized employing the OPLS 2005 force field. 
9.3.2 Induced fit docking. 
Binding site for the first Glide docking phase (Glide Standard Precision 
Mode) of the Induced Fit Workflow (Induced Fit Docking, protocol 2015–2, 
Glide version 6.4, Prime version 3.7, Schrödinger)
103, 104
 is calculated on the 
2CG9 structure
313
, mapping onto a grid with dimensions of 36 Å (outer box) 
and 20 Å (inner box), centered on residues 628–630, 640–641, 670–675 
(Hsp90 residues numbering as in the PDB entry 2CG9). Maestro’s default 
protocol was used for the first (Initial Glide docking) and the second step 
(Prime Induced Fit) considering 20 poses per ligand; these poses were retained 
from the initial docking and then were passed to Prime (Prime version 3.7, 




docked (third step) into their corresponding low energy protein structures 
(Glide Extra Precision Mode) with resulting complexes ranked according to 
GlideScore. 
9.3.3 Molecular Dynamics Simulations 
The starting structures for the Molecular Dynamics (MD) simulations were 
prepared with the System Builder in Desmond.
319
 Na+ ions were added to the 
system to ensure electroneutrality, and the SPC
323
 (simple point charge) water 
model was used for solvation in a rectangular box with a 10 Å buffer distance, 
resulting in a system with approximately 17,8000 atoms. OPLS-2005 force 
field parameters available in the Schrödinger Suite was used for the entire 
system (protein and substrates). The MD simulation workflow was run with 
the default parameters in the Maestro interface to Desmond
319
 accounting for a 
total simulation time of 100 ns, using a recording interval of 1.2 ps, and an 
ensemble class NPT (300 K and 1.01 bar). Before the simulation, a relaxation 
of the system was performed using the default equilibration protocol in 
Desmond
319
 with multisim procedure, which is a vital step to prepare a 
molecular system for production-quality MD simulation. In particular, 
Maestro’s default relaxation protocol was used, which have included two 
stages of minimization (restrained and unrestrained) followed by four stages of 
MD runs with gradually diminishing restraints. 
9.3.4 Generation of three libraries of compounds deriving 
from the new disclosed inhibitor 103 and docking studies 
The structures of the amines, commercially available at Sigma Aldrich 
Company, were converted from 2D structures to 3D structures suitable for the 




LLC, 2015). Reagent Preparation was used for the generation of the building 
blocks, with a cleavage of a hydrogen atom of the amine group. By means of 
Combiglide, the final .bld file was combined with the scaffolds obtaining the 
novel libraries, each containing 1,629 compounds, which were processed with 
LigPrep and minimized with Optimized Potentials for Liquid 
Simulations  (OPLS) 2005 force field.  The final libraries contained 
2887 compounds.  
The same prepared three-dimensional protein used for docking experiments 
performed on compounds 100 and 103 was used for the calculation (PDB 
code: 2CG9).
313
 The final libraries were submitted to the virtual screening 
workflow onto the crystal structure of the chaperone, performing the three 
rounds of docking experiments: the High-Throughput Virtual Screening 
(HTVS), the Standard Precision (SP) and the Extra-Precision (XP) Glide mode 
experiment, with a gradually increasing precision in sampling and scoring. 
The final small libraries of compounds filtered in the last step (XP) were 
undergone to a set of filters and selected setting the key interactions with 
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Metabolism, Elimination 
ADP Adenosine Diphosphate 
ATP Adenosine Triphosphate 
CADD Computer-aided drug discovery 
CDK Cyclin-Dependent Kinase 
CH3CN Acetonitrile 
cPGES cytosolic Prostaglandin E2 Synthase 
COX Cyclooxygenase 
COXib COX-2 selective inhibitor 
Cys Cysteine 
DIPEA N,N-Diisopropylethylamine 
DMSO Dimethyl Sulfoxide 
EGCG (-)-Epigallocatechin-3-gallate 
EtOAc Ethyl acetate 
ESI-MS                Electrospray mass spectrometry 
List of Abbreviations 
280 
 
FISA Hydrophilic component of the SASA 
FLAP 5-Lipoxygenase Activating Protein 
GA Genetic Alghoritm 
GPCR G-Protein Coupled Receptors 
Grp94 94 kDa gluclose-regulated protein 
GSH Glutathione 
HFIP Hexafluoroisopropanol 
Hsc70 Heat Shock Cognate 70 
HSF1 Heat Shock Factor 1 
Hsp Heat Shock Protein 
HSR    Heat Shock Response 
HTVS High-throughput virtual screening 
IC50 Half  Maximal Inhibitory 
Concentration 
IFD Induced Fit Docking 
IKK IκB Kinase 
IL Interleukin 
iSnAP Iteractive Stannyl Amine Protocol 
KD Dissociation Constant 
LBDD Ligand-based Drug Design 
LBS Ligand Binding Site 
LO Lipoxygenase 












MAPEG Membrane-Associated Proteins in 
Eicosanoid and Glutathione 
metabolism 
MD Molecular Dinamics 
MGST Microsomal Glutathione S-
Transferase 
MOM Methoxymethyl 
mPGES-1             microsomal Prostaglandin E2 
Synthase-1 
mPGES-2            microsomal Prostaglandin E2 
Synthase-2 
MS Mass Spectrometry 
NET Neutrophil extracellular traps 
NF-κB                Nuclear factor kappa-light-chain-
enhancer of activated B cells 
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NMR Nuclear Magnetic Resonance 
NO Nitric oxide 
NSAID Non-Steroideal Antiinflammatory 
Drug 
PAINS Pan assay interference compounds 
PG Prostaglandin 
PIP Piperazine 
PLA2 Phospholipase A2  
PRR Pattern Recognition Receptors 
PET Petroleum ether 
RDC   Radicicol 
ROS Reactive oxygen species 
RP-HPLC                    Reverse Phase- High Performance 
Liquid Chromatogrphy 
QPlogBB Predicted brain/blood partition 
coefficient 
QPlogPo/w Predicted octanol/water partition 
coefficien 
QPlogS Predicted aqueous solubility 
QPPCaco Predicted apparent Caco-2 cell 
permeability in nm/sec 
QPPMDCK Predicted apparent MDCK cell 
permeability in nm/sec. 
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QPlogHERG Predicted IC50 value for blockage of 
HERG K+ channels 
RtvFG Number of reactive functional groups 
SASA Total solvent accessible surface area 
(SASA) in square angstroms using a 
probe with a 1.4 Å radius 
SBDD Structure-based Drug Design 
SCX2 Propyl Sulfonic acid supported on 
silica 
SnAP Stannyl Amine Protocol 
SP Standard Precision 
SPR Surface Plasmon Resonance 
STAT3 Signal Transducer and Activator of 
Transcription 3 
TLRs Toll-Like Receptors 
TM Thiomorpholine 
TMSCl Chlorotrimethylsilane 
TNFα Tumor Necrosis Factor alpha 
Trap1   Hsp75/tumor necrosis factor receptor 
associated protein 1 
TXA2 Tromboxane 
VEGF Vascular Endothelial cell Growth 
Factor 
VSW Virtual screening workflow 
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XP Extra Precision 
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